Porphyrin metabolism in congenital erythropoietic porphyria by Guo, Rong
Open Research Online
The Open University’s repository of research publications
and other research outputs
Porphyrin metabolism in congenital erythropoietic
porphyria
Thesis
How to cite:
Guo, Rong (1992). Porphyrin metabolism in congenital erythropoietic porphyria. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 1992 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
OX- \, Slr'l 'S 
L) IV (LFE->-reJc--r~ 
PORPHYRIN METABOLISM IN 
CONGENITAL ERYTHROPOIETIC PORPHYRIA 
A thesis submitted in support of candidature for the 
degree of Doctor of Philosophy in the Open University. 
by 
Rong Guo, 1992 
King's College Hospital, London 
in collaboration with 
MRC Toxicology Unit, Carshalton, Surrey 
A vt:.h or Ih.> Mb~.r: e, ~ 2. r... 1-1-1 b 
btt-Ce.- t>-f s~"N'\~",~-':o;\.: ~q~L 
... 
CONTENTS 
Abstract 
Acknowledgement 
Abbreviations 
i 
ii 
iii 
CHAPTER 1. 
1.1. 
1.1.1. 
1.1.2. 
1.2. 
1.2.1. 
1.2.2. 
1.2.3. 
1.2.4. 
1.3. 
1.3.1. 
1.3.1.1. 
1.3.1.2. 
1.3.2. 
1.3.2.1. 
1 • 3 • 2 .2. 
1.3.3. 
1.4. 
CHAPTER 2. 
2.1. 
2 . 2 . 
2.3. 
2.3.1. 
2.3.2. 
2 • 3 .3. 
2.3.4. 
2.3.5. 
2.3.5.1. 
2.3.5.2. 
2.3.5.3. 
2.3.5.4. 
2.3.5.5. 
2.3.5.6. 
2.3.6. 
2.4. 
2.5. 
CHAPTER 3. 
3.1. 
3.2. 
3.2.1. 
INTRODUCTION 
Haem Biosynthetic Pathway 
Porphyrins and the haem biosynthetic 
pathway 
The regulation of haem biosynthesis 
Porphyrias 
Enzyme defects in porphyrias 
Clinical manifestation of porphyrias 
Molecular genetics of porphyrias 
The possible mechanism of the photosensi-
tivity in porphyrias 
Analytical Techniques For The study Of 
Porphyrin Metabolism 
Spectrophotometry 
UV absorption spectrometry 
Fluorescent spectrometry 
Chromatography 
Thin-layer chromatography 
High-performance liquid chromatography 
Mass spectrometry 
Aims Of The Present study 
EFFECT OF ORAL CHARCOAL TREATMENT IN A CASE 
OF CONGENITAL ERYTHROPOIETIC PORPHYRIA 
Introduction 
Case Report 
Experimental 
Material and reagents 
Charcoal treatment procedure 
Duodenal porphyrins 
Preparation of erythrocytes and plasma 
Sample preparation for HPLC separation 
Porphyrins in urine 
Extraction of porphyrins in faeces 
Direct esterification of porphyrins in 
faeces 
Extraction of porphyrins from erythrocytes 
Extraction of porphyrin from plasma 
Determination of the activities of HMB-S 
and Uro III-S 
High-performance liquid chromatography 
(HPLC) of porphyrins 
Results And Discussion 
Conclusions 
1 
1 
7 
9 
10 
14 
19 
20 
22 
22 
22 
22 
23 
23 
24 
27 
28 
29 
32 
33 
33 
34 
34 
35 
35 
35 
36 
37 
37 
38 
38 
38 
40 
57 
ISOLATION, IDENTIFICATION AND CHARACTER-
IZATION OF NEW PORPHYRIN METABOLITES IN THE 
URINE AND PLASMA OF PATIENTS WITH CEP 
Introduction 58 
Experimental 61 
Materials and reagents 61 
3.2.2. 
3 • 2 . 3 • 
3 • 2 • 4 • 
3.2.5. 
3.2.6. 
3.2.7. 
3.2.8. 
3.2.9. 
3.2.10. 
3.2.11. 
3.2.12. 
3 .3. 
3.4. 
3.5. 
3.5.1. 
3.5.2. 
3 .5. 3 • 
3.5.4. 
3.5.5. 
3.5.6. 
3.5.7. 
3.5.8. 
3.5.9. 
3.6. 
CHAPTER 4. 
4.1. 
4.2. 
4.2.1. 
4 • 2 .2. 
4.2.3. 
4.2.4. 
4.2.5. 
Separation and isolation of the new 
porphyrin metabolites in the urine of 
patients with CEP by HPLC 
Solid-phase extraction of the urinary 
porphyrins 
Esterification of porphyrins 
Acetylation of hydroxylated porphyrins 
Hydrolysis of porphyrin esters 
Reduction and aromatisation of hydroxylated 
porphyrins 
61 
62 
64 
64 
65 
65 
Synthesis of meso-hydroxyuroporphyrin I 
and III 65 
uroporphyrin 
66 
Dehydration of the hydroxylated 
methyl esters by heating 
Dehydration and decarboxylation of hydroxy-
lated uroporphyrins by heating 
Alkaline hydrolysis of peroxyacetic acid 
uroporphyrin I 
Separation and isolation of the new 
porphyrin metabolites in the plasma of 
patients with CEP by HPLC 
Spectrophotometry 
Liquid Secondary Ion Mass Spectrometry 
(LSIMS) 
Results and Discussion 
HPLC of polar porphyrins in the urine of a 
patient with CEP 
Identification of meso-hydroxyuroporphyrin 
I 
Identification of B-hydroxypropionic acid 
uroporphyrin I 
Identification of hydroxyacetic acid 
uroporphyrin I 
Identification of peroxyacetic acid 
uroporphyrin I 
Identification of hydroxy heptacarboxylic 
acid porphyrins in the urine of patients 
with CEP 
Identification of hydroxy- and peroxyacetic 
acid- uroporphyrin I derivatives in the 
plasma of patients with CEP 
Stability of hydroxy- and peroxyacetic 
acid- porphyrins 
Electronic absorption spectra of hydroxy-
and peroxyacetic acid- porphyrins 
Conclusions 
THE ORIGIN OF HYDROXY- AND PEROXYACETIC 
ACID- PORPHYRINS IN CEP 
Introduction 
Experimental 
Materials and reagents 
HPLC of porphyrins in clinical samples 
and reaction mixtures 
preparation of blood sample 
Incubation of porphyrin(ogen) with red 
cell haemolysates 
Incubation of porphobilinogen (PBG) with 
67 
67 
67 
68 
70 
70 
70 
71 
77 
84 
85 
96 
98 
102 
103 
113 
114 
114 
114 
115 
117 
118 
4.2.6. 
4.2.7. 
4.2.8. 
4.3. 
4.3.1. 
4.3.2. 
4.3.3. 
4.3.4. 
4.3.5. 
4.3.5.1. 
4.3.5.2. 
4.3.5.3. 
4.3.5.4. 
4.3.5.5. 
4.3.6. 
4.3.7. 
4.3.8. 
4.3.9. 
4.3.10. 
4.3.11. 
4.4. 
red cell haemolysates 
Incubation of uroporphyrinogen I with red 
cell haemolysates in presence of reducing 
agents 
Incubation of uroporphyrinogen I with red 
cell haemolysates in presence of carbon 
monoxide 
Incubation of uroporphyrinogen I with 
plasma and leucocytes 
Results And Discussion 
Source of hydroxy- and peroxyacetic acid-
uroporphyrin I 
Reaction of uroporphyrin I with red cell 
haemalysates 
Reaction of uroporphyrinogen I with 
red cell haemolysates 
Comparison of the formation of peroxyacetic 
acid uroporphyrin I with red cell 
haemolysates from normal subject and 
patient with CEP 
optimization of reaction conditions 
for the formation of peroxyacetic acid 
uroporphyrin I 
Relationship between the volume of 
red cell haemolysates and the production 
119 
120 
121 
121 
122 
122 
124 
124 
131 
133 
133 of peroxyacetic acid uroporphyrin I 
Relationship between the concentration of 
Uro'gen I and the production of peroxyacetic 
acid uroporphyrin I 135 
Relationship between incubation time 
and production of peroxyacetic acid 
uroporphyrin I with red cell haemolysates 
pH optimum for the production of 
peroxyacetic acid uroporphyrin I 
Relationship between incubation 
temperatures and the formation of 
peroxyacetic acid uroporphyrin I 
Effect of reducing agents on the formation 
of peroxyacetic acid uroporphyrin I 
Inhibition of the production of 
peroxyacetic acid uroporphyrin I by 
carbon monoxide 
Reaction of Uro'gen I with plasma and 
leucocytes 
Formation of peroxyacetic acid 
heptacarboxylic acid porphyrinogen I in 
red cell haemolysates 
Formation of peroxyacetic acid 
pentacarboxylic acid porphyrinogen I in 
red cell haemolysates 
Attempted formation of peroxyacetic 
acid coproporphyrinogen I in red cell 
haemolysates 
Conclusions 
135 
138 
138 
141 
144 
144 
145 
148 
151 
155 
CHAPTER 5. MECHANISMS OF THE FORMATION OF HYDROXYLATED 
AND PEROXYACID UROPORPHYRIN DERIVATIVES 
5.1. Introduction 157 
5.2. 
5.2.1. 
5.2.2. 
5.2.2.1. 
5.2.2.2. 
5.2.3. 
5.2.4. 
5.2.5. 
5.2.6. 
5.2.7. 
5.3. 
5.3.1. 
5.3.2. 
5.3.3. 
5.3.4. 
5.3.5. 
5.3.6. 
5.3.7. 
5.3.8. 
5.4. 
Experimental 
Material and reagents 
Incubation of Urolgen I with liver 
microsomes 
Preparation of liver microsomes 
Reaction procedure 
Incubation of Urolgen I with Tris-HCl 
buffer 
Incubation of Urolgen I with haematin, 
methaemalbumin and dihydroxymalic acid in 
Tris-HCl buffer 
Incubation of Urolgen I in xanthine-
xanthine oxidase system 
Incubation of Urolgen I with hydrogen 
peroxide/Fe-EDTA system 
Analysis and isolation of the reaction 
product by HPLC 
Results And Discussion 
Formation of peroxyacetic acid uroporphyrin 
I in a liver microsomal system induced by 
3,4-TCB 
Effect of light on the formation of 
peroxyacetic acid uroporphyrin I 
The effect of haematin, methaemablumin 
and dihydroxymaleic acid on the formation 
157 
157 
158 
158 
159 
159 
160 
161 
162 
163 
164 
164 
165 
of peroxyacetic acid uroporphyrin I 170 
The formation of peroxyacetic acid uroporphy-
rin I from xanthine-xanthine oxidase system 175 
Formation Of Peroxyacetic Acid Uroporphyrin 
I From Commercial H202 183 Disappearance of porphyrins during the form-
ation of peroxyacetic acid uroporphyrin I 189 
Attempted formation of peroxyacid copro-
porphyrinogen I by the action of H20 Z Mechanism of formation of peroxyacetlc 
acid uroporphyrin I and the formation 
of hydroxylated uroporphyrins 
Conclusion 
191 
191 
197 
CHAPTER 6. GENERAL DISCUSSION AND FUTURE DEVELOPMENT 
6.1. 
6.2. 
6.3. 
6.4. 
6.5. 
6.5. 
6.5.1. 
6.5.2. 
Charcoal Therapy in CEP and possible 
Alternative Treatment 199 
Distribution and Metabolism of Hydroxylated 
and Peroxyacid Uroporphyrin Derivatives 
in vivo 
Formation of Hydroxy- and Peroxyacetic 
Acid- Uroporphyrin I in vivo 
possible Inhibition of the Enzyme Activities 
by the Hydroxy- and peroxyacetic Acid-
Uroporphyrin Derivatives 
cutaneous Photosensitivity in CEP 
Further Studies 
Further Studies of the Mechanism of the 
Formation of Hydroxy- and peroxyacetic 
Acid Uroporphyrin I Derivatives 
Isolation and Identification of Novel 
Components in the Urine and Plasma from 
201 
205 
208 
209 
209 
6.5.3. 
Publications 
References 
Patients with CEP 
Biological Significance of Hydroxy- and 
Peroxyacetic Acid Uroporphyrin I 
Derivatives 
210 
211 
212 
213 
ABSTRACT 
Meso-hydroxyuroporphyrin I, B-hydroxypropionic acid 
uroporphyrin I, hydroxyacetic acid uroporphyrin I and 
peroxyacetic acid uroporphyrin I have been isolated from the 
urine and plasma of patients with congenital erythropoietic 
porphyria (CEP) by high-performance liquid chromatography 
and characterized by liquid secondary ion mass spectrometry 
and chemical properties. The physico-chemical properties of 
these compounds have been studied. 
The hydroxy- and peroxyacetic acid- uroporphyrin I 
derivatives are the true metabolites of uroporphyrinogen I 
in vivo and their presence in urine and plasma is a common 
feature of CEP. The absence of these derivatives in duodenal 
aspirate and faeces suggests that they are of erythropoietic 
origin. 
The mechanism of formation of the hydroxy- and 
peroxyacetic acid- uroporphyrin I has been investigated. 
Peroxyacetic acid uroporphyrin I is formed from 
uroporphyrinogen I in the presence of H202 and iron while the hydroxylated uroporphyrin I derivatives are most 
probably produced by hydroxyl radicals generated during the 
formation of peroxyacetic acid uroporphyrin I. Destruction 
of porphyrins is found in the same reaction and can be 
prevented bydesferrioxamine, indicating that it is due to 
hydroxyl radicals. 
The formation of peroxyacetic acid- and hydroxy-
uroporphyrin I derivatives are uroporphyrinogen I 
concentration dependent. These derivatives can only be 
formed when uroporphyrinogen I is accumulated to a certain 
concentration (approx. 1-2 ~M) and the formation is then 
proportional to the uroporphyrinogen I concentration. The 
peroxylation reaction has been shown to take place only at 
the acetic acid side-chains of porphyrinogen and not at the 
propionic acid side-chains. The peroxylation reaction can 
therefore take place whenever a porphyrinogen with an acetic 
acid substituent is accumulated. 
Oral charcoal therapy failed to reduce the porphyrins 
accumulated in vivo in a patient with CEP. Uroporphyrin I, 
the major porphyrin accumulating in CEP, was not excreted 
into bile and interruption of the enterohepatic circulation 
by binding porphyrins onto charcoal therefore does not 
benefit CEP. It may, however, be effective in the treatment 
of hepatic porphyrias in which the accumulated porphyrins 
are mainly excreted via the gut lumen. 
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CHAPTER 1 INTRODUCTION 
1.1. Haem Biosynthetic Pathway 
1.1.1. Porphyrins and the haem biosynthetic pathway 
Porphyrins are fully conjugated macrocycles consisting 
of four pyrrole rings linked by four methine bridges, 
designated as a, S, T and 0 (Fig. 1.1). The four pyrrole 
rings A, B, C and 0 allow eight side-chain sUbstituents to 
be attached at positions 1 to 8. The pattern of side chain 
sUbstitution determines the physical and chemical properties 
of each individual porphyrin. Porphyrins exhibit intense red 
fluorescence when exposed to long wavelength ultraviolet 
light near the 400 nm region due to the conjugated double-
bond structure. Porphyrinogens are the reduced form of 
porphyrin with 6 more protons. It does not fluoresce under 
UV light and porphyrinogens are easily oxidized back to the 
corresponding porphyrin in the presence of oxygen. 
Porphyrinogens, not porphyrins (except protoporphyrin), 
are the intermediates of the biosynthetic pathway which lead 
to the formation of haem, an iron-chelated tetrapyrrole. 
Haem is the prosthetic group for a number of proteins 
including haemoglobin, myoglobin, catalase, peroxidases, 
cytochromes P-450, etc. without haem, most essential 
biochemical pathways in the body could not function. Haem 
biosynthesis takes place in all cells that contain 
functioning mitochondria, mainly in the haemopoietic tissues 
and liver. Adult humans synthesize about 0.45 mmol of haem 
each day. Approximately 80% of haem synthesis occurs in bone 
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marrow where it is utilized for the production of 
haemoglobin. Most of the remaining haem synthesis occurs in 
the liver for the production of cytochrome P-450, catalase 
and various mitochondrial cytochromes (Elder, 1983). The 
pathway for haem biosynthesis in liver is the same as that 
in the bone marrow and other haem-forming tissues of the 
body. Although the intermediates of the pathway are 
identical, it has not been confirmed that the enzymes which 
catalyze these steps are structurally the same in various 
tissues. Thus, the properties of the enzymes in liver may 
differ from those in the bone marrow and other haem-forming 
tissues (Bloomer & Bonkovsky, 1989). 
The haem biosynthetic pathway is a series of 
irreversible reactions, consisting of eight discrete enzyme-
catalyzed steps (Fig. 1.2.). The first and the last three 
steps take place in mitochondria while the rest occur in the 
cytosolic compartment of the cells. The first step is the 
formation of 5-aminolaevulinic acid (ALA) from succinyl-
coenzyme A and glycine catalyzed by ALA synthase (ALA-S). 
The activity of ALA-S is the lowest in the pathway and is 
tightly controlled by the end product, haem. It is the rate-
limiting enzyme of the pathway. The ALA formed passes from 
the mitochondria into the cytoplasm of the cell where two 
molecules of ALA condense to form the mono-pyrrole 
porphobilinogen (PBG) catalyzed by PBG synthase (PBG-D). 
The next two steps act together to polymerize four molecules 
of PBG to form the cyclic tetrapyrrole, uroporphyrinogen 
III, catalyzed by two independent and sequential cytosolic 
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4 
enzymes. The first enzyme, hydroxymethylbilane synthase 
(HMB-S), also called PBG deaminase catalyzes the 
condensation of four PBG in a head-to-tail manner to form a 
symmetrical linear tetrapyrrole, hydroxymethylbilane (RMB). 
This is a highly unstable compound. The second enzyme, 
uroporphyrinogen III synthase (Uro'gen III-S) catalyzes its 
cyclization and rearrangement to uroporphyrinogen III, the 
first porphyrinogen in the pathway. The mechanism of 
rearrangement has not been fully elucidated. A spiral 
intermediate has been proposed (Battersby et al., 1978; 
1979). In the absence of Uro'gen III-S, HMB spontaneously 
cyclizes to uroporphyrinogen I. Uro'gen I and III are 
isomers, both have four acetic acid and four propionic acid 
side chain sUbstituents on the four pyrrole rings. Uro'gen I 
is a symmetrical structure, while Uro'gen III has its ring D 
inverted by the enzyme. Only Uro'gen III is the intermediate 
of the haem biosynthetic pathway and is utilized to form 
haem. Normally excess Uro'gen III-S activity is present, 
which greatly favours the formation of the type III isomer. 
In contrast to Uro'gen III, Uro'gen I and its metabolite, 
coproporphyrinogen (Copro'gen) I, are not biologically 
active and accumulate only under certain pathological 
conditions. The next step is the last step of the pathway in 
the cytoplasm. Uroporphyrinogen decarboxylase (Uro'gen-D) 
catalyzes the sequential removal of the four carboxyl groups 
of the acetic acid side-chains sUbstituents in Uro'gen I and 
III to form copro'gen I and III, through hepta-, hexa- and 
penta-carboxyl intermediates. Copro'gen I cannot proceed any 
further in the pathway and is excreted from the body. The 
5 
pathway now re-enters the mitochondria. Coproporphyrinogen 
oxidase (Copro'gen-O), catalyzes the oxidative 
decarboxylation of Copro'gen III to protoporphyrinogen 
(Proto'gen) IX by removal of the carboxyl group and of the 
two protons from the propionic acid groups on rings A and B 
to form vinyl groups. This step proceeds with the 
preliminary formation of harderoporphyrinogen, an 
intermediate with one vinyl group on ring A and a propionic 
acid group on ring B (Elder et al., 1978). 
Protoporphyrinogen IX oxidase (Proto'gen-O) catalyzes the 
oxidation of Proto'gen IX to protoporphyrin IX, the only 
porphyrin in this pathway, by removing 6 protons to form the 
highly conjugated double-bond structure. Although Proto'gen 
IX is readily auto-oxidized to protoporphyrin IX in vitro 
under aerobic condition at physiologic temperature and pH, 
an enzyme which catalyzes this oxidation has been identified 
in yeast, rat liver (Jacobs & Jacobs, 1982), human 
fibroblast, erythrocytes and leucocytes (Kappas et al., 
1983). Chemical evidence has also been obtained for its 
existence (Jackson et al., 1974; smith et al., 1976). The 
last enzyme in this pathway is ferrochelatase, which 
catalyzes the insertion of ferrous iron into protoporphyrin 
IX to form haem. 
The same pathway is also shared by other important 
compounds which carry out vitally crucial functions in 
living systems. vitamin B12 , a cobalt chelated corrin, 
branches off during the decarboxylation of Uro'gen III, and 
chlorophyll, a magnesium chelated chlorin, branches out 
6 
from protoporphyrin IX (Granick & Beale, 1978). 
1.1.2. The regulation of haem biosynthesis 
In normal circumstance, the synthesis of porphyrinogens 
and haem occurs in amount which is just sufficient to 
provide for the body's metabolic requirement. Only small 
amount of intermediates (less than 2.5% of the total amount 
of ALA used for haem) are lost from the pathway due to 
intracellar oxidation of porphyrinogens to their porphyrins 
or by diffusion out of cells (Elder , 1982). This 
balance is achieved by a precise regulation of the haem 
biosynthetic pathway. 
It is suggested that the regulation of the haem 
biosynthetic pathway has distinct features in different haem 
biosynthetic tissues (Sassa, 1976; Rutherford et ale 1979; 
Sassa & Urabe, 1979; Hoffman et al., 1980). In liver, the 
rate of haem biosynthesis is largely controlled by a 
negative-feedback effect of haem on ALA-S through three 
different mechanisms: (1) repression of the synthesis of new 
enzyme (Whiting & Granick, 1976); (2) interference with the 
transfer of newly synthesized enzyme from cytosol to 
mitochondria (Yamauchi et al., 1980); (3) direct inhibition 
of the enzyme activity (Scholnick et al., 1969). Several 
authors have proposed that the liver regulatory system is 
based on the existence of a free hepatic haem pool, in which 
haem combines with an unidentified aporepressor to adjust 
the synthesis of ALA synthase. Depletion of the regulatory 
pool allows ALA synthase to be synthesized at a greater 
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rate. As the regulatory pool is repleted, synthesis of the 
enzyme slows (Bloomer & Bonkovsky, 1989). The regulation of 
the enzyme synthesis by end-product repression makes 
effective short-term control possible because the turnover 
of ALA-S is very rapid (Elder,1983). other factors also 
influence hepatic ALA-S activity. The administration of 
glucose or other carbohydrates decrease the activity 
(Bloomer & Bonkovsky, 1989), while a wide range of drugs, 
such as barbiturates, certain steroids and some chemicals 
increase the activity (Elder & Path, 1982; Bloomer & 
Bonkovsky, 1989). The activity of ALA-S also appears to be 
increased as a compensatory effect in most of porphyrias, 
and this action is responsible for the excessive production 
of intermediary metabolites proximal to the enzymic blocks 
in these diseases (Hindmarsh, 1986). Another enzyme, HMB-S, 
is present at a similarly low activity in liver, which may 
also exert some control on the pathway. Thus under the 
conditions of increased ALA production, ALA and PBG 
accumulate and are excreted in excessive amounts. 
In erythroid cells although ALA-S, like in the liver, 
is under negative feedback control by haem, it does not 
appear to be the rate controlling enzyme. Ferrochelatase 
rather than ALA-S may be the rate - limiting enzyme (Kappas 
et al., 1983; Bloomer & Bonkovsky, 1989; Conder et al., 
1991). Haem regulates the uptake of iron by reticulocytes, 
thereby influencing the supply of iron for ferrochelatase 
(Ponka & Schulman, 1986). In the cell types other than liver 
and erythroid cells, the control of haem biosynthesis has 
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been little studied. It seems that the regulation is not 
similar to that in the liver (Kappas et al., 1983). 
Two general features of the pathway in vivo should be 
noted: 1. The substrate concentrations are far lower than 
the Michaelic constants of the corresponding enzymes. 2. The 
activity of HMB-S is much lower than the activities of the 
enzymes in the remainder of the pathway. Therefore, any HMB 
formed 1S likely to be converted immediately to 
protoporphyrin IX, and unstable porphyrinogen intermediates 
are therefore protected from oxidation to the corresponding 
porphyrins and their consequent loss from the pathway. In 
this case, theoretically, only when an enzyme activity is 
decreased to well below 50% of normal does substrate 
accumulate and can the relevant porphyrins be detected 
(Elder & Path, 1982). 
1.2. porphyrias 
Porphyrias are a group of genetic diseases in which 
enzyme defects in the haem biosynthetic pathway cause 
excessive accumulation of porphyrins and porphyrin 
precursors leading to clinical manifestations, mainly 
neurologic dysfunction and cutaneous photosensitization. 
Porphyrias may be classified according to the clinical 
presentation: acute porphyria associated with acute 
neurologic manifestations or cutaneous porphyria with skin 
photosensitization. They may also be classified according to 
the main source of excessive porphyrin production: hepatic 
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porphyria, in which the excessive porphyrin is mainly 
produced in liver or erythropoietic porphyria in which bone 
marrow is the main site of the excessive porphyrin 
production (Table 1.1). I 
1.2.1. Enzyme defects in porphyrias 
Haem synthesis in vivo is tightly controlled by haem 
itself. In spite of the presence of enzyme defects in the 
haem biosynthetic pathway, haem deficiency is neither a 
constant nor prominent feature of any type of porphyria, 
unless there is haemolysis (Elder, 1986). This is guaranteed 
by the regulation of the biosynthetic pathway: negative 
feedback control on ALA-S by haem and the far lower 
concentration of substrates than the Michaelic constant of 
the corresponding enzymes. When an enzyme activity is 
defective, the concentration of the corresponding substrate 
is increased by the negative feedback mechanism to such an 
extent that it is sufficient to overcome the enzyme defect 
in order to maintain a normal or near normal rate of the 
haem synthesis. As its intracellular concentration 
increases, the substrate may be lost from the pathway by 
diffusion out the cells or oxidation to porphyrin by 
molecular oxygen. The porphyrins may be trapped in cells, or 
excreted into urine or faeces depending on its chemical 
characteristic or solubility. The accumulation of excessive 
intermediates in the body may result in neurologic 
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Table 1.2. Enzyme Defects and Intermediates Accumulation in Human Porphyrias 
Defective Enzyme 
Activity 
ALA-Dehydrase 
(EC 4.2.1.24.) 
HMB-Synthase 
(EC 4.3.1.8.) 
Uro'gen 111-
synthase 
(EC 4.2.1.75.) 
Uro'gen-
Decarboxylase 
(EC 4.1.1.37.) 
Intermediates Accumulated 
Large amounts of urinary ALA and coproporphyrin, 
accompanied by elevated erythrocyte protoporphyrin. 
Large amount of ALA and PBG, accompanied by uroporphyrin 
isomers due to nonenzymic cyclization of PGB, in the urine. 
Large amount of uroporphyrin I and to a lesser extent of 
hepta-, hexa-, penta-carboxylic porphyrin I and 
coproporphyrin I in the urine; faecal coproporphyrin I 
is greatly increased; erythrocytes contain variable but 
increased uroporphyrin I and coproporphyrin I. 
Markedly increased uroporphyrin, heptacarboxylic porphyrin 
and to a lesser extent hexa-, and penta-carboxylic 
porphyrin and coproporphyrin in urine. Faecal porphyrins 
Disease 
ALA-D 
Deficiency 
Acute Intermit-
tent Porphyria 
Congenital 
Erythropoietic 
Porphyria 
Porphyria 
Cutanea Tarda 
(Table 1.2. continued) 
Copro'gen-
Oxidase 
(EC 1.3.3.3.) 
Proto'gen-
Oxidase 
(EC 1.3.3.4.) 
Ferrochelatase 
( EC 4. 99 . 1 . 1. ) 
are complex and contain high concentrations of 
isocoproporphyrin. 
Mainly coproporphyrin III in urine and faeces; ALA and 
PBG are increased during acute attack and accompanied 
by increased hepta-, hexa- and penta-carboxylic porphyrins. 
Protoporphyrin may also be elevated in faeces, but is 
less than coproporphyrin III. 
Faecal protoporphyrin and to a lesser extent 
coproporphyrin III are increased, accompanied by x-
porphyrin; urinary porphyrin is mainly coproporphyrin; 
ALA and PBG increased during acute attack. 
Increased free protoporphyrin in erythrocytes, plasma, 
bile and faeces. 
Hereditary 
Coproporphyria 
Variegate 
Porphyria 
Erythrohepatic 
Protoporphyria 
Table 1.1. Clinical Manifestation and Excess Porphyrin Source porphyrias 
Disease Acute Neurologic cutaneous Porphyrin Source 
Attacks Lesions 
ALA-D Deficiency + hepatic 
Acute Intermittent Porphyria + hepatic 
Congenital Erythropoietic Porphyria + erythropoietic 
Porphyria cutanea Tarda + hepatic 
Hereditary Coproporphyria + + hepatic 
Variegate Porphyria + + hepatic 
Erythrohepatic Protoporphyria + erythropoietic and hepatic 
disorders, skin lesions, or other symptoms, thus causing 
porphyrias. Each particular enzyme defect in the pathway, 
except ALA-S, leads to a certain pattern of intermediates 
accumulation, to cause specific porphyria (Table. 1.2.). In 
the case of the defect in ALA-S, the accumulated substrates, 
succinate and glycine, are intermediates for several 
biochemical pathways, so conventionally it is not considered 
as porphyria (Strake et al., 1990). Although the patterns of 
excreted urinary or faecal porphyrins are adequate for the 
differentiation of the porphyrias, the assay of enzyme 
activities may also be necessary, especially in the 
detection of latent carriers. 
The existence of latent porphyria suggests that the 
enzyme abnormality by itself may not be sufficient to cause 
expression of the disease. Moreover, biochemical and 
clinical manifestations in one patient may vary considerably 
over time, or different individuals may respond differently 
to the similar enzyme deficiency. Thus, other factors must 
combine with the enzyme defect to produce biochemica] 
manifestations of the diseases (Elder & Path, 1982; Bloomel 
& Bonkovsky, 1989). The known factors include increase~ 
requirement for haem biosynthesis (Bloomer & Bonkovsky. 
1989), certain exogenous chemicals, some drugs, hormones an( 
alcohol. 
1.2.2. Clinical manifestation of porphyrias 
Porphyrias mainly manifest in two clinical syndromes: 
(1) acute attacks which manifest as dysfunction of central 
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peripheral and autonomic nervous system. (2) skin lesions 
due to photosensitization by increased porphyrin 
accumulation. 
Acute attacks of porphyria occur in ALA-D deficiency 
porphyria (also called plumboporphyria), acute intermittent 
porphyria (AlP), hereditary coproporphyria (HCP) , and 
variegate porphyria (VP). Patients with any of these acute 
porphyrias may generally enjoy good health, but are at the 
risk of developing severe neurovisceral attacks. The attacks 
are transient and most commonly followed by complete 
remission. They may, however, prove fatal. Repeated attacks 
are common. The attacks are clinically very similar in each 
of these disorders. The commonest symptom is severe lower 
abdominal pain, often colicky, lasting for hours to days. 
Vomiting may occur, and constipation is usual. These reflect 
the involvement of the autonomic nervous system. other 
symptoms and signs are protean and include mental 
disturbances, muscular weakness which may progress to 
quadriparesis and respiratory paralysis, hypertension, 
tachycardia, etc. Residual paralysis, hypertension and renal 
failure are long-term sequelae. Patients with HCP and VP ma~ 
also present with cutaneous photosensitization. During ar 
attack, despite the differing sites of the defects in the 
haem biosynthetic pathway, all patients excrete a massivE 
excess of porphyrin precursors ALA and PBG (except ALA-I 
deficiency, in which only ALA is increased) in their urine l 
while during remission the levels of ALA and PBG are usuall~ 
normal (Elder, 1983; Hindmarsh, 1986; Bloomer & Bonkovsky 
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1989; Moore et al., 1990}. 
Acute attacks are often precipitated by drugs such as 
barbiturates, sulphonamides, oral contraceptives and enzyme 
- inducing anticonvulsants and antidepressants. Alcohol 
consumption, endogenous and exogenous steroid hormonal 
factors, cigarette smoking, infections and strict dieting or 
fasting can also trigger acute attacks (Elder, 1983; Moore 
et al., 1990). 
Although there have been many studies on the 
pathogenesis or mechanism of the neurological dysfunction 
due to altered haem synthesis, the situation is still not 
clear. Some hypotheses have been proposed, and two of most 
attractive ones have been intensively investigated (Bloomer 
& Bonkovsky, 1989; Moore et al., 1990; Straka, et al., 
1990). The first is that the neurologic manifestations are 
caused by ALA and/or PBG. Either ALA or PBG, or both may be 
directly neurotoxic. This hypothesis is supported by the 
fact that acute attacks of porphyria with neurologic 
dysfunction do not occur unless ALA and PBG are over-
produced, and during remission the urinary excretion of ALA 
and PBG return to normal. ALA may be more important than PBG 
in this aspect, because in patients with acute attack due tc 
ALA-D deficiency PBG is not over-produced (Laiwah et al., 
1987; Bloomer & Bonkovsky, 1989). Also in the patients witt 
lead poisoning where ALA-D is depressed the clinicaJ 
manifestations resemble AIP. The second is that neurologica: 
manifestations result from haem deficiency. Haem deficienc~ 
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in neurons may cause inadequate concentration of 
mitochondrial cytochromes, resulting in the death of neuron 
due to serious decrease in synthesis of ATP, or increase the 
susceptibility of neurons to other injuries including toxic 
effects. Haem deficiency in hepatocytes plays a key role in 
the over-production of ALA and PBG. It also alters the 
metabolism of tryptophan, the precursor of 5-
hydroxytryptamin (serotonin), which has a variety of effects 
on the nervous system. Experiments showed that depletion of 
hepatic haem in rats reduced hepatic tryptophan pyrrolase 
activity which caused elevated levels of tryptohan and 5-
hydroxy tryptophan in the brains of the animals (Litman & 
Correia, 1986). In human being it was reported that 
overexcretion of 5-hydroxyindoleacetic acid, the end product 
of serotonin metabolism was found in a few patients with 
symptomatic acute porphyria (Ludwig & Epstein, 1961). 
Therefore haem deficiency may play a role in the 
pathogenesis of the acute porphyric attack (Laiwah et al., 
1987; Bloomer & Bonkovsky, 1989; Moore et al., 1990; Straka 
et al., 1990). 
Photocutaneous lesions of porphyrias do not occur in 
ALA-D deficiency and AlP, but may be found in all the other 
porphyrias. In the patients with HCP and VP, photocutaneous 
lesions are not a constant manifestation, while in the 
patients with PCT, CEP and EHP, it is virtually always the 
major clinical symptom. The abnormal skin photosensitivit} 
usually manifests in two distinguishable morphologic 
patterns. In EHP, the skin lesions is characterized by acutE 
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photo-toxicity reaction in the sun-exposed area. The typical 
acute reaction begins within several minutes' exposure to 
sunlight with itching or stinging pain, sometimes followed 
by crusting and petechiae. Vesicles may occur on the face 
and hands. After repeated attacks, the skin may become 
thickened, waxy and pitted with small circular or linear 
scars, especially over the bridge of the nose, around the 
mouth, and over the knuckles. Cutaneous fragility, large 
bullae and mutilation are very rare in EHP. While in other 
cutaneous porphyrias such as PCT, CEP, VP and HCP, the skin 
lesions are fundamentally similar, although their severity 
varies, and develop in a different morphologic array from 
EHP. Burning, itching, stinging of sun-exposed skin or 
development of erythema and edema are rare and may only 
occur in individuals with very large porphyrin accumulations 
in their skin or plasma, or those subjected to prolonged 
intense light exposure. The most prominent abnormality is 
increased fragility of sun-exposed skin, from which the 
epidermis sheers away with minor trauma to leave raw 
erosions and blistering eruptions. Subepidermal bullae are 
frequent, and erosions of various sizes form at the junction 
of the epidermis with the dermis and heal slowly with 
crusting, scaring and milia formation. Cumulative damage in 
severe cases can result in cicatricial deformities of 
eyelids and lips, acral osteolysis of digits, dystrophic 
nails, and destruction of the cartilage of the nose and 
ears. Scaring alopecia, mottled or diffuse 
hyperpigmentation, and photo-onycholysis with temporary OI 
permanent loss of nails may occur. Hypertrichosis of the 
18 
eyebrows temples, and sides of the face are common. In CEP, 
the teeth usually show characteristically pink fluorescence 
with ultraviolet illumination. They may also appear reddish-
brown in colour in normal light due to porphyrin deposition 
(Poh-Fitzpatrick, 1982; Elder, 1983; Bloomer & Bonkovsky, 
1989). The pathogenesis or mechanism of the cutaneous lesion 
and the reason of existing two morphologic patterns of the 
cutaneous lesion are discussed in section 1.2.4 .. 
1.2.3. Molecular genetics of porphyrias 
All porphyrias are due to enzyme defects in one of the 
steps which convert ALA to haem and are encoded by a single 
autosomal gene. Each gene is expressed in all cells which 
are capable of haem biosynthesis. The only exception is 
sporadic PCT which is probably not a genetic disease. AlP, 
PCT, HCP, VP and EHP are inherited as autosomal dominants 
while ALA-D deficiency and CEP are autosomal recessive 
traits. Two very uncommon porphyrias are inherited as 
homozygous autosomal dominant trait: hepatoerythropoietic 
porphyria (HEP, Uro'gen-D defect) and harderoporphyria 
(Copro-O defect). Like most other inherited disorders 
porphyrias also show genetic heterogeneity. Different 
mutations may produce the same phenotype (Elder, 1986). For 
example, in AlP which is the most thoroughly studied 
porphyria at the molecular level, four distinct allelic 
mutations for HMB-S have been demonstrated (Mustajoki ~ 
Desnick, 1985; Desnick et al., 1985). In PCT, a number of 
different mutations at the uro'gen-D locus have beer 
identified (Verneuil, 1986). Evidence also shows that somE 
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mutations which decrease the activity of cytosolic enzymes 
in the liver may not always be found in erythrocytes, 
examples include some patients with AlP (HMB-S deficiency) 
and peT (Uro'gen -D deficiency) (Elder et al., 1980; Desnick 
et al., 1985). The gene defects in the other porphyrias have 
not yet been characterized. Suggestions have been made that 
two distinct genes may encode ALA-S for hepatic and 
erythropoietic sources (Grandchamp & Nordmann, 1988; Moore 
et al., 1990). These advances and further studies will help 
us to improve the understanding of haem biosynthesis and the 
pathogenesis of the porphyrias. The identification of 
genetic defects in the porphyrias will also provide a new 
tool for the most accurate diagnosis of porphyrias, 
especially in latent carriers. 
1.2.4. The possible mechanism of the photosensitivity 
in porphyrias 
Porphyrinogens, the true intermediates of the haem 
biosynthetic pathway (apart from protoporphyrin), do not 
induce photosensi ti vi ty. However, the accumulated 
porphyrinogens due to enzyme deficiencies, are susceptible 
to oxidation to their corresponding porphyrins in presence 
of oxygen in vivo. The excess porphyrins which are deposited 
in the epidermal layer or are circulating in the dermal 
blood vessels absorb light, entering an "excited state". 
These excited porphyrins tend to return to the ground state 
by losing their energy through light emission (fluorescence) 
or transferring electrons to molecular oxygen to forn 
singlet oxygen and possibly other free radicals. Singlet 
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oxygen in turn damages tissues through several mechanisms 
including oxidation of membrane lipids, cross-link of 
proteins, and oxidative damage to nucleic acids, with 
consequent interference of proper functions of cellular 
activities or organelles (Bloomer & Bonkovsky, 1989; Elder, 
1990; Straka et al., 1990). 
Different porphyrins appear to cause distinct 
photocutaneous symptoms, possibly due to their different 
physical and chemical properties (Bloomer & Bonkovsky, 1989; 
Straka et al., 1990). In experimental models, hydrophobic 
protoporphyrin is shown to accumulate predominantly in 
mitochondria and inserts into biological membranes, while, 
in contrast, hydrophilic uroporphyrin accumulates 
predominantly in lysosomes and is not associated to any 
significant degree with membranes (Sandbaerg et al., 1982). 
This may be the reason why there are different 
photocutaneous symptoms in porphyrias. For example, in 
erythrohepatic protoporphyria (EHP) where protoporphyrin 
accumulates, the photocutaneous symptom is characterized by 
acute erythema, burning and itching of light exposed skin, 
particularly the face and the back of the hands. In 
porphyria cutanea tarda where uroporphyrin accumulates, the 
photocutaneous symptom is characterized by increased 
fragility of light exposed skin, particularly where bullous 
lesions and erosions occur (Bloomer & Bonkovsky, 1989; 
Straka et al., 1990). 
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1.3. Analytical Techniques for the study of Porphyrin 
Metabolism 
1.3.1. spectrophotometry 
1.3.151. UV absorption spectrometry 
Porphyrins display a characteristic UV absorption 
spectra, consisting of a major band at about 400nm which is 
called the "Soret" band, and ,four smaller absorption bands 
between 500 and 630nm in neutral solvents which are called 
the "etio" spectrum. The Soret band generally has 10 to 15 
times greater absorption (molar extinction coefficient of 2 
to 5 x 105 ) than the next major band, which occurs at around 
500nm. with the formation of a porphyrin dication in diluted 
aqueous Hel, or the formation of metalloporphyrins, the four 
small bands of the etio spectrum are replaced by two bands 
(Smith, 1975Ai Kappas et al., 1983). The Soret band is 
therefore, the choice for spectrophotometric determination. 
The existence of Soret band is due to the fully conjugated 
nucleus of the macrocycle, therefore, porphyrinogens do not 
have a Soret band, but show very weak absorption at 220-240 
nm (Smith, 1975Ai Mauzerall, 1978i Lim et aI, 1988). 
1.3.1.2. Fluorescent spectrometry 
Porphyrins are readily excited by light at around 395-
420 nm and emit intense red fluorescence at about 589-620 
nm, depending on molecular structure. Spectrofluorometric 
methods provide much more sensitivity and specificity thar 
UV absorption spectrometry (Kappas et al., 1983). 
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Porphyrinogens do not fluoresce. 
Metalloporphyrins generally fluoresce at shorter 
wavelength than the corresponding free porphyrins, and need 
higher energy for excitation. The fluorescence of many 
metalloporphyrins is strongly solvent-sensitive and 
therefore excited state energies are solvent-dependent (Hopf 
& Whitten, 1975). However, not all metalloporphyrins are 
fluorescent. Haem, protoporphyrin chelated with Fe (II), and 
porphyrins chelated to Mn, Co, Cu and Ag which are 
paramagnetic metals do not fluoresce, while those chelated 
to Zn, Mg and Pb which are diamagnetic metals do (Hopf & 
Whitten, 1975; Kappas et al., 1983). 
1.3.2. Chromatography 
1.3.2.1. Thin-layer chromatography 
Thin-layer chromatography (TLC) is a very widely used 
technique for separating porphyrins. The separation is most 
commonly carried out on silica gel plates with a mixture of 
polar and non-polar organic solvents such as chloroform, 
dichloromethane and carbon tetrachloride mixed with ethyl 
acetate and ethanol as the developing solvents. Practically 
all of the common classes of porphyrins methyl esters from 
uroporphyrin to protoporphyrin have been separated by TLC. 
The porphyrin methyl esters migrate according to the number 
of carboxyl groups. The lesser carboxyl groups they have, 
the faster they move on TLC plate. The porphyrin methyl 
esters separated by TLC are easily recovered by removal of 
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the adsorbent band from the plate and extracting the 
porphyrin methyl ester from the supporting material with a 
solvent mixture slightly more polar than that used for 
developing the chromatography. The separation can be 
improved by repeating the development of the plate or by 
two-dimensional TLC (Elder, 1971Ai Fuhrhop & Smith, 1975A). 
Free porphyrin carboxylic acids can also be separated by 
TLC, but the developing solvent system is more complex 
(smith, 1975B). Although TLC is less suitable to the 
separation of the porphyrin isomer it is still a useful 
technique for the screening of porphyrins and for small 
scale preparative isolation of porphyrin methyl esters. 
1.3.2.2. High-performance liquid chromatography 
Porphyrin analysis has been greatly improved by the 
development of HPLC which provides more efficient 
separation, more accurate identification and quantitation of 
porphyrins. Porphyrins can be separated either as methyl 
esters by normal-phase chromatography (also called 
absorption chromatography) or as free acids by reversed-
phase or reversed-phase ion-pair chromatography. The 
separation of porphyrin methyl esters by normal-phase 
chromatography was the first attempt of separating porphyrin 
by HPLC (Cavaleiro et al., 1974) and the principle is 
similar to that of TLC. The porphyrin methyl esters are 
sequentially eluted with increasing number of ester side-
chains, thus protoporphyrin dimethyl ester is the first and 
uroporphyrin octamethyl ester the last to be eluted (Lim et 
ale 1988). Although the resolution, speed of analysis and 
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reproducibilities have substantially improved with the use 
of microparticulate (3-10 ~m) silicas, and aminopropyl-
bonded silica columns, there are disadvantages associated 
with separation of porphyrin methyl esters by HPLC. 
Porphyrins have to be converted into esters for analysis. 
The esterification procedure is time consuming and may lead 
to undesirable complications. Porphyrin methyl esters may 
partially hydrolysed on the column and will therefore not be 
eluted from the silica column and remain undetected. Metal 
chelates and mixed methyl-ethyl esters may form during the 
derivatization, which will lead to errors in identification 
and quantitation (Lim, 1991). However, the esterification 
procedure provides a much cleaner porphyrin extract 
(especially from faeces) for HPLC analysis, and the higher 
capacity of normal-phase columns can be used for preparative 
separation. 
The above problems can be avoided by separating the 
porphyrins as free acids. Ion-exchange HPLC was tried with 
little success due to poor column efficiency and resolution 
(Evans et al., 1975). Reversed-phase ion-pair chromatography 
achieved the separation of free porphyrins with two to eight 
carboxylic acid groups, the elution order is the more polar 
porphyrin, uroporphyrin, first followed by hepta-, hexa-, 
penta-carboxylic acid porphyrins, coproporphyrin and 
protoporphyrin. This system, however, has its limitations, 
such as the limited separation of type I and III isomers 
(only occurs for coproporphyrins) and the requirement for a 
higher column temperature and the re-equilibration time 
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between analyses is long (Rossi & Curnow, 1986). 
Reversed-phase HPLC (usually on ODS columns) with 
aqueous buffer-organic modifier as eluents has shown great 
potential for porphyrin separation and has provided a very 
powerful tool for porphyrin analysis. The most commonly used 
systems are phosphate buffer with methanol or acetonitrile 
(Englert et al., 1979i Ford et al.,1981i Sakai et al., 1983 i 
Schreiber et al.,1983i Johnson et al.,1988), and ammonium 
acetate buffer with methanol and/or acetonitrile as mobile 
phases (Lim et al.,1988). The use of ammonium acetate buffer 
has many advantages. Ammonium acetate buffer provides the 
right pH for porphyrin separation. It is highly soluble in 
aqueous methanol and acetonitrile, allowing high molar 
concentrations to be used. Therefore, it has high buffering 
capacity to allow the acid extracts of porphyrin free acids 
to be injected directly onto the reversed-phase column 
without damaging it. It is also a good masking agent for 
residual silanol groups on reversed-phase columns thus 
improving the resolution and the peak shape. Ammonium 
acetate is relatively volatile, and can be easily removed if 
necessary. The retention mechanism is mainly hydrophobic 
interaction, but ion-pair mechanism may also play a role 
(Lim & Peters, 1984). The elution order of the porphyrins is 
from polar to non-polar. Gradient elution using ammonium 
acetate buffer with a mixture of acetonitrile and methanol 
as organic modifiers can simultaneously separated porphyrins 
with two to eight carboxylic acid groups, including the 
naturally occurring type I and type III isomers (Li et al., 
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1989). While using the same system under different isocratic 
elution conditions, the separation of four coproporphyrin 
isomers, four penta- carboxylic acid porphyrin III isomers, 
five penta'gen isomers, six hexa'gen III isomers, and four 
hepta'gen III isomers can be achieved (Lim,1991). Uro I,ll 
and III isomers can be completely separated, but the 
resolution of isomer III and IV still remains 
unsatisfactory. The use of base deactivated silica (BDS) and 
polymer-based reversed-phase columns with ammonium acetate-
methanol/acetonitrile system can further improve the 
separation of certain isomers. 
1.3.3. Mass spectrometry 
Mass spectrometry is a valuable technique which can 
provide accurate information concerning the molecular mass, 
molecular composition, and a number of other distinctive 
features (Smith, 1975A). Thus it has played a very important 
role in the structure determination of all the new 
porphyrins discovered in recent years. In this thesis the 
molecular weights of the new porphyrins are determined by 
liquid secondary ion mass spectrometry (LSIMS). The 
principle of LSIMS is that porphyrin methyl esters gain one 
proton to give a molecular ion (MH+) during the bombardment 
by caesium ion (Cs+) beam. The ratio of mass to charge (m/z) 
of this ion gives the exact molecular weight. The naturally 
occurring porphyrin free acids have very low volatility and 
cannot be readily analysed directly by MS (Jackson, 1989). 
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1.4. Aims of study 
The main objective of this thesis is to study in detail 
porphyrin metabolism in patients with CEP. The following 
areas are covered: 
1. To investigate whether oral charcoal treatment is 
effective for reducing porphyrin levels in patients with 
CEP. 
2. To isolate, identify and characterize new porphyrin 
metabolites in the urine and blood of patients with CEP. 
3. To elucidate the origin, mechanism of formation and 
biological significance of the new porphyrin metabolites. 
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CHAPTER 2 
EFFECT OF ORAL CHARCOAL TREATMENT IN A CASE OF 
CONGENITAL ERYTHROPOIETIC PORPHYRIA 
2.1. Introduction 
Congenital erythropoietic porphyria (CEP) , also known 
as erythropoietic porphyria, congenital porphyria or 
Gunther's disease, is an extremely rare disease. It was the 
first porphyria to be described in 1874 by Schultz (1874) 
and one patient with CEP had been studied over 25 years in 
the early 20th century by Gunther. Since then less than 100 
cases have been reported (Marver & Schmid, 1972; Nordmann & 
Deybach, 1982; Goldberg et al., 1987; Bickers & Patrick, 
1987) . 
Congenital erythropoietic porphyria is transmitted in 
an autosomal recessive manner. The enzyme defect lies at the 
level of Uro'gen III-S. The predominant site of the 
metabolic abnormality is the erythropoietic system. The 
enzyme defect leads to a highly abnormal accumulation of 
porphyrins in bone marrow, peripheral blood, and other 
organs. These reflect the three main manifestations of CEP: 
chronic photo-dermatitis with photosensitivity, massive 
porphyrinuria, and haematological abnormalities. The 
neurological symptoms observed in the acute porphyrias do 
not occur in this type of porphyria. A similar disease can 
also occur in bovines (Rimington, 1955; Rimington & with, 
1973; Miyagi et al., 1976; Moore et al., 1978). 
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The onset of CEP usually occurs at birth or during 
early infancy, but late onset does happen occasionally 
(Kramer et al., 1965; Weston et al., 1978). The first 
symptom in infants suggesting CEP is often pink to dark 
brown staining of the diapers due to large amounts of 
porphyrins in the urine. The characteristic cutaneous 
photosensitivity causes the most mutilating skin lesions of 
the porphyrias. It presents as vesicules or bullae following 
sun exposure, mainly on the face and the back of the hands. 
;. The vesiculae contain a serous fluid which may exhibit a red 
fluorescence under ultraviolet light. Subepidermal lesions 
progress to crusted erosion and secondary infections which 
heal slowly with scarring and either hyperpigmentation or 
more rarely, hypopigmentation. Repetitive damage and 
infections may lead to severe mutilation of aural and nasal 
cartilage, and digits, as well as functional limitation. All 
exposed or already affected areas of the skin of patients 
remain more sensitive to slight injury, and a diffuse 
thickening of the skin is a common feature after several 
years. Hypertrichosis appears in most patients but alopecia 
may also occur. Erythrodontia (red-stained teeth) is a 
common finding in both deciduous and permanent teeth and it 
is pathognomonic of CEP. The eyes may be affected in the 
form of severe ulcerations, ectropion or cataract (Kappas et 
al., 1989). 
Haemolysis frequently occurs and it is a striking 
feature of CEP. In most patients, the anaemia is only slight 
and is well-compensated by enhanced erythrocyte production. 
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However, in some cases anaemia may be severe and sometimes 
life threatening, requiring multiple transfusions (Nordmann 
& Deybach, 1982). The signs of heightened erythropoiesis 
including hyperplastic red bone marrow, reticulocytosis, and 
increased plasma iron turnover may be found. Erythroblasts 
are found in peripheral blood. The fragility of the 
erythrocytes is apparently increased, and the life span is 
often shorter than normal. The erythrocytes fluoresce bright 
red under ultraviolet light and the bones are reddish-brown, 
discoloured by accumulated porphyrins. Pronounced 
splenomegaly is observed in almost every patient (Ippen & 
Fuchs, 1980; Nordmann & Deybach, 1982). 
The urine always contains greatly increased 
uroporphyrin and to a lesser extent coproporphyrin. Small 
amounts of hepta-, hexa- and penta-carboxylic acid 
porphyrins are also excreted. Though the type I isomers 
predominate, uroporphyrin III is also definitely increased 
in all patients (Wintrobe et al., 1981). Urinary excretion 
of 5-aminolevulinic acid and porphobilinogen is all normal. 
Faeces contain large amount of coproporphyrin I, with only 
small amounts of uroporphyrin I and protoporphyrin within 
normal range. The plasma also contains excessive 
uroporphyrin I and coproporphyrin I. Erythrocytes contain 
variable but always increased concentrations of uroporphyrin 
I and coproporphyrin I, and protoporphyrin is usually normal. 
The treatment of CEP includes limiting exposure to 
sunlight, avoiding trauma to the skin, and treatment of skin 
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infection. B-Carotene and barrier creams can be used to 
prevent the effects of light on the skin. Transfusion of 
packed erythrocytes can suppress the endogenous 
erythropoiesis and reduce the production by negative-
feedback control, as well as correct the anaemia. Haematin 
may be worth trying to avoid the risk of multiple 
transfusions. Splenectomy can reduce the haemolysis, lessen 
the porphyrin excretion, and diminish the skin 
manifestations. There is little evidence, however, for 
significant long-term improvement. Therefore, no efficient 
therapy has been established for this disease. (Ippen & 
Fuchs, 1980; Nordmann & Deybach, 1982; Bloomer & Bonkovsky, 
1989) . 
It has been suggested that oral charcoal may be used to 
reduce the excessive circulating and tissue porphyrin levels 
(Pimstone et al., 1987) in HEP and CEP (Tishler & Winston, 
1990). The evidence, however, is inconclusive. This chapter 
describes the detailed study of a case of CEP following 
treatment with oral charcoal to assess the effectiveness of 
this form of treatment for CEP. 
2.2. Case Report 
The patient who is now aged 23 years old, was found to 
have congenital erythropoietic porphyria at 2 months of age 
when he presented with persistent neonatal jaundice, 
haemolysis and cutaneous photosensitivity. There was no 
history of consanguinity. Erythrocyte Uro'gen III-S activity 
was reduced to 19% of normal in the subject and to 
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approximately 50% in both parents and in his sister (Wright 
& Lim, 1983) consistent with autosomal recessive inheritance 
and also indicating that the sister was a carrier. He was 
treated with intermittent blood transfusions and splenectomy 
was carried out at the age of 7 years. Regular medication 
also included ascorbic acid, B-carotene, folic acid, 
penicillin after the splenectomy, and avoidance of sunlight. 
From the age of 10 years he received regular subcutaneous 
infusions of des ferri ox amine at night. Despite these measures 
he continued to have extensive photomutilation of the hands 
and face, with shortening of the digits, and when 20 years 
old he complained of pain in the spine and sternum and was 
found to have compression fractures of 2 vertebrae. 
Treatment of osteoporosis with clodronate (dichloromethylene 
bisphosphonate) was also carried out (Pullon et al., 1991). 
At the time when this study was performed he was also on a 
more intensive regime of blood transfusions (2-3 units at 
approximately 4 weeks intervals) which raised the 
haematocrit from a mean of 0.24 to 0.36%. 
2.3.Experimental 
2.3.1. Material and reagents 
Ammonium acetate, glacial acetic acid, 
trichloroacetic acid, I 2 , concentrated HCI, concentrated 
NaHC0 3 , NaOH, ethylenediaminetetraacetic acid 
(EDTA), Triton X-100, MgCI 2 , dimethyl sulphoxide 
(DMSO), diethyl ether and chloroform were AnalaR grade from 
BDH Chemicals (Poole, Dorset, U.K.). Acetonitrile and 
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methanol were HPLC grade from Rathburn Chemicals 
(Walkerburn, Peeblesshire, Scotland). Porphobilinogen and 
uroporphyrin were from Sigma Chemical Co. (Poole, Dorset). 
Tris(hydroxymethyl)aminoethane (Tris) was obtained from 
Boehringer Mannheim GmbH. (F.R.G.). 
2.3.2. Charcoal treatment procedure 
After an 8-week "run-in" period with his usual 
maintenance regime, activated charcoal (Medicoal, Lundbeck, 
Farillon Ltd) was ingested as an aqueous suspension taken 
through a straw, in 5 divided doses to a total of 50g daily 
for 3 weeks. Blood samples for porphyrins, haemoglobin, 
haematocrit, electrolyte and creatinine, and 24 hour urine 
collections, were obtained weekly, and blood samples were 
obtained also before and after blood transfusions throughout 
the ll-week study period. During the first 24 hours of 
administration of charcoal, blood samples were obtained at 3 
hour intervals. Stool samples were obtained weekly. 
The quantity of porphyrins and the activity of HMB-S 
and Uro'gen III-S were analysed by HPLC procedures (Wright & 
Lim, 1983; Lim et al., 1988), other measurements were done 
by standard laboratory methods. 
2.3.3. Duodenal porphyrins 
After an overnight fast, a triple-lumen tube was passed 
under fluoroscopic control. Isotonic saline (0.15 M) 
solution adjusted to pH 7 with 0.1 M NaOH and containing 
[ 14 C] polyethylene glycol (PEG) as a non-absorbable marker 
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was infused at a rate of 10 ml/min through a port in the 
proximal duodenum. After equilibration for 1h, duodenal 
content was aspirated at 1 ml/min from proximal and distal 
ports 15 cm apart for 3 consecutive 30 min periods. 
Porphyrin content in the aspirates was measured by HPLC, and 
levels/min at the distal aspiration port were obtained from 
the product of porphyrin concentration and flow rates, 
calculated by established methods based on differences in 
the concentrations of PEG in the perfusate and aspiration 
sample (Cooper et al., 1966; Pimstone et al., 1987). 
The aspirate was acidified with concentrated HCI (0.5 
ml HCI to 5 ml of sample) to dissolve any precipitated 
calcium salts which absorb porphyrins. After centrifugation 
the sample was ready for HPLC analysis. 
2.3.4. Isolation of erythrocytes and plasma 
Heparinized blood, 10 ml, was centrifuged at 2000 g for 
10 min. The plasma was transferred to a clean tube. The 
buffy coat leucocytes was removed and discarded with a 
Pasteur pipette. The erythrocytes was washed three times 
with ice cold 0.15 M NaCI and centrifugation at 2000 g for 
10 min after each wash. The plasma and packed red cells were 
stored at -20oC if not used immediately. 
2.3.5. Sample preparation for HPLC separation 
2.3.5.1. porphyrins in urine 
Urine, 24 h collection, was collected in plastic 
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container with boric acid as preservative. Random urine 
samples were collected into universal bottles. The samples 
were kept at -30oC in the dark until use. All urine samples 
were treated with concentrated HCI (5 ml per 100 ml 
urine) to dissolve any precipitated porphyrins and to 
prevent the formation of metalloporphyrins. 
2.3.5.2. Extraction of porphyrins in faeces 
Faeces, 25-50 mg, was placed in a graduated centrifuge 
tube for analysis and a larger sample (approx. 250 mg) was 
put into a suitable vessel to be dried down for quantitative 
calculation. concentrated HCI, 1 ml, was added to the 
centrifuge tube and vortex-mixed until the particles 
disintegrated. The sample was allowed to stand for 5 min 
with occasional vortex-mixing. Then ether, 3 ml, was added 
and the contents of the tube were thoroughly vortex-mixed 
to give an emulsion followed by addition of 3 ml of water. 
To avoid undue degradation of protoporphyrin, the water must 
be added within 10 min of the acid addition. After 
centrifugation, the upper ether layer containing chlorophyll 
derivatives and carotenoids, and the pad of insoluble 
material at the interface were discarded. The lower acidic 
aqueous layer contained the porphyrins. This phase was 
flushed with N2 for 10-20 min to remove any residual ether 
which may interfere with the HPLC analysis. The volume was 
recorded and the solution was now ready for HPLC analysis 
(Rossi & Curnow, 1986). 
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2.3.5.3. Direct esterification porphyrins in faeces 
Wet faeces (0.5 g) was thoroughly mixed with 5 ml of 
10% (v/v) sUlphuric acid in methanol. The mixture was 
refluxed for 20 min or left standing overnight in the dark 
at room temperature. The mixture was then thoroughly mixed 
and centrifuged at 2000g for 10 min. The supernatant was 
transferred to a separating funnel and the residual was 
washed with 10% sulphuric acid in methanol with 
centrifugation. The supernatants were combined, and the 
resulting porphyrin methyl esters were extracted with 
chloroform. The extractant was washed with saturated aqueous 
NaHC03 and then sufficient water. After filtering through a 
filter paper, the organic solution was evaporated to dryness 
at about 40°C under N2 . 
The porphyrin methyl esters were either separated by 
TLC or hydrolysed with 25% HCl for 72 h in the dark at room 
temperature for HPLC analysis. 
2.3.5.4. Extraction of porphyrin from erythrocytes 
The packed erythrocytes (25 ~l) were lysed by mixing 
with 75 ~l of distilled water in a 10 ml centrifuge tube. 
The red cell haemolysate was then vortex-mixed for 1 min 
with 100 ~l of 20% TCA/DMSO (1:1, v/v) containing 
mesoporphyrin as internal standard. The mixture was stood at 
room temperature for 5 min with occasional vortex-mixing and 
then centrifuged at 2,000 g for 10 min at 40 C in a CoolSpin. 
The supernatant was transferred to a clean tube for HPLC 
analysis. 
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2.3.5.5. Extraction of porphyrin from plasma 
Plasma (100 ~l) was thoroughly vortex-mixed for about 2 
min with 100 ~l of 20% TCA/DMSO (1:1, v/v) containing 
mesoporphyrin as internal standard in an Eppendorff 
centrifuge tube. The mixture was centrifuged for 3 min at 
10,000g and the supernatant was transferred into a clean 
tube for HPLC analysis. 
2.3.5.6. Assay of the activities of HMB-8 and Uro III-8 
The method described by Wright and Lim (1983) was 
used. Packed RBC, 30 ~l, was added to 1.4 ml of O.OS M Tris-
HCI buffer, pH 8.2S, containing 74 ~M MgCl 2 and 0.1% Triton 
X-100. After mixing, the solution was heated at S6 0 C for 1 h 
to deactivate Uro'gen III-S. The mixture was cooled to room 
temperature and 3 ~l of fresh packed RBC was added. The 
mixture was pre-incubated at 37 0 C for S min and the 
reaction was started by adding SO~1 of PBG (7.4 ~M) as 
substrate. The incubation was continued for a further 30 min 
at 37 0 C in the dark. The reaction was stopped by adding 1.S 
ml of 10%TCA containing O.S% 12 (w/v). After centrifugation 
the supernatant was subjected to for HPLC analysis. 
2.3.6. High-performance 
porphyrins 
liquid chromatography (HPLC) of 
A varian Associates (Walton-on-Thames, Surrey, U.K.) 
Model SOOO liquid chromatography with a Varian w-
100 variable wavelength detector set at 40S nm and a 
Perkin-Elmer LS3 fluorescent detector set at excitation 400 
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and emmision 618 nm, respectively, was used. Samples were 
injected via a Rheodyne (Cotati, CA, USA) 7125 injector 
fitted with a 500 ~l loop. The separation was carried out on 
a 250 mm x 5 mm Hypersil-ODS column (Shandon Scientific, 
Runncorn, Cheshire, U.K.). Unless otherwise stated the 
mobile phase generally consisted of solvent A: 9% (v/v) of 
acetonitrile in 1 M ammonium acetate buffer, pH 5.16 and 
solvent B: 10% (v/v) of acetonitrile in methanol. The 
elution 
required. 
program varied according to the separations 
The flow rate was 1 ml per min throughout. The 
elution programme for the quantitation of porphyrins from 
uro- to copro-porphyrin in urine, plasma and erythrocytes 
was by linear gradient elution from 0% to 90% solvent B in 
30 min, followed by isocratic elution at 90% solvent B for 
10 min. The column was re-equilibrated at 0% solvent B for 
10 min before the next injection. 
The elution program for the quantitation of faecal 
porphyrins was isocratic elution at 15% solvent B for 10 
min; linear gradient elution from 15 to 70% sovent B from 10 
to 45 min; linear gradient elution from 70 to 95% solvent B 
from 45 to 50 min, followed by isocratic elution at 95% 
solvent B for a further 10 min. 
The elution program for the quantitation of duodenal 
aspirates porphyrins was as follows: time 0 to 20 min, 50% 
solvent B to 70% solvent B; time 20 to 30 min, 70% solvent B 
to 95% solvent B; time 30 to 40 min, isocratic elution at 
95% solvent B. 
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2.4. Results and Discussion 
Blood transfusion temporarily increased the erythrocyte 
Uro'gen III-S activity and incompletely suppressed the 
endogenous erythropoiesis. This led to a decrease of plasma 
and urinary porphyrins, and also improved the symptoms. This 
effect required regular transfusion with a haematocrit 
maintained between 34 and 42%. 
Under the usual treatment conditions the activity of 
erythrocyte Uro'gen III-S was 38-86 nmol Uro III/ml RBC per 
hour (normal 159-352 nmol Uro III/ml RBC per hour). A rise 
of the activity was observed immediately after blood 
transfusion. No significant change was seen during the 
administration of charcoal (Fig. 2.1.). 
The total urinary porphyrin excretion determined by 
HPLC (Fig. 2.2.) was 79-283 ~mol/24h under the usual 
treatment condition for the patient (normal total porphyrins 
< 0.35 ~mol/24h with <0.04 ~mol Uro I/24h). The total 
porphyrins in the plasma (Fig. 2.3.) were 2.5-4.1 ~mol/l 
(0.01-0.02 ~mol/l in normal subject) and in the erythrocytes 
(Fig. 2.4.) ranged from 3.2-10.6 ~mol/l (0.4-1.7 ~mol/l in 
normal subjects). The majority (approx. 75%) was Uro I with 
much less (approx. 15%) of Copro I and small amount of 
hepta-, hexa- and penta-carboxylic porphyrins (Table 2.1.). 
In the faeces (Fig. 2.5.) Copro I was the major porphyrin 
with some Copro III, penta I, a little Uro I and traces of 
hepta-, hexa-carboxylic acid porphyrins and protoporphyrin 
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Fig. 2.1. Erythrocyte Uro'gen III-S Activity in Congenital Erythropoietic Porphyria 
Treated with Blood Transfusion and Oral Charcoal 
The average of the activity before charcoal treatment was 67.18 + 14.7 nmol 
Uro III/ml RBC per hour (mean± SD) and after charcoal treatment was 65.23 + 7.32 
nmol Uro III/ml RBC per hour. 
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Fig.2.2. HPLC Separation of Urinary Porphyrins of a Patient with CEP 
Peak 1, uroporphyrin I; peak 2, heptacarboxylic acid porphyrin I; peak 3, 
hexacarboxylic acid porphyrin isomers; peak 4, pentacarboxylic acid porphyrin I; 
peak 5, coproporphyrin I. 
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Fig.2.4. HPLC Separation of Erythrocyte Porphyrins of a Patient with CEP 
Peak 1, uroporphyrin Ii peak 2, coproporphyrin I. 
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Fig.2.S. HPLC Separation of Faecal Porphyrins of a Patient with CEP 
Table 2.1. Porphyrin Levels in urine, Plasma 
in a Patient with Congenital Erythropoietic porphyria 
Normal Range 
Total Porphyrin 
Porphyrin (% of Total) 
Uro I 
Copro I 
Hepta to penta 
Urine 
(p.mol/24h) 
< 0.35 
79-283 
75 
15 
8 
Plasma 
(p.mol/l) 
0.01-0.02 
2.5-4.1 
66 
14 
18 
and Erythrocytes 
RBC 
(p.mol/ 1) 
0.4-1.7 
3.2-10.6 
83 
17 
< 0.001 
IX. A series of new porphyrins were also found in the urine 
and plasma, which will be discussed in later chapters. The 
changes in 24h urinary porphyrin excretion suggested a 
delayed inverse relationship of the urinary porphyrins 
following the rise in haematocrit following blood 
transfusion, consistent with reduced porphyrin synthesis 
when endogenous erythropoiesis was reduced. This 
relationship was not, however, as distinct as previously 
reported (Piomelli et al., 1986), and was not found during 
the administration of charcoal (Fig. 2.6.). A small decrease 
in plasma and erythrocytes porphyrin levels were seen during 
the first 24 h of charcoal administration particularly in 
the first three samples at 3 h intervals (Fig.2.7.), but 
this was not detectable in samples collected during the 
following 3 weeks (Fig. 2.8.). The pattern of variability of 
plasma porphyrin levels parallelled the findings in the 
urine with no indication of reduction due to charcoal. 
Compliance with charcoal ingestion was excellent from 
inspection of stool specimens. 
The porphyrin pattern in the duodenal aspirates is 
similar to faecal porphyrin. More than 95% of the total 
porphyrins were coproporphyrin I, with small amount of 
coproporphyrin III, very little pentacarboxylic porphyrin I 
and III, and traces of uroporphyrin I making up the rest 
(Table 2.2.). Three unknown peaks which were very small 
appeared before and after coproporphyrin isomers (Fig. 2.9). 
The porphyrin concentrations obtained in consecutive 30 min 
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Fig. 2.6. Urinary Porphyrin Excretion in Congenital Erythropoietic Porphyria Treated 
with Blood Transfusions and Oral Charcoal 
The peaks of the haernatocrit plot indicate transfusion of 2-3 unit of 
packed red cells. 
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Fig. 2.7. Uroporphyrin I Levels in Plasn1a and Erythrocytes after Oral Charcoal 
Blood samples were obtained before the first dose of charcoal and at 3 hour 
intervals during the administration of lag doses at 4 hour intervals to a total 
of 50g. 
The average of erythrocyte uroporphyrin I before charcoal treatment was 
6.06 + 2.57 ~mol/l (mean + SO) and during the first 25 h after charcoal 
treatment 1\7as 3.93 + 0.34 J-Lmol/l (mean + SO); the average of plasma uroporphyrin 
I before charcoal treatment was 2.45 + 0.57 J-Lmol/l (mean + SO) and during the 
first 25 h after charcoal treatment was 2.07 + 0.298 ~mol/l-(mean + SO). 
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Fig. 2.8. Plasn1a Uroporphyrin I Levels in a Case of Congenital Erythropoietic 
Porphyria Treated with Blood Transfusions and Oral Charcoal 
Slight reduction of the high levels of plasma uroporphyrin is apparent in 
the week following blood transfusions, but there was no further reduction during 
the 21 days of charcoal administration. The average of the plasma uroporphyrin I 
before charcoal treatment was 2.45 + 0.57 Mmol/l (mean + SO) and after charcoal 
treatment was 2.16 + 0.32 Mmol/l (mean ± SO). -
Table 2.2. porphyrins in Duodenal Aspirates of the Patient with 
Congenital Erythropoietic Porphyria 
1. 
2. 
3 . 
Total Porphyrin 
(nmol/l) 
229 
100,386 
20,738 
Porphyrin Levels* 
(nmol/min) 
13 
4,206 
782 
porphyrins (% of total) 
4-1 4-111 5-1 5-111 8-1 
91.3 
95.8 
95.8 
3.3 
3.4 
2.0 
2.1 0.65 
0.6 0.21 
1.7 0.46 
1.60 
0.01 
0.02 
*At distal port: porphyrin concentration (nmol/ml) x "flow rate" (ml/min). 
Flow rate was calculated as described in Sec. 2.3.3 .. 
1., 2., and 3.: samples collected from three consecutive 30 min periods 
(see Sec. 2.3.3.). 
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Fig. 2.9. HPLC Separation of Duodenal Aspirate Porphyrin of a Patient with CEP 
Peak 1, pentacarboxylic acid porphyrin I; peak 2, pentacarboxylic acid 
porphyrin III; peak 4, coproporphyrin I; peak 5, coproporphyrin III; peak 3, 6 
and 7, unknown. 
samples were consistent with the onset of contraction of the 
gallbladder with the peak porphyrin concentration occurring 
during the second 30 min period. The quantity in this sample 
was so great that coproporphyrin crystallised out on 
cooling. 
The addition of oral charcoal for 21 days in a dose 
close to the level of tolerability failed to reduce 
porphyrin levels or to improve this patient's clinical 
status. A previous report of benefit sustained over a period 
of 9 months in a case of "congenital erythropoietic 
porphyria " is not directly comparable since that patient 
had deficiency of Uro-D characteristic of porphyria cutanea 
tarda (Pimstone et al., 1987) as well as a congenital 
dyserythropoietic anaemia (Kushner et al., 1982), and not 
classical Gunther's disease. It seems unlikely that major 
differences in response depend on the particular brand of 
charcoal used, since although differences in binding 
affinities can be demonstrated in vitro (Tishler & Winston, 
1985), the binding of porphyrins to charcoal in the faeces 
is so firm that quantitative extraction is not possible even 
under the most rigorous conditions, including the use of 
concentrated HCI or in situ methylation. Differences in 
response may in part be related to the quantity of charcoal 
used and to the frequency of its administration, thus 
180g/day of Acta Char was ingested by the patient as 
described by {Pimstone et al., 1987}. An additional factor 
may be the porphyrin load, and it is notable that in the 
patient described here the plasma and urinary levels were 
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higher than in previously reported cases treated with 
charcoal or hypertransfusl'on (T bl a e 2.3.), although similar 
values have previously been t d (I repor e ppen & Fuchs, 1980). 
More importantly, however, it would seem likely that any 
benefit of charcoal would depend on the extent of the 
enterohepatic circulation of porphyrins and thus also on 
the proportion of hydrophilic porphyrins in the plasma. 
Pimstone et ale (1987) measured duodenal porphyrin 
concentration and flow rates after contracting the 
gallbladder with cholecystokinin, as a measure of hepatic 
secretion rate, and found that approximately 95% of the 
porphyrins measured at the ampulla of vater were reabsorbed 
15 cm distally. In the present study the porphyrin level at 
the ampulla was not measured because the proximal aspiration 
port was just rostral, but the very high concentrations 
obtained 15 cm distally make it unlikely that such a high 
proportion could already have been reabsorbed in this short 
portion of the gut under our more "physiological" conditions 
of spontaneous gallbladder function. The values obtained 
indicate minimum values of 150 ~moles (about 100 mg) of 
porphyrins excreted into the gut in this 90 min period, 
compared with 200 mg/24h calculated by Pimstone et al.(1987) 
for their case. Even on the conservative assumption that 
there may be only 7 equivalent cycles of gallbladder 
discharge per 24h, up to 1 mmole or 650 mg of porphyrins 
would be excreted into the gastrointestinal tract in this 
patient. From the porphyrin content of his faecal samples 
(3430 nmoles/9 dry weight), of which more than 95% was 
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Table 2.3. Porphyrin Levels in congenital Erythropoietic porphyria 
Plasma (ILmol/l) Urine (ILmol/24h) Literature Source 
0.56-0.88 23.3-58.3 Piomelli et ale (1986)a 
0.33 18.7-21.0 Pimstone et ale (1987)b 
1.51 96.8 Tishler & Winston (1990)ab 
2.53-4.03 79-283 This caseab 
3.50-6.65 38.5-171* Ippen & Fuchs (1980) 
*: ILmol/l; a: transfused; b: oral charcoal. 
coprOporphyrin I, and total dry weight (25-30 gj24h) 
reabsorption of up to 90% can be deduced, consistent in this 
case also with a major degree of enterohepatic circulation 
of porphyrins. It is notable also that the stool porphyrin 
concentration reported here is 10 times greater than that 
found by Tishler & Winston , (1985). Uroporphyrin itself, 
however, does not reach the gastrointestinal tract in 
significant amounts and was not detected in duodenal 
aspirates (Pimstone et al., 1987) or in bile (Mukerji et 
al., 1985), and lack of significant uroporphyrin excretion 
in duodenal aspirates was also confirmed in our patient. 
Binding of porphyrins in the gut lumen, with interruption of 
their enterohepatic circulation, could favour 
decarboxylation of uroporphyrinogen, resulting in an 
increase in less polar porphyrins excreted in bile, with a 
fall in plasma uroporphyrin. In our case, uroporphyrin 
accounted for 75% of the plasma porphyrin compared with only 
6.9%, or up to 24% including heptacarboxylic porphyrins in 
the case of Pimstone et al. (1987). These differences could 
in part explain the apparent lack of response to charcoal in 
this patient. 
The present study does not support previous suggestive 
findings that oral charcoal may be of value in the 
symptomatic treatment of congenital erythropoietic 
porphyria. Oral charcoal given for 31"days in another 
patient with "probable" congenital erythropoietic porphyria 
(Tishler & Winston, 1990) reduced the plasma and erythrocyte 
levels of porphyrin but no clinical benefit was apparent. In 
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another report of a 12 year old boy with congenital 
erythropoietic porphyria (Rift et al., 1990), charcoal 
reduced urine , plasma and erythrocyte porphyrin levels 
during a 6 months treatment period, but no details were 
given of any improvement in clinical symptoms. 
Clear distinction has not previously been made in the 
literature between the report of dramatic beneficial effect 
of charcoal in a single case of congenital erythropoietic 
porphyria due to deficiency of uroporphyrinogen 
decarboxylase (Pimstone et al., 1987) and those with the 
classic deficiency of Uro'gen 111-8 (Gunther's disease). It 
may be appropriate to refer to the classical disease as 
congenital erythropoietic porphyria and to the other as 
hepatoerythropoieticporphyria. Evidence of clinical benefit 
of charcoal administration in CEP is not available. The 
reasons for these differences have been discussed above. 
2.5. Conclusions 
Oral charcoal was of no value in the symptomatic 
treatment of a patient with congenital erythropoietic 
porphyria (Gunther's disease). This was probably because the 
major porphyrin in plasma, uroporphyrin I which is believed 
to play an important role in the disorder, was not excreted 
in bile and interruption of the enterohepatic circulation of 
the large load of coproporphyrin by binding to charcoal was 
insufficient to shift the equilibrium from uroporphyrinogen 
I to coproporphyrinogen I with a resulting decrease in 
plasma uroporphyrin. 
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CHAPTER 3 
ISOLATION, IDENTIFICATION AND CHARACTERIZATION OF NEW 
PORPHYRIN METABOLITES IN THE URINE OF PATIENTS WITH CEP 
3.1. Introduction 
One of the characteristic features of congenital 
erythropoietic porphyria (CEP) is the excretion of a large 
amount of uroporphyrin I in the urine. Thin-layer 
chromatography (TLC) of the porphyrin methyl esters isolated 
from the urine of CEP patients consistently showed the 
presence of porphyrins migrating below the major 
uroporphyrin band (Fig. 3.1). These polar porphyrins, often 
called sub-uroporphyrins, are thought to be partially 
hydrolysed porphyrin methyl esters. Analysis of the 
underivatized urinary porphyrins in these patients by high-
performance liquid chromatography, however, still showed the 
presence of polar porphyrins eluted before uroporphyrin and 
near the solvent front (Fig. 3.2). These observations would 
suggest that the polar porphyrins detected by TLC and HPLC 
are most probably unidentified porphyrin metabolites. This 
chapter describes in detail the isolation, identification 
and characterization of new porphyrin metabolites in the 
urine and plasma of patients with CEP. An attempt has also 
been made to correlate the presence of these metabolites 
with uroporphyrinogen III synthase (Uro 111-8) activity and 
the concentrations of porphyrins in the urine and blood of 
CEP patients. 
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Fig. 3.1. TLC Separation of Urinary Porphyrin Methyl Esters 
froll1 a Patient with CEP. 
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Fig. 3.2. HPLC Separation of Urinary Porphyrin of a Patient 
with CEP. 
Peak 1, uroporphyrin I; peak 2, heptacarboxylic acid 
porphyrin I; peak 3, hexacarboxylic acid porphyrin isomers; 
peak 4, pentacarboxylic acid porphyrin Ii peak 5, copro-
porphyrin I. 
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3.2. Experimental 
3.2.1. Materials and reagents 
Uro I and III octamethyl esters were from Sigma 
Chemical Co. (Poole, Dorset, U.K.). Thallic 
trifluoroacetate was from Aldrich Chemical Co. 
(Gillingham, Dorset UK) ~-- . , ... n..uuuonlum acetate, acetic 
anhydride, glacial acetic acid, ethylenediaminetetraacetic 
acid (EDTA), zinc acetate, trichloroacetic acid, 1 2 , 
concentrated HCI, concentrated H2S04 , NaHC03 , KOH, NaOH, 
dimethylsulphoxide Ca(OH)2' metallic sodium, mercury, 
(DMSO), carbon tetrachloride, chloroform, dichloromethane, 
dimethylformamide (DMF) , tetrahydrofuran, s02 gas and 
pyridine were AnalaR grade from BDH Chemicals (Poole, 
Dorset, U.K.). Acetonitrile, ethyl acetate, ethanol and 
methanol were HPLC grade from Rathburn Chemicals 
(Walkerburn, Peeblesshire, Scotland, U.K.). Alumina 90 
(70-230 mesh) for column 
(Darmstadt, Germany) . 
chromatography was from E.Merk 
C18 Bond Elut extraction 
cartridge was from Analytichem International (Habor 
City, CA, USA.). 
3.2.2. separation and isolation of the new porphyrin 
metabolites in the urine of patients with CEP by HPLC 
The HPLC system consisted of a Varian Associates 
(Walton-on-Thames, Surrey, UK) model 5000 pump and a Varian 
UV-100 variable wavelength detector set at 400 nm. The 
acidified urine (200 ~l portions) was directly injected by 
a Rheodyne (Cotati, CA, USA) 7125 injection valve fitted 
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with a 500 ~l loop. The separation was carried out on a 25 
cm x 25 mm Hypersil-ODS column (Shandon Scientific, Runcorn, 
Cheshire, UK) by gradient elution. The gradient mixtures 
were 9% (v/v) acetonitrile in 1 M ammonium acetate buffer pH 
5.16 (Solvent A) and 10% (v/v) acetonitrile in methanol 
(solvent B). The elution program was as follows. Time 0 to 
16 min, 0% solvent B (100% solvent A) to 11% solvent B; time 
16 to 24 min, isocratic elution at 11% solvent B; time 24 
to 38 min, 11% solvent B to 24% solvent B; time 38 to 60 
min, 24% solvent B to 60% solvent B and time 60 to 80 min, 
60% solvent B to 80% solvent B. The flow rate was 1 ml/min 
throughout. The column was then re-equilibrated at 0% 
solvent B for 10 min before injection of next sample. The 
chromatogram is shown in Fig. 3.3. The peaks 1, 2, 3, 4, 5 
and 6 were collected into individual flasks containing 
little EDTA solid. The acetonitrile and methanol content in 
the eluates were removed by evaporation at 30-40oC under 
nitrogen. The purity of the isolated porphyrins was 
checked by HPLC. Repurification was carried out if neces-
sary. 
3.2.3. Solid-phase extraction of the urinary porphyrins 
After evaporating the acetonitrile and methanol by 
heating at 30-40°C under N2 , the individual peak collection 
was mixed with a equal volume of 0.5 M ammonium acetate 
buffer, pH 5.16 to further dilute any residual organic 
solvent. The mixture was loaded under vacuum into a C18 Bond 
Elut cartridge which had been pre-washed successively with 5 
ml of methanol and 3 x 5 ml of 0.5 M ammonium buffer, pH 
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Fig. 3.3. HPLC Separation of Urinary Porphyrin of a Patient with CEP. 
(/' 
5.16. The cartridge was washed with 2 x 5 ml of 0.5 M 
ammonium acetate buffer H h . t' d , P 5.16. T e porphyr1ns re a1ne on 
the ca t . 
r r1dge were then recovered by elution with methanol : 
acetonitrile (v/v, 1:1) until little UV fluorescence 
remained on the cartridge. The eluent was evaporated to 
dryness under nitrogen at 30-400C. 
3.2.4. Esterification of porphyrins 
The porphyrins were dissolved in 2 ml of 10% (v/v) 
conc. H 2S0 4 in methanol or ethanol and the solution was 
left standing for 20 h at 4°C in the dark. The mixture was 
then transferred into a separating funnel containing 
chloroform (3 ml) and extracted rapidly with 6 ml water. 
The chloroform layer was washed successively with aqueous 
saturated sodium bicarbonate solution (5 ml) and water (5 
ml). The organic layer was filtered through a 5.5 cm filter 
paper (Whatman No.1) pre-wetted with chloroform and the 
filtrate was evaporated to dryness at 30°C under nitrogen. 
3.2.5. Acetylation of hydroxylated porphyrins 
The method of Jackson et ale (1968) was used for the 
preparation of meso-acetoxycoproporphyrin III. The 
porphyrin methyl ester was redissolved in 200 ~l of 
pyridine and 50 ~l of acetic anhydride, mixed thoroughly 
and stood at room temperature for two hours in the dark. 
The solution was evaporated to dryness at 30-400C under 
nitrogen. The residue was analysed by mass spectrometry. 
64 
3.2.6. HYdrolysis of porphyrin esters 
Porphyrin methyl or ethyl esters were dissolved in 25% 
of HCI and then hydrolysed in the dark at room temperature 
for 72 hours. The esters may also be dissolved in conc. HCI 
and then diluted to 25% with water. 
3.2.7. Reduction and aromatization of hydroxylated 
porphyrins 
The free porphyrin was dissolved in 0.01 M KOH flushed , 
with nitrogen and stoppered. The porphyrin was reduced with 
3% (w/w) sodium amalgam until no UV fluorescence was 
detectable. The resulting solution was transferred into a 
clean tube, and aromatized by adding an equal volume of a 
saturated solution of 12 in 10% trichloroacetic acid. The 
mixture was allowed to stand in room temperature for 5 min 
and then analysed by HPLC. 
3.2.8. synthesis of meso-hydroxyuroporphyrin I and III 
The procedure used was similar to that described for 
the synthesis of meso-hydroxycoproporphyrin I (Barnett et 
ale , 1973). Zinc (II) uroporphyrin I and III octamethyl 
estes were prepared by treating the porphyrin ester in 
chloroform with zinc acetate in methanol at 50°C for 10 min 
as described by Fuhrhop & smith (1975). Any excess zinc 
acetate was washed away with water at the end of the 
reaction. The organic layer containing zinc uroporphyrin was 
collected after filtering through a filter paper pre-wetted 
with chloroform. The filtrate was evaporated to dryness 
under nitrogen at 30-400C. 
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The resulting zinc (II) uroporphyrin I or III 
octamethyl ester (app. 2 mg) in 2.5 ml of dichloromethane 
was mixed with thallic trifluoroacetate (3 mg) in 1 ml of 
tetrahydrofuran, and stirred for 1 min. Water (50 ~l) in 
tetrahydrofuran (1 ml) was added, and the mixture was 
stirred for a further 10 min. The solution was treated 
briefly with S02 gas followed by addition of 100 ~l concen-
trated HCl. After being stirred for 5 min the mixture was 
poured into water (20 ml) and extracted with dichloromethane 
(10 ml). The organic layer was filtered through a filter 
paper pre-wetted with chloroform. The filtrate was 
evaporated to dryness under N2 . The residue was redissolved 
in chloroform and loaded into a Pasteur pipette half-filled 
with alumina 90 which was previously washed with chloroform. 
The column was eluted with chloroform (10 ml) and then 10 ml 
of chloroform/methanol (1:1, v/v). The chloroform/methanol 
fraction contained meso-hydroxyuroporphyrin octamethyl 
ester. The solvent was removed by evaporation under N2 · The 
residue was hydrolysed with 25% HCl and purified by HPLC as 
described in Sec. 3.2.6. and 3.2.2., respectively. 
3.2.9. Dehydration of the hydroxylated uroporphyrin methyl 
esters by Heating 
The porphyrin methyl ester was dissolved in 0.5 
ml dimethylformamide in a pyrex tube. The solution was 
flushed with nitrogen and the tube was capped and heated 
at 1350C for 2 hours in the dark. After cooling to room 
temperature, the solution was transferred into a 
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separating funnel containing chloroform (1 ml). The mixture 
was extracted after water (2 ml) was added. The chloroform 
layer was passed through a filter paper pre-wetted with 
chloroform. The filtrate was evaporated to dryness at 30°C 
under nitrogen. 
spectrometry. 
The residue was analysed by mass 
3.2.10. Dehydration and decarboxylation of hydroxylated 
uroporphyrins by heating 
The porphyrin free acid was dissolved in 0.5 M HCI in 
a Pyrex tube, flushed with nitrogen, capped and then heated 
at 135°C for 30 min or 1 h. After cooling to room 
temperature, the solution was analysed by HPLC. 
3.2.11. Alkaline hydrolysis of peroxyacetic acid 
uroporphyrin I 
Peroxyacetic acid uroporphyrin I was dissolved in 0.1 M 
KOH, NaOH or Ca(OH)2 and the solution was heated at 30-400C 
for 5min. The pH of the solution was adjusted to between 5-
7 and the product was analysed by HPLC. 
3.2.12. separation and isolation of the new porphyrin 
metabolites in the plasma of patients with CEP by HPLC 
The plasma was prepared as described in Sec. 2.3.5.5 .. 
For larger scale extraction of the new porphyrin 
metabolites, the pooled plasma (20 ml) was vortex-mixed with 
the equal volume of 20% TCA (w/v)-DMSO (v/v, 1:1). After 
centrifugation the supernatant was collected. The residue 
was again vortex-mixed with 5 ml of 20% TCA-DMSO (v/v, 1:1), 
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cent . 
rlfuged and the supernatant was collected. The pooled 
supernatants were diluted 1:15 (v/v) with 0.5 M ammonium 
acetate buffer (pH 5.16) and loaded under suction onto a C18 
Bond-Elut Cartridge. The porphyrins were then extracted as 
described in S 3 2 3 ec. ... . 
The porphyrins were re-dissolved in 0.3 M HCl and 
separated by HPLC. The HPLC condition and the elution 
program were the same as described in Sec. 3.2.2. except 
that any peaks eluted after 30 min were washed out by 95% 
solvent B. The individual peaks 1-7 (Fig. 3.4) were 
collected into separate flasks containing little EDTA solid. 
The organic solvent was removed and the porphyrins were 
recovered by solid-phase extraction on C18 Bond Elut 
cartridges as described in Sec. 3.2.3 .. 
3.3. spectrophotometry 
A Kontron Uvikon 860 spectrophotometer operated in 
Lambda-scan absorption mode with scanning wavelengths from 
250 to 700 nm was used for recording the electronic 
spectra. Both H (quartz-halogen) and D2 (deuterium) lamps 
were on with lamp change at 340 nm. The porphyrin free 
acids were dissolved in 0.5M HCl for peaks 1-4 and O.lM 
HCl for peaks 5 and 6 (Fig. 3.3.). Peak detection and 
trace area functions were used to identify the exact 
wavelength of the peaks as required. 
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Fig. 3 .4. HP~C Separation of PlaSI11a Porphyrin of a Patient with CEP. 
3.4. Liquid 
A VG 
Secondary Ion 
Analytical 
Mass Spectrometry (LSIMS) 
(Manchester, U.K.) ZAB2-E 
mass spectrometer, operated at 8 KeV accelerating vOltage 
and fitted with a caesium gun (35 KeV,0.5 ~A emission) was 
used for LSIMS. Porphyrin esters were dissolved in a small 
volume (ca. 10 ~l) of chloroform:methanol (2:1, v/v) and 
1 ~l was added to the standard stainless steel LSIMS 
target probe previously prepared with thioglycerol (1 
~l) as liquid matrix. Mass spectra were acquired in the 
positive ion mode at 30 s/decade using the VG Analytical 
11-250J data system in continuous multichannel 
analysis mode at a resolution of 1500 RP. 
Accurate mass measurement was carried out using 
peak matching at a resolution of 7000RP. Internal 
reference masses were produced by adding uroporphyrin I 
octamethyl ester and aqueous sodium iodide solution to the 
sample. The protonated and sodiated molecular species 
([MH]+ 943.3613 and [MNa]+ 965.3433) were used as 
reference peaks. 
3.5. Results and Discussion 
3.5.1. HPLC of polar porphyrins in the urine of a patient 
with CEP 
Fig. 3.2. has clearly shown that there are unknown 
polar porphyrins eluted before uroporphyrin. The gradient 
elution programme was therefore modified so that these 
porphyrins could be separated. The HPLC separation is shown 
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in Fig. 3.3. There were six unidentified porphyrins, 
numbered 1-6, detected and their identification and 
characterization are described in the following sections. 
3.5.2. Identification of meso-hydroxyuroporphyrin I 
Peak 1 (Fig. 3.3.) had a characteristic pink porphyrin 
fluorescence. The mass spectra of the methyl and ethyl 
esters gave the MH+ signals at m/z 959 and 1071, 
respectively (Fig. 3.5. and 3.6.), indicating the presence 
of eight carboxylic acid groups and an increase of 16 mass 
unit over Uro octamethyl ester (MH+, m/z 943) and octaethyl 
ester (MH+, m/z 1055) , respectively. This indicated that the 
compound is closely related to uroporphyrin and strongly 
pointed to a sUbstitution of uroporphyrin by a hydroxy 
group. 
To confirm the presence of -OH group, the octamethyl 
ester of peak 1 was treated with acetic anhydride in 
pyridine. The acetyl derivative was analysed by LSIMS and a 
MH+ signal at m/z 1001 (Fig. 3.7.), an increase of 42 mass 
unit, was obtained confirming the presence of a hydroxy 
group. 
Accurate mass measurement of the methyl esters of peak 
1, with uroporphyrin I octamethyl ester and aqueous sodium 
iodide solution as the internal reference, were performed. 
The methyl ester gave MH+ 959.3532, only 1.0 ppm less than 
the theoretical value of 959.3562 for C4sH55017N4' the 
elemental formula of a hydroxylated uroporphyrin. 
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Fig. 3.7. LSIMS of Acetylated Meso-Hydroxyuroporphyrin I Methyl Ester 
Assuming that the hydroxylated porphyrin is a 
uroporphyrin I derivative, there are four possible positions 
in which an -OH group can be attached to the uroporphyrin I 
structure (Fig. 3.8.). These are meso-hydroxy-, B-
hydroxypropionic acid-, hydroxyacetic acid- and N-hydroxy-
derivatives. To identify the position of the hydroxy group 
in peak 1, the free porphyrin in 0.1 KOH was reduced with 3% 
(w/w) sodium amalgam followed by aromatization with 12 . The 
reaction gave Uro I as the only product when analysed by 
HPLC and LSIMS. The reaction proved that the hydroxy group 
was located at the meso-position (Jackson et al., 1968) and 
established that the porphyrin was the type I isomer. The 
structure is shown in Fig. 3.8. 
That the assigned structure was correct was confirmed 
by synthesis of meso-hydroxyuroporphyrin I by means of the 
thallic trifluoroacetate method (Barnett et al., 1973) 
described for the preparation of oxophlorins. The synthetic 
meso-hydroxyuroporphyrin I had exactly the same retention 
time as peak 1 under various HPLC conditions. It gave the 
same molecular weights for its methyl ester and acetoxy 
derivative as the natural peak 1 when analysed by LSIMS. 
When the synthetic meso-hydroxyuroporphyrin I was reduced 
with 3% Na/Hg followed by aromatization with 12 it also gave 
Uro I as the only product. This further proved that peak 1 
is meso-hydroxyuroporphyrin I. 
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3.5.3. Identification of B-hydroxypropionic acid 
uroporphyrin I 
Peak 2 (Fig. 3.3.) also has a characteristic porphyrin 
fluorescence. The mass spectrum of the methyl ester showed a 
MH+ signal at m/z 959 and that of the ethyl ester showed a 
MH+ signal at m/z 1071. This was similar to the meso-
hydroxyuroporphyrin I and indicated that the compound also 
had eight carboxylic acid groups and was probably an isomer 
of meso-hydroxyuroporphyrin I. An increase of 16 mass unit 
over Uro octamethyl ester (MH+, m/z 943) and octaethyl ester 
(MH+, m/z 1055) suggested sUbstitution by a -OH group. The 
methyl ester gave an accurate mass of MH+ 959.3544, 1.9ppm 
less than the theoretical value of 959.3562 for C4sH55017N4' 
the elemental formula of a hydroxylated uroporphyrin. 
Acetylation of the methyl ester gave a MH+ signal at m/z 
1001 when analysed by LSIMS. An increase of 42 mass 
confirmed the presence of a -OH group. 
Peak 2 (Fig. 3 .3. ) was eluted after meso-
hydroxyuroporphyrin I. Since in reversed-phase HPLC 
uroporphyrin I eluted before uroporphyrin III, it is 
possible that peak 2 is the type III isomer of meso-
hydroxyuroporphyrin I. Meso-hydroxyuroporphyrin III was 
therefore synthesized and analysed by HPLC. It was eluted 
immediately after meso-hydroxyuroporphyrin I (Fig. 3.9.) and 
was clearly resolved from peak 2. This rules out the 
possibility that peak 2 is the type III isomer of meso-
hydroxyuroporphyrin I. There are four possible isomers of 
meso-hydroxyuroporphyrin III. Under the HPLC conditions 
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Fig. 3.9. HPLC Separation of Synthetic Meso-H ydroxyuroporphyrin I and III. 
Peak 1, meso-hydroxyuroporphyrin I; peak 2, meso-hydroxyuroporphyrin III; peak 
3, Uro I; peak 4, Uro III; peak 5, late eluting peaks. 
used, no separation of these type III isomers was achieved. 
Since peak 2 is not meso-hydroxyuroporphyrin III, the 
other three hydroxylated uroporphyrin I structures (Fig. 
3.8) have to be considered. Reduction of peak 2 with Na/Hg 
followed by re-oxidation with 12 gave a signal of Uro I (MH+ 
943), a dehydration product (MH+ 941) with substantially 
unchanged material (MH+ 959) when the crude reaction product 
was analysed by LSIMS (Fig.3.10.). This suggested that the 
compound was derived from Uro I and the -OH group was 
situated in a position which was easily dehydrated. The most 
probable structure is B-hydroxypropionic acid uroporphyrin I 
(Fig. 3.8.), since only a -OH group on the B-position of 
propionic acid can be easily dehydrated. A -OH group on the 
pyrrole N position is unstable while a -OH group on the 
acetic acid function cannot be dehydrated. The methyl ester 
of peak 2 was subjected to dehydration by heating in 
dimethylformamide (DMF) and the product analysed by LSIMS. 
The product gave a MH + signal at m/z 941 (959-18) (Fig. 
3.11.) clearly showing dehydration of the parent compound. 
The porphyrin free acid of peak 2 was also subjected to 
dehydration by heating. It gave two products when analysed 
by HPLC (Fig. 3.12). Analysis by LSIMS showed that apart 
from the dehydration product (MH+ 941) a decarboxylation 
derivative was also found. This derivative has a MH+ signal 
at m/z 883 and a possible structure is shown in the reaction 
scheme in Fig. 3.13 .. The above HPLC, chemical and LSIMS 
evidences all pointed to peak 2 being B-hydroxypropionic 
acid uroporphyrin I. 
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3.5.4. Identification of hydroxyacetic acid uroporphyrin I 
Peak 3 (Fig. 3.3.) has the characteristic porphyrin 
fluorescence. The mass spectra of the methyl and ethyl 
esters showed MH+ signals at m/z 959 and 1071, respectively, 
similar to those of meso-hydroxy- and B-hydroxypropionic 
acid-uroporphyrin I. This compound must be therefore also a 
hydroxylated uroporphyrin. Accurate mass measurement for the 
methyl ester gave MH+ 959.3557, 0.5 ppm less than the 
theoretical value of 959.3562 for C48H55017N4' the molecular 
formula of a hydroxylated uroporphyrin. Acetylation of the 
methyl ester gave a MH+ signal at m/z 1001 when analysed by 
LSIMS. An increase of 42 mass unit corresponded to an 
acetoxy derivative and confirmed the presence of a -OH 
group. Thus peak 3 is an isomer of meso-hydroxy- and B-
hydroxypropionic acid-uroporphyrin I. Reduction with Na/Hg 
followed by re-oxidation with 12 gave only a trace of Uro I 
and largely unchanged material when the product was analysed 
by HPLC and LSIMS. The formation of Uro I showed that this 
compound was also derived from Uro I. 
The methyl ester of peak 3 was subjected to dehydration 
by heating in dimethylformamide (DMF) and then analysed by 
LSIMS and HPLC. No dehydration product was detected. This 
indicated that the -OH group was sUbstituted at a position 
which was difficult or not possible for it to be 
dehydrated. The only possible structure for this to occur is 
with the hydroxy group located on an acetic acid sUbstituent 
84 
(Fig. 3.8.). To further confirm that peak 3 cannot be 
dehydrated the porphyrin free acid was subjected to heating 
in 0.5 M HCl and the product analysed by HPLC and LSIMS. 
HPLC analysis showed that two products were formed (Fig. 
3.14) and both compounds had an identical MH+ signal at m/z 
901 (Fig. 3.15. & 3.16.). This indicated decarboxylation of 
the hydroxylated uroporphyrin I without dehydration, 
confirming that the -OH group is located on the acetic acid 
function. The structures of the two decarboxylated 
hydroxyacetic acid uroporphyrin I, hydroxyacetic acid 
heptacarboxylic porphyrin I, are shown in Fig. 3.17. Since 
Uro I is a symmetrical molecule there can be only one 
hydroxyacetic acid Uro I derivative and there are two 
possible ways of decarboxylating the hydroxyacetic acid Uro 
I. The decarboxylation products are expected to form in a 
ratio of 2:1 as clearly shown by the HPLC analysis. 
3.5.5. Identification of peroxyacetic acid uroporphyrin I 
Peak 4 is different from the above three hydroxylated 
uroporphyrin I derivatives in that it has a greenish-yellow 
colour instead of the purple-brown colour, but like the 
hydroxylated derivatives it gave a characteristic red 
porphyrin fluorescence. 
+ . 1 The mass spectrum of the methyl ester gave a MH slgna 
at m/z 945 (Fig. 3.18.), an increase of 2 Da over 
uroporphyrin octamethyl ester. There are four possible 
structures in which the MH+ signal is m/z 945. These are 
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Fig. 3. 18. LSIMS of Peroxyacetic Acid Uroporphyrin I Methyl Ester 
phlorin, thioacid-, peroxyacetic acid- and peroxypropionic 
acid-uroporphyrin I (Fig. 3.19). 
A phlorin structure is easily oxidised to the 
corresponding porphyrin by various oxidizing agents, for 
example, air, iodine or chloranil (Woodward, 1962). Since 
peak 4 was very stable under aerobic condition and could not 
be oxidised to the porphyrin by 12 (freshly prepared iodine 
saturated in 10% TeA), the phlorin structure can be ruled 
out. 
The ethyl ester of peak 4 showed the MH+ signal at m/z 
1043 (Fig. 3.20.), representing an increase of seven 
methylene units over methyl ester. This clearly showed that 
the compound possessed seven and not eight carboxylic acid 
groups. Thus one of the side-chain carboxylic acid groups of 
uroporphyrin has been modified and the thioacid, 
peroxyacetic acid and peroxypropionic acid structures are 
all possible. 
Since it is possible to differentiate between a 
thioacid and a peroxyacid structure by high resolution mass 
spectrometry, the accurate mass of the methyl ester was 
measured. The accurate mass of the methyl ester gave a 
MH+ signal at m/z 945.3416, very close (+1.0 ppm) to the 
theoretical value of 945.3406 the 
elemental formula of a peroxyacid uroporphyrin. For a 
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or a phlorin structure 
(C48H57016N 4)' the measured mass units were +19.8 ppm and 
-37.6 ppm of the theoretical values, respectively. Peak 4 
was therefore established as a peroxyacid uroporphyrin I. 
Acetylation of the methyl ester with pyridine and 
acetic anhydride was achieved only with difficulty. The mass 
spectrum of the acetylated product showed a MH+ 987 signal 
(Fig. 3.21.) but substantial starting material (MH+ 945) 
remained. This is in contrast to the hydroxylated 
derivatives of uroporphyrin I which were easily acetylated 
and is consistent with a peroxyacid structure. 
To confirm that peak 4 is peroxyacid uroporphyrin, 
this compound was treated by dilute alkali, such as O.lM KOH 
and Ca(OH)2. The compound was completely converted into Uro 
I which was identified by HPLC and mass spectrometry. Peak 4 
was therefore clearly peroxyacid uroporphyrin I. Further 
confirmation was obtained by heating the compound in dilute 
HCI in the dark when Uro I was formed as the only product. 
Peroxylation of a carboxylic acid group may take place 
on either an acetic acid or a propionic acid group. The 
final structural assignment requires nuclear magnetic 
resonance (NMR) spectroscopy. since the compound was not 
present in sufficient quantity in the urine, insufficient 
sample had been isolated for NMR studies. At present, the 
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Fig. 3.21. LSIMS of Acetylated Derivative of Methyl Esters of Peroxyacetic Acid 
Uroporphyrin I Methyl Ester 
peroxyacetic acid uroporphyrin I structure is favoured. An 
attempt to isolate an analogous coproporphyrin derivative in 
the urine and faeces of the patients with hereditary 
coproporphyria containing a high concentration of 
coproporphyrin was unsuccessful. This indicated that the 
peroxylation reaction in vivo may take place only on acetic 
acid group and not on propionic acid group. The studies on 
the mechanism of formation of peroxyacid porphyrins in 
Chapter 5 have, however, confirmed the peroxyacetic acid 
structure. 
3.5.6. Identification of hydroxyheptacarboxylic acid 
porphyrins in the urine of patients with CEP 
Fig. 3.3. has clearly shown that there were two other 
peaks, 5 and 6, eluted between uroporphyrin and 
heptacarboxylic acid porphyrin. The mass spectra of the 
methyl esters and ethyl esters of these two compounds were 
identical, with the MH+ signal, at m/z 901 and 999 (Fig. 
3.22.), respectively. This is an increase of 16 Da over the 
methyl and ethyl esters, respectively, of heptacarboxylic 
acid porphyrin (MH+, m/z 885 and 983) indicated that they 
were hydroxylated heptacarboxylic porphyrins. When peak 5 
and 6 were subjected to reduction with Na/Hg followed by 
oxidation with saturated 12 in 10% TCA, no significant 
change was found as analysed by HPLC. These closely 
resembled peak 2, B-hydroxypropionic acid uroporphyrin I and 
peak 3, hydroxyacetic acid uroporphyrin I. 
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since the compounds were not converted to 
heptacarboxylic porphyrin I, they are most probably and B-
and 
hydroxypropionic acid hydroxyacetic acid heptacarboxylic 
A 
porphyrin I. Peak 6 was confirmed as hydroxyacetic acid 
heptacarboxylic acid porphyrin I by heating hydroxyacetic 
acid uroporphyrin I when a compound with identical retention 
time to peak 6 was formed (Fig. 3.23.). Peak 5 is most 
probably B-hydroxypropionic acid heptacarboxylic porphyrin I 
as when B-hydroxypropionic acid uroporphyrin I was heated 
and analysed by HPLC a peak corresponding to peak 5 was 
detected together with its dehydration and decarboxylation 
products (Fig. 3.24.). 
3.5.7. Identification of hydroxy- and peroxyacetic acid-
uroporphyrin I derivatives in the plasma of patients with 
CEP 
The HPLC separation of porphyrins in the plasma of 
patients with CEP is shown in Fig. 3.4 .. There were seven 
peaks eluted before Uro I. Peaks 1 and 4 had not been 
identified because they were not found in the urine of the 
patients with CEP and sufficient amounts for isolation and 
positive identification were not available. Peak 8 was the 
of 
large amountAuroporphyrin I present in the plasma. 
Peak 2 co-eluted with synthetic meso-
hydroxyuroporphyrin I under all HPLC conditions. It was 
therefore identified as meso-hydroxyuroporphyrin I. This was 
confirmed by sodium amalgam reduction of the compound 
followed by aromatization with iodine, which eliminated 
98 
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peak 1, hydroxyacetic acid uroporphyrin Ii 
peak 2 & 3, decarboxylation products of 
hydroxyacetic acid uroporphyrin I. 
Peak 2 had the same retention time 
2 
as (b) peak 6. 
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the hydroxyl group to give uroporphyrin I. 
Peak 3 had exactly the same retention time as authentic 
meso-hydroxyuroporphyrin III and therefore was identified as 
meso-hydroxyuroporphyrin III. This assignment was confirmed 
by reduction of the compound followed by re-oxidation which 
gave uroporphyrin III as the only product. 
Peak 5 had identical chromatographic and chemical 
behaviour to that of B-hydroxypropionic acid uroporphyrin I 
isolated from the urine of patients with CEP and was 
therefore assigned as B-hydroxypropionic acid uroporphyrin 
I. This compound was easily dehydrated by heating in diluted 
HCl to give the monoacrylic derivative as previously 
described (Sec. 3.5.3.). 
The chromatographic and chemical properties of peak 6 
were identical to those of hydroxyacetic acid uroporphyrin I 
isolated from the urine of patients with CEP. On heating in 
dilute HCl no dehydration product was formed, indicating 
that the hydroxyl group was attached to an acetic acid group 
and therefore difficult to dehydrate. Some partial 
decarboxylation products were formed instead, as described 
in section 3.5.4 .. Thus it was identified as hydroxyacetic 
acid uroporphyrin I. 
Peak 7 had the characteristic greenish-yellow colour 
with a typical red porphyrin fluorescence under uv 
illumination, similar to peroxyacetic acid uroporphyrin I 
101 
isolated from the urine of patients with CEP. It gave 
uroporphyrin I when reacted with 0.1 M KOH or Ca{OH)2 and 
was stable under acidic conditions. It also had the same 
retention time under all conditions as peroxyacetic acid 
uroporphyrin I isolated from the urine from CEP patients. 
This peak was therefore identified as peroxyacetic acid 
uroporphyrin I. 
3.5.8. stability of hydroxy- and peroxyacetic acid-
porphyrins 
Meso-hydroxyuroporphyrin I was reasonably stable in 
acid and no change was observed when dissolved in 5 M HCI 
for 10 min in the dark. It was stable in weak alkaline, e.g. 
0.1 M KOH, but was less stable in stronger alkaline 
solutions. When the compound was dissolved in 0.7 M KOH for 
10 min in the dark, less than half of the original material 
was detected by HPLC. When it was dissolved in 0.85 M KOH 
for 10 min in the dark, the colour of the solution turned 
into greenish-yellow and lost its UV fluorescence. The 
resulting solution was analysed by HPLC and nothing was 
detected by the fluorescent detector. This indicated that 
under strong alkaline condition the highly conjugated 
macrocycle of the porphyrin was opened. 
Meso-hydroxyuroporpyrin I was not very stable to heat. 
When it was heated at 135°C for 30 min in the dark, the 
compound was reduced to about 1/3 of the original amount 
when analysed by HPLC. A late eluting peak was formed which 
was detected by UV-VIS but not by fluorescent detection. 
102 
When it was heated at 135°C for 1 h, nothing was detected 
with the fluorescent detector and the late eluting peak 
detected by the UV-VIS detector was increased. This also 
indicated ring opening on prolonged heating of the compound. 
B-Hydroxypropionic acid-, hydroxyacetic acid 
uroporphyrin I, B-hydroxypropionic acid- and hydroxyacetic 
acid heptacarboxylic acid porphyrins were stable in both 
acid and alkaline solutions, in contrast to meso-
hydroxyuroporphyrin I. 
Peroxyacetic acid uroporphyrin I was stable in acid but 
was hydrolysed to uroporphyrin I in alkaline solution. It 
was also unstable to heat. When it was heated at 135°C in 
dilute HCI in the dark for 30 min, Uro I was found and this 
was increased with increasing time of heating. 
3.5.9. Electronic absorption spectra of hydroxy- and 
peroxyacetic acid- porphyrins 
Spectrophotometric determination showed that meso-
hydroxy-, B-hydroxypropionic acid-, hydroxyacetic acid-
uroporphyrin I, B-hydroxypropionic acid heptacarboxylic acid 
porphyrin I and hydroxyacetic acid heptacarboxylic acid 
porphyrin I in acid solution had characteristic visible 
absorption spectra of porphyrin dication which resembled Uro 
I (Fig.3.25-30). They all had one major Soret band and two 
satellite bands with a weaker band as a shoulder attached to 
the first one. 
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Fig. 3.30. Electronic Absorption Spectra of Hydroxyacetic Acid Hcptacarboxylic Acid Porphyrin 
The Soret band of meso-hydroxyuroporphyrin I is 410nm, 
longer than Uro I (405 nm) which is consistent with a 
sUbstitution attached to the conjugated macrocircle ring 
(Williams & Fleming, 1987). The Soret bands of B-
hydroxypropionic acid- and hydroxyacetic acid uroporphyrin I 
are 405.5 and 405 nm, respectively, very close to Uro I. 
The spectrum of peroxyacetic acid uroporphyrin I is 
different from Uro I (Fig.3.31.). The Soret band was split 
and the two major satellite bands at about 540-620 nm were 
replaced by a single band at the wavelength of 619.0 nm. 
The electron absorption spectra showed that the Soret 
Bands of B-hydroxypropionic acid- and hydroxyacetic acid-
heptacarboxylic acid porphyrins were at 404.5 and 403.5nm, 
respectively. The slightly shorter wavelength than 
uroporphyrin is consistent with the loss of a carboxylic 
acid group (williams and Fleming, 1987). Compared with the 
Soret Band of meso-hydroxy-, B-hydroxypropionic acid- and 
hydroxyacetic acid- uroporphyrin I, these two compounds are 
very different from meso-hydroxyuroporphyrin I but are 
close to B-hydroxypropionic acid- and hydroxyacetic acid-
uroporphyrin I. The Soret band of B-hydroxypropionic acid 
heptacarboxylic acid porphyrin had slightly longer 
wavelength than the hydroxyacetic acid heptacarboxylic acid 
porphyrin which resembled the observed longer wavelength of 
B-hydroxypropionic acid uroporphyrin I than hydroxyacetic 
acid uroporphyrin I. This further confirms that peak 5 (B-
hydroxypropionic acid heptacarboxylic acid porphyrin I) in 
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Fig. 3.31. Electronic Absorption Spectra of Peroxyacetic Acid Uroporphyrin I 
Table 3.1. Wavelength of the porphyrin Dications in Diluted Hel 
Porphyrin Soret Band satellite Band I satellite Band II 
URO I 405 nm 551 nm 592 nm 
meso-OH Uro I 410 nm 555 nm 613 nm 
B-OH propionic acid Uro I 405.5 nm 552 nm 593.5 nm 
OH-acetic acid Uro I 405 nm 551 nm 593 nm 
CH2-COOOH Uro I 394.5 & 406.5 nm 619 nm 
B-OH propionic acid-7COOH porphyrin 404.5 nm 551 nm 593 nm 
OH-acetic acid-7COOH porphyrin 403.5 nm 550.5 nm 592.5 nm 
Fig.3.3. is the metabolite of B-hydroxypropionic acid 
uroporphyrin I, and that peak 6 (hydroxyacetic acid 
heptacarboxylic acid porphyrin I) is the metabolite of 
hydroxyacetic acid uroporphyrin I. 
The absorption wavelengths of uroporphyrin I, meso-
hydroxyuroporphyrin I, B-hydroxypropionic acid uroporphyrin 
I, hydroxyacetic acid uroporphyrin I, peroxyacetic acid 
uroporphyrin I, B-hydroxypropionic acid heptacarboxylic acid 
porphyrin and hydroxyacetic acid heptacarboxylic acid 
porphyrin are listed in Table 3.1. 
3.6. Conclusions 
Meso-hydroxyuroporphyrin If B-hydroxypropionic acid 
uroporphyrin If hydroxyacetic acid uroporphyrin If 
peroxyacetic acid uroporphyrin If B-hydroxypropionic acid 
heptacarboxylic acid porphyrin I and hydroxyacetic acid 
heptacarboxylic porphyrin I have been isolated from the 
urine of patients with CEP and characterised by HPLC f 
chemical behaviour and LSIMS. The hydroxy- and peroxyacetic 
acid uroporphyrin I derivatives have also been identified in 
the plasma of these patients together with a little meso-
hydroxyuroporphyrin III. These compounds are most probably 
derived from uroporphyrin I or uroporphyrinogen I which 
accumulated in large quantity in patients with CEP due to 
uroporphyrinogen III synthase deficiency. The origin and 
mechanism of formation of these new porphyrin metabolites 
have been investigated and are described in the following 
chapters. 
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APPENDIX 
Meso-hydroxyuroporphyrin I, B-hydroxypropionic acid 
uroporphyrin I, hydroxyacetic acid uroporphyrin I and 
peroxyacetic acid uroporphyrin I were isolated and characterised 
mainly from the urine of one patient with confirmed CEP. The 
clinical history and biochemical findings of the patient are as 
follows. 
The patient (MD) was a 23 years old man, who was diagnosed 
as congenital erythropoietic porphyria at 2 months of age when he 
presented with persistent neonatal jaundice, haemolysis and 
cutaneous photosensitivity. There was no history of 
consanguinity. Erythrocyte Uro'gen 111-8 activity was reduced to 
19% of normal in the subject and to approximately 50% in both 
parents and in his sister (Wright & Lim, 1983) consistent with 
autosomal recessive inheritance and also indicating that the 
sister was a carrier. He was treated with intermittent blood 
transfusions and splenectomy was carried out at the age of 7 
years. Regular medication also included ascorbic acid, B-
carotene, folic acid, penicillin after the splenectomy, and 
avoidance of sunlight. From the age of 10 years he received 
regular subcutaneous infusions of desferrioxamine at night. 
Despite these measures he continued to have extensive 
photomutilation of the hands and face, with shortening of the 
digits, and when 20 years old he complained of pain in the spine 
and sternum and was found to have compression fractures of 2 
vertebrae. Treatment of osteoporosis with clodronate 
(dichloromethylene bisphosphonate) was carried out (Pullon et 
al., 1991). At the time when this study was performed he was also 
i 
on a more intensive regime of blood t f' rans USlons (2-3 units at 
approximately 4 weeks intervals). 
Biochemical investigation over eight weeks revealed that the 
activity of erythrocyte Uro'gen III-S was 38-86 nmol Uro III/ml 
RBC per hour. Urinary porphyrin excretion was 79-283 ~mol/24h 
", 
with 75% of Uro I, 15% of Copro I, 8% of hepta to penta-
carboxylic acid porphyrins dominated in type I isomers and 1.6% 
of uroporphyrin I derivatives. Plasma porphyrin was 2.5-4.1 
~mol/l with 66% of Uro I, 14% of Copro I, 18% of hepta to penta-
carboxylic acid porphyrins and 0.6% of uroporphyrin I 
derivatives. Erythrocyte porphyrin was 3.2-10.6 ~mol/l with 83% 
of Uro I and 17% of Copro I, other porphyrins were not 
detectable. 
After the uroporphyrin I derivatives were identified in the 
urine of MD, their existence in the urine of another four 
patients with CEP was investigated. The HPLC chromatograms of 
urinary porphyrin of three out of the four patients showed 
identical patterns with the patient MD. In the urine of the 
fourth patient (CB), only traces of meso-hydroxyuroporphyrin I 
and B-hydroxypropionic acid uroporphyrin I were found. Further 
analysis showed that the activity of Uro'gen III-S was 75.1 
nmol/ml RBC per h, the porphyrin level in his urine was 3.732 
~mol/24h and in his plasma was 26.485 nmol/l, both dominated in 
Uro I together with some Copro I. Therefore uroporphyrin I 
excretion in patient CB was much lower than that in patient MD. 
This indicated that the existence of uroporphyrin I derivatives 
was closely related to the level of uroporphyrin I in vivo which 
was be discussed in more detail in section 6.3 .. 
ii 
CHAPTER 4 
THE ORIGIN OF HYDROXY- AND PEROXYACETIC ACID- PORPHYRINS IN 
CEP 
4.1. Introduction 
Meso-hydroxyuroporphyrin I, B-hydroxypropionic acid 
uroporphyrin I, hydroxyacetic acid uroporphyrin I and 
peroxyacetic acid uroporphyrin I have been identified in the 
urine and plasma of patients with CEP. Their origin, 
however, is unknown. It is possible that these compounds are 
formed artifactly in the blood or urine due to the 
relatively high concentration of Uro I present in these body 
fluids, particularly in stored samples. It is equally 
possible that they are true metabolites derived from Uro I 
or Uro'gen I in vivo by an oxidation process. This chapter 
investigates the source and the origin of hydroxy- and 
peroxyacetic acid porphyrins in CEP. 
4.2. Experimental 
4.2.1. Materials and reagents 
Ammonium acetate, glacial acetic acid, 
trichloroacetic acid, 1 2 , concentrated HCI, NaHCo3 , NaOH, 
ethylenediaminetetraacetic acid (EDTA), NH 4CI, sucrose, 
KHC0 3 , ascorbic acid, Triton X-lOO, MgCI 2 , dimethyl 
sulphoxide (DMSO), diethyl ether and chloroform were 
AnalaR grade from BDH Chemicals (Poole, Dorset, U.K.). 
Acetonitrile and methanol were HPLC grade from Rathburn 
114 
Chemicals (Walkerburn, Borders, Scotland, U.K.). 
Tris(hydroxymethyl)aminoethane (Tris) was from Boehringer 
Mannheim GmbH. (F.R.G.). Heparin was from Paines & Byrme 
Ltd. (Greenford, UK). Porphobilinogen, uroporphyrin, 
coproporphyrin, glutathione, dithiothreitol and Dextran (MW 
500,000), were from Sigma Chemical Co. (Poole, Dorset). 
4.2.2.HPLC of porphyrins in clinical samples and reaction 
mixtures 
A Varian Associates (Walton-on-Thames, Surrey, U.K.) 
Model 5000 liquid chromatography with a varian w-
100 variable wavelength detector set at 405 nm and a 
Perkin-Elmer LS3 fluorescent detector set at excitation 400 
and emmision 618 nm, respectively, was used. Samples were 
injected via a Rheodyne (Cotati, CA, USA) 7125 injector 
fitted with a 500 ~l loop. The separation was carried out on 
a 250 mm x 5 mm Hypersil-ODS column (Shandon Scientific, 
Runncorn, Cheshire, U.K.). Unless otherwise stated the 
mobile phase generally consisted of solvent A: 9% (v/v) of 
acetonitrile in 1 M ammonium acetate buffer, pH 5.16 and 
solvent B: 10% (v/v) of acetonitrile in methanol. The 
elution program varied according to the separations 
required. The flow rate was 1 ml/min throughout. The 
elution programs were as follows. 
1. For the quantitation of meso-hydroxyuroporphyrin I, 
B-hydroxypropionic acid uroporphyrin I, hydroxyacetic acid 
uroporphyrin I and peroxyacetic acid uroporphyrin I in the 
urine and plasma: 
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Time 0 to 16 min, 0% solvent B (100% solvent A) to 11% 
solvent B; time 16 to 24 min, isocratic elution at 11% 
solvent B; time 24 to 38 min, 11% solvent B to 24% solvent 
B; time 38.1 to 48min, isocratic at 95% solvent B to wash 
the column. 
For complete profile of the porphyrins, run the 
gradient from 0 to 38 min as above, then from time 38 to 60 
min, 24% solvent B to 60% solvent B and time 60 to 80 min, 
60% solvent B to 80% solvent B. The column was then re-
equilibrated at 0% solvent B for 10 min before injection 
of next sample. 
2. For the analysis of porphyrins in duodenal aspirates 
and faeces: 
Isocratic elution at 15% B for 10 min; linear gradient 
elution from 15 to 70% B from 10 to 45 min; linear gradient 
elution from 70 to 95% B from 45 to 50 min, followed by 
isocratic elution at 95% B for a further 10 min. 
3. For measurement of the production of peroxyacetic 
acid uroporphyrin I in the incubation mixture of red cell 
haemolysates with Uro'gen I or PBG as substrate: 
Isocratic elution at 15% solvent B for 30 min, followed 
by isocratic elution at 95% for 10 min. Re-equilibrate the 
column at 15% solvent B for 10 min before the next 
injection. 
4. For investigation of hydroxylated uroporphyrin in 
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the reaction mixture of red cell haemolysates with Uro'gen I 
as sUbstrate: 
Time 0 to 30 min, 0% solvent B to 3% solvent Bi time 30 
to 40 min, 3% solvent B to 9% solvent Bi time 40 to 50 min, 
9% solvent B to 20% solvent Bi time 50.1 min, 95% solvent B 
to elute late eluting peaks. 
5. For analysis of the incubation mixture of red cell 
haemolysates with heptacarboxylic acid porphyrinogen I as 
substrate: 
Isocratic elution at 19% solvent B for 34 min, followed 
by 95% solvent B for 10 min to wash the column. 
6. For analysis of reaction mixture of red cell 
haemolysates with pentacarboxylic acid porphyrinogen I as 
substrate: 
Time 0 to 40 min, 15% solvent B to 40% solvent Bi time 
40.1 min 95% solvent B for 5 min to wash the rest. 
7. For analysis of reaction mixture of red cell 
haemolysates with Copro'gen I as substrate: 
Isocratic elution at 55% solvent B. 
4.2.3. preparation of blood sample 
Erythrocytes and plasma were prepared as described in 
Sec. 2.3.4. 
Leucocytes were prepared by erythrocytes sedimentation 
and NH4CI buffer lysis (Cuttes, 1970). Heparinized blood, 20 
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ml, was added to an equal volume 3% (w/v) Dextran solution 
(MW 500,000) in 0.15 M NaCI, mixed and centrifuged at 2100 g 
for 10 min at 4°C. The supernatant was removed with a 
Pasteur pipette. The leucocyte layer was pipetted into a 
clean tube. Any contaminated red blood cells (RBC) were 
lysed by adding 7-8 ml of ice-cold NH4CI buffer pH 7.4 (8.3g 
NH 4CI, 19 KHC0 3 and 1ml of 0.1 molll EDTA per litre) and 
standing on ice for 7 min. After centrifugation, the 
supernatant was decanted and the leucocytes were washed 
thrice with ice cold saline. If the RBC contamination was 
not completely eliminated, NH 4CI buffer lysis could be 
repeated. The leucocytes were then resuspended in 0.25 M 
sucrose containing 0.05 M Tris-HCI buffer, pH 7.4 and 5 
units of heparin per 20 ml of blood. The leucocytes were 
lysed by freezing and thawing thrice before use. If not used 
immediately, the leucocytes were stored at -30°C. 
4.2.4. Incubation of porphyrin(oqen) 
haemolysates 
with red cell 
Uro'gen I, Uro I, hepta'gen I, penta'gen I, Copro'gen I 
and Copro I were used as substrates, respectively. Packed 
RBC, 15 ~l, were pre-incubated with 1.4 ml of 0.05 M Tris-
HCI buffer, pH 8.25, containing 74 ~M MgCl2 and 0.1% Triton 
X-100 at 37°C in the dark for 5 min. The reaction was 
started by adding 50 ~l of porphyrinogen and continuously 
incubated for a further 10 min. The reaction was stopped by 
adding 1.5 ml of 10% TCA containing 0.5% 1 2 . After mixing 
and centrifugation the supernatant was injected into the 
HPLC for analysis. 
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Parallel blanks were prepared by 1. using boiled RBC; 
2. using incubation buffer instead of RBC; and 3. using 
incubation buffer instead of porphyrinogen. When 
porphyrinogens other than Uro'gen were incubated with RBC, 
10% TCA containing 12 / DMSO (v/v, 1:1) was used to stop the 
reaction and extract the porphyrins. 
4.2.5. Incubation of porphobilinogen (PBG) with red cell 
haemolysates 
Method 1. Packed RBC 30 ~l, were added into 1.4 ml of 
0.05 M Tris-HCI buffer, pH 8.25, containing 74 ~M MgCl2 and 
0.1% Triton X-100. After mixing, the mixture was heated at 
560 C for 1 h to deactivate Uro'gen III-S. The mixture was 
cooled to room temperature and 3 ~l of fresh unheated RBC 
were added. The mixture was pre-incubated at 370 C for 5 min 
and then the reaction was started by adding 50~1 of PBG (8.3 
~g) as the substrate. The incubation was continued for a 
further 30 min at 37 o C, in the dark. The reaction was 
stopped by adding 1.5 ml of 10%TCA containing 0.5% 12 , After 
centrifugation the supernatant was ready for HPLC analysis. 
Method 2. Packed RBC 30 ~l, were added into 1.4 ml of 
0.05 M Tris-HCI buffer pH 8.25, containing 74 ~M MgCl 2 and 
0.1% Triton X-100. The mixture was heated to 56°C for 1 h, 
cooled to room temperature and pre-incubated at 37°C for 5 
min. The mixture then incubated with PBG as described in 
method 1 without further addition of fresh red cells. 
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4.2.6. Incubation of uroporphyrinoqen I with red cell 
haemolysates in presence of reducinq aqents 
1. Addition of reducing agents in the incubation 
buffer: 
Reducing agents glutathione, ascorbic acid and 
dithiothreitol were dissolved in Tris-HCl buffer, pH 8.25, 
containing 74 ~M MgCl2 and 0.1% Triton X-100, respectively. 
The concentrations of each reducing agents in the buffer 
were as follows: glutathione 0.5, 1, 2, and 3 mM; ascorbic 
acid 0.5, 1, 2, 3, 50, 100 and 300 mM; and dithiothreitol 10 
mM (pH was adjusted to 6.8). 
Packed RBC, 15 ~l, were pre-incubated with 1.4 ml of 
0.05 M Tris-HCl buffer pH 8.25, containing 74 ~M MgCl2 , 0.1% 
Triton X-100 and various concentrations of glutathione, 
ascorbic acid or dithiothreitol, respectively, at 37°C in 
the dark for 5 min. The reaction was started by adding 50 ~l 
of 80 ~M uroporphyrinogen I and continuously carried out as 
described in Sec. 4.2.4 .. 
2. Addition of reducing agents in the Uro'gen I 
solution: 
Uro'gen I, 160 ~M, was reduced with 0.5% Na/Hg and then 
diluted with equal volume of Tris-HCl buffer, pH 8.25, 
containing 74 ~M MgCl 2 , 0.1% Triton X-100, and glutathione 
(1, 2, 4, 6 and 8 mM) or dithiothreitol (2, 4, 6, 8 and 
10mM) , respectively. 
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Packed RBC, 15 ~l, were pre-incubated with 1.4 ml of 
0.05 M Tris-HCl buffer pH 8.25, containing 74 ~M MgC1 2 , 0.1% 
Triton X-100 at 37°C in the dark for 5 min. The reaction was 
started by adding 50 ~l of 80 ~M uroporphyrinogen I prepared 
as above and continuously carried out as described in Sec. 
4.2.4 .. The final concentrations of glutathione in the 
reaction mixture were 0.017, 0.034, 0.068, 0.102 and 0.137 
mM; and dithiothreitol were 0.034, 0.068, 0.102 and 0.137 
and 0.170 roM. 
4.2.7. Incubation of uroporphyrinogen I with red cell 
haemolysates in presence of carbon monoxide 
Packed RBC, 15 ~l, were added into 4 x 1.4 ml of 0.05 M 
Tris-HCl buffer pH 8.25, containing 74 ~M MgC1 2 , 0.1% Triton 
X-100 in a sealed tube (vol. 4 - 4.5 ml). Two of the tubes 
were equilibrated with 80% of carbon monoxide in oxygen for 
2 min with shaking. The other two tubes contained 80% 
nitrogen in oxygen. The tubes were pre-incubated for 5 min 
in the dark at 37°C. Then the reaction was started by 
injecting 10 ~l of Uro'gen I (15 nmol) into each of the 
tubes with a syringe and continuously incubated for further 
10 min. The reaction was stopped by addition of 1.5 ml of 
10% TCA containing 0.5% 12 , again, through a syringe. After 
mixing and centrifugation, the supernatant was injected into 
the HPLC for analysis. 
4.2.8. Incubation of uroporphyrinogen I with plasma and 
leucocytes 
Leucocytes prepared as described in Sec.4.2.3. were 
121 
divided into two portions, one was used in the reaction 
mixture and the other was boiled for blank control. Plasma, 
100 ~l, was also boiled for blank control. 
Plasma, 100 ~l, or leucocytes isolated as described 
above was pre-incubated with 1.4 ml of 0.05 M Tris-HCl 
buffer, pH 8.25, containing 74 ~M MgC1 2 and 0.1% Triton x-
100 at 37°C in the dark for 5 min. The reaction was started 
by adding 50 ~l of 80 ~M uroporphyrinogen I and continuously 
carried out as described in Sec. 4.2.4 .. 
4.3. Results and Discussion 
4.3.1. Source of hydroxy- and peroxyacetic acid-uroporphyrin 
I 
In order to find out whether the accumulation and 
excretion of hydroxy- and peroxyacetic acid uroporphyrin I 
derivatives in plasma and urine is a common feature of 
patients with CEP, urine and plasma of CEP patients with 
different degree of clinical and biochemical manifestations 
were analysed. Fresh urine samples were analysed to 
eliminate the possibility that these compounds were derived 
artifactly in stored samples. 
In CEP patients where urinary Uro I levels were high 
(78-283 ~mol / 24 h) hydroxy- and peroxyacetic acid 
uroporphyrin I derivatives were easily detected. In one 
patient who excreted much lower levels of urinary 
uroporphyrin I (2.28-4.22 ~mol/24h) only traces of meso-
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hydroxyuroporphyrin I and B-hydroxypropionic acid 
uroporphyrin I were found and hydroxyacetic acid 
uroporphyrin I and peroxyacetic acid uroporphyrin I were 
hardly detectable. These results show that the presence of 
hydroxy- and peroxyacetic acid- uroporphyrin I derivatives 
in the urine is a common feature of CEP. 
Since hydroxy- and peroxyacetic acid- uroporphyrin I 
derivatives must be formed by an oxidation process, they may 
originate from the oxidation of uroporphyrinogen I by air 
when they are excreted out of the body in the urine. 
oxidation of uroporphyrinogen I in the dark by air and with 
1 2 , however, produced no hydroxy- and peroxyacetic acid-
derivatives. The urine of patients with acute intermittent 
porphyria during acute attack when high concentrations of 
PBG are excreted were also analysed. Again no hydroxy- nor 
peroxyacetic acid- uroporphyrin I derivatives were detected. 
Since PBG in the urine will condense to form 
uroporphyrinogens which then oxidised to form uroporphyrins, 
it again shows that simple aerial oxidation of 
uroporphyrinogen to porphyrin is not responsible for the 
production of hydroxy- and peroxyacetic acid- uroporphyrins. 
Hydroxy- and peroxyacetic acid- uroporphyrin I derivatives 
were also undetectable in the duodenal aspirates and faeces 
of the patient with CEP who excreted relatively large amount 
of these compounds in the urine. This indicated that 
hydroxy- and peroxyacetic acid- uroporphyrin I derivatives 
were not formed in the liver of CEP patients and they 
therefore are likely to be of erythropoietic origin since 
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these compounds were detected in the plasma of patients with 
CEP. To test this hypothesis the reaction of Uro'gen I with 
erythrocytes from CEP and normal subjects was investigated 
in detail in order to find out whether in the presence of an 
excess of Uro'gen I hydroxylation and peroxylation reactions 
could take place. 
4.3.2. Reaction of uroporphyrin I with red cell haemolysates 
When uroporphyrin I was incubated with red cell 
haemolysates no hydroxy- nor peroxyacetic acid- derivatives 
were found. These derivatives must be therefore derived from 
uroporphyrinogen I rather than Uro I. 
4.3.3. Reaction of uroporphyrinogen I with red cell 
haemolysates 
When uroporphyrinogen I was incubated with red cell 
haemolysates, a peak with the same retention time as the 
natural peroxyacetic acid uroporphyrin I was detected under 
various HPLC conditions (Fig. 4.1.). This peak was 
collected, purified and analysed by LSIMS as described in 
chapter 3. The methyl and ethyl esters gave MH+ signals at 
945 and 1043, respectively (Fig. 4.2. & 4.3.), identical to 
the peroxyacetic acid isolated from the urine of patients 
with CEP. To confirm this, the free porphyrin in this 
fraction was treated with 0.1M KOH when it was completely 
converted into UroI.Thus this peak must also be peroxyacetic 
acid uroporphyrin I. Hydroxylated uroporphyrin I derivatives 
were also formed in small quantity (Fig. 4.1). These will be 
discussed in more detail in Chapter 5. The above results 
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Reaction Mixture of UfO' gen I with Red Cell Haen10lysates 
clearly show that in the presence of excess of Uro'gen I, 
reactions occur in the red cells which convert Uro'gen I 
into its hydroxy- and peroxyacetic acid derivatives. 
To further confirm that the formation of peroxyacetic 
acid uroporphyrin I was from uroporphyrinogen I,PBG was used 
as the substrate in the incubation mixture with red cell 
haemolysates. In the absence of Uro'gen III-S 
hydroxymethylbilane (HMB) cyclises non-enzymically to 
Uro'gen I. Thus when heated red cell haemolysates was 
incubated with PBG, a sUbstantial amount of Uro'gen I was 
generated. This reacted with red cell haemolysates giving a 
peak with the exactly the same retention time as the natural 
peroxyacetic acid uroporphyrin I (Fig. 4.4.). This proved 
that the peroxyacetic acid uroporphyrin I was derived from 
Uro'gen I by reaction with red cells. 
In the presence of Uro III-S, HMB is converted to 
Uro'gen III. Thus when unheated red cell was added to the 
incubation mixture with PBG, four peaks which eluted before 
Uro I were detected (Fig. 4.5.). The same four peaks were 
obtained when Uro'gen III was incubated with red cell 
haemolysates. LSIMS analysis of the methyl and ethyl esters 
showed that they were peroxyacetic acid uroporphyrins with 
the MH+ signals at m/z 945 and 1043, respectively. Treatment 
of each of these compounds with 0.1 M KOH converted them 
into Uro III. They were therefore the four type III isomers 
of peroxyacetic acid uroporphyrin. Since Uro III is an 
unsymmetrical compound it is expected to rise to four 
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peroxyacetic acid derivatives. One of the peroxyacetic acid 
uroporphyrin III isomers co-eluted with the type I isomer. 
These results show that red cells can convert both excess 
Uro'gen I and III into the peroxyacetic acid derivatives. 
In control experiments where boiled red cells were 
incubated with Uro'gen I, very little peroxyacetic acid 
uroporphyrin I was formed, indicating that the denatured 
protein lost its ability to catalyse the reaction. 
4.3.4. Comparison of the formation of peroxyacetic acid 
uroporphyrin I with red cell haemolysates from normal 
subject and patient with CEP 
Red cell haemolysates from a normal person and from a 
patient with CEP were investigated. When 30 ~l of heated red 
cell haemolysates were incubated with PBG the peroxyacetic 
acid uroporphyrin I generated were similar in both the 
normal and CEP reaction mixtures. When unheated red cell 
haemolysates were used, however, the peroxyacetic acid 
uroporphyrin I peak in the reaction mixture of CEP was only 
slightly decreased and three very small type III isomers of 
peroxyacetic acid uroporphyrins were detected. In the 
reaction mixture of unheated normal red cells, the 
peroxyacetic acid uroporphyrin I peak was reduced to about 
one third of that with heated red cells but the type III 
isomer peaks were much larger than those in the reaction 
mixture with the erythrocytes from the patient with CEP 
(Table 4.1.). 
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Table 4.1. comparison of the Formation of Peroxyacetic Acid uroporphyrin I and III 
with Red Cell Haemolysates from Normal Subject and Patient with CEP 
Subject 
Normal 
CEP 
I: 
III: 
unit: 
I 
150 
158 
Heated Red Cells 
111-1 111-2 111-3 
peroxyacetic acid uroporphyrin I. 
peroxyacetic acid uroporphyrin III. 
peak height in rom. 
Unheated Red Cells 
1+111 
52 
109 
111-1 111-2 111-3 
18 
12 
18 
14 
20 
14 
Note: One of the type III isomers co-eluted with the type I isomer. Assuming that 
roughly equal proportions of the four type III isomers are formed, the unheated red 
cells of normal subject and CEP patient should produce about 19 and 13 mm of the 
fourth isomer, respectively. 
When unheated red cell haemolysates were incubated with 
PBG, the HMB generated by HMB-S was used by Uro'gen III-S as 
substrate to generate Uro'gen III. In the patient with CEP 
where Uro'gen III-S is defective, Uro'gen III production is 
less than the spontaneous cyclisation of HMB to 
uroporphyrinogen I. Since the formation of peroxyacetic acid 
uroporphyrin was proportional to the Uro'gen concentration 
in the reaction mixture (Sec. 4.3.5.2.), more peroxyacetic 
acid uroporphyrin I was therefore produced by the red cells 
of the patient with CEP and more type III isomers by the 
normal red cells which synthesised more uroporphyrinogen 
III. 
4.3.5. optimization of reaction conditions for the formation 
of peroxyacetic acid uroporphyrin I 
4.3.5.1. Relationship between the volume of red cell 
haemolysates and the production of peroxyacetic acid 
uroporphyrin I 
To determine the optimum volume of red cell 
haemolysates for the production of peroxyacetic acid 
uroporphyrin I, fixed concentration of Uro'gen I (final 
conc. 16.9~M) was incubated with various amount of red cell 
haemolysates. The result showed that at this concentration 
of Uro'gen I peroxyacetic acid uroporphyrin I production was 
linear to the volume of red cell haemolysates up to 15~1 as 
shown in Fig. 4.6 .. 
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This is the typical result of five experiments. 
4.3.5.2. Relationship between the concentration of Uro'qen 
I and the production of peroxyacetic acid uroporphyrin I 
To investigate the optimum concentration of Uro'gen I 
used in the reaction mixture for the production of 
peroxyacetic acid uroporphyrin I, a fixed volume of red cell 
haemolysates (15~1) was incubated with various concentration 
of Uro'gen I. The result showed that the production of 
peroxyacetic acid uroporphyrin I was linear to the 
concentration of Uro'gen I up to 10~M. The rate of the 
formation then slowed down and levelled off at 15~M (Fig. 
4.7.). The failure of calculating the kinetic constant (Km) 
indicated that the formation of peroxyacetic acid 
uroporphyrin I is not due to an enzymic reaction. 
4.3.5.3. Relationship between incubation time and production 
of peroxyacetic acid uroporphyrin I with red cell 
haemolysates 
When Uro' gen I was incubated wi th red cell 
haemolysates, the production of peroxyacetic acid 
uroporphyrin I was very rapid and reached the maximum value 
within one minute. There was no significant difference in 
the formation of peroxyacetic acid uroporphyrin I when 
incubation was carried out between 1 and 20 min. Incubation 
longer than 20min, however, caused a slow decrease in 
peroxyacetic acid uroporphyrin I production as shown in Fig. 
4.8 .. When incubation was carried out for 12 hand 18 h, the 
amount of peroxyacetic acid uroporphyrin I detected was 
about 30% of that after 10 min incubation. Uro I recovered 
was also reduced, but to a much lesser extent. No additional 
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This is the mean of four experiments. 
peaks were detected. Addition of EDTA (lmM) into the 
incubation buffer did not affect the result. 
4.3.5.4. pH optimum for the production of 
acid uroporphyrin I 
peroxyacetic 
When 15 ~M of red cell haemolysates was incubated with 
Uro'gen I (final Conc. 2.7 ~M), the maximum production of 
peroxyacetic acid uroporphyrin I was at approximate pH 8 as 
shown in Fig.4.9. At pH above 9, the amount of peroxyacetic 
acid uroporphyrin I detected decreased rapidly. There are 
two possible reasons for this observation. The first is that 
the formation of peroxyacetic acid uroporphyrin I was 
inhibited, the second is that peroxyacetic acid uroporphyrin 
I was not stable under alkaline conditions and tended to 
convert into Uro I spontaneously under these conditions 
(Sec. 3.5.5.). This will be discussed in next chapter. 
4.3.5.5. Relationship between incubation temperature and 
the formation of peroxyacetic acid uroporphyrin I 
Uro'gen I (final Conc. 2.7~M) was incubated with 15~1 
of red cell haemolysates at various temperature. The result 
surprisingly showed that the maximum amount of peroxyacetic 
acid uroporphyrin I was detected at 0-10°C. At higher 
incubation temperatures the yield of peroxyacetic acid 
uroporphyrin I was lower as shown in Fig. 4.10 .. The reason 
for this behaviour was not clear. 
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This is the mean of two experiments. 
4.3.6. Effect of reducing agents on 
of peroxyacetic acid uroporphyrin I 
the formation 
Since peroxyacetic acid uroporphyrin I must be formed 
by an oxidation process experiments were carried out to 
determine whether reducing agents can inhibit its 
production. 
The reducing agent glutathione was used for this 
investigation. Uro'gen I (final Conc. 2.7 ~M) was incubated 
with 15 ~l of red cell haemolysates in buffer containing 
0.5, 1, 2 and 3 roM of reduced glutathione, respectively. The 
results clearly showed that glutathione inhibited the 
formation of peroxyacetic acid uroporphyrin I by more than 
60% (Table 4.2.). Addition of glutathione into the Uro'gen I 
solution to give a much lower final concentration of 0.017, 
0.034, 0.068, 0.102 and 0.137 mM in the reaction mixture 
also inhibited the formation of peroxyacetic acid 
uroporphyrin I (Table 4.3.). 
other reducing agents, such as ascorbic acid and 
dithiothreitol, were also tested for inhibition with similar 
positive results. The formation of peroxyacetic acid 
uroporphyrin I was inhibited by the presence of both 
ascorbic acid and dithiothreitol. 
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Table 4.2. Effect Of Glutathione In The Reaction Mixture On The 
Formation Of Peroxyacetic Acid uroporphyrin I (PAAU) 
Glutathione 
(roM) 
Control 
0.5 
1 
2 
3 
PAAU produced 
(nmol/ml RBC) 
12.0 
3.85 
3.26 
3.41 
4.60 
This is the typical result of two experiments. 
Percentage of 
Control (%) 
100 
32.1 
27.2 
28.4 
38.3 
Table 4.3. Effect Of Glutathione In Uro'gen I Solution On The 
Formation Of Peroxyacetic Acid uroporphyrin I 
Glutathione 
(roM) 
Control 
0.017 
0.034 
0.068 
0.102 
0.137 
PAAU produced 
(nmol/ml RBC) 
11.2 
10.7 
10.4 
7.88 
7.79 
7.97 
This is the typical result of two experiments. 
Percentage of 
Control (%) 
100 
95.9 
92.7 
70.5 
69.7 
71.3 
4.3.7. Inhibition of the production of peroxyacetic acid 
uroporphyrin I by carbon monoxide 
The principal component in red cell haemolysates is 
haemoglobin. To investigate whether haemoglobin is involved 
in the formation of peroxyacetic acid uroporphyrin I, red 
cell haemolysates, 15~1, were saturated with 80% CO in ° 
2 
prior to the reaction followed by incubating with Uro'gen I 
in a sealed tube. The formation of peroxyacetic acid 
uroporphyrin I under this condition was reduced to nearly 
50% of that produced in the sealed tube with the same volume 
of 80% N2 in 02. This result indicated that haemoglobin 
played a very important role in the formation of 
peroxyacetic acid uroporphyrin I, which will be discussed in 
Chapter 5. 
4.3.8. Reaction of Uro'qen I with plasma and leucocytes 
Hydroxylated and peroxyacetic acid uroporphyrin I have 
been identified in the plasma. To investigate the source of 
these derivatives, plasma (100 ~l) was incubated with 
Uro'gen I and compared with the parallel blanks using boiled 
plasma or water instead of plasma. In the incubation mixture 
with fresh plasma peroxyacetic acid uroporphyrin I was 
detected, but the quantity formed was about 10% of that in 
the incubation mixture with 30 ~l of RBC and Uro'gen I (2.7 
~M). Leucocytes (isolated from 10 and 20ml of blood) were 
also incubated with Uro'gen I. However, the peroxyacetic 
acid uroporphyrin I detected in the reaction mixture with 
boiled leucocytes was 16% more than that with unboiled 
leucocytes but was less than that with plasma. The HPLC 
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separation profiles of both reaction mixtures with plasma 
and leucocytes were qualitatively similar to that with red 
cell haemolysates. These results further confirm the 
requirement of haemoglobin for the production of 
peroxyacetic acid uroporphyrin I. 
4.3.9. Formation of peroxyacetic acid heptacarboxylic acid 
porphyrinogen I in red cell haemolysates 
To investigate whether heptacarboxylic acid 
porphyrinogen I can similarly form a peroxyacetic acid 
derivative, it was incubated with 15~1 of red cell 
haemolysates at 37°C in the dark for 10min. Since there was 
no peroxyacetic acid heptacarboxylic acid porphyrin found in 
the urine of patients with CEP, the products formed in the 
reaction mixture were compared with the three reaction 
blanks with boiled RBC, incubation buffer instead of RBC and 
without heptacarboxylic acid porphyrinogen I. Seven peaks 
were found in the reaction mixture which were essentially 
absent in the blanks (Fig.4.11.). To isolate these peaks in 
sufficient quantities for LSIMS characterization, the 
reaction mixtures were pooled and the porphyrins were 
extracted by C18 cartridge before HPLC separation. Each peak 
was collected individually, repurified, and esterified for 
LSIMS analysis. 
The MS spectra of peaks 5, 6 and 7 gave the same MH + 
signal at m/z 887 (Fig. 4.12.). A 2 Oa over the heptamethyl 
ester of heptacarboxylic acid porphyrin (MH+, m/z 885) 
clearly suggested that these three peaks were peroxyacid 
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analogues of heptacarboxylic acid porphyrin I. Assuming 
that, like peroxyacetic acid uroporphyrin I, peroxylation 
took place at the acetic acid function then, there are three 
possible peroxyacetic acid derivatives which can be formed 
from heptacarboxylic acid porphyrinogen I (Fig. 4.13.) 
Peak 4 gave the MH+ signal at m/z 901 (Fig. 4.14.), 
increase of 16 Da unit over the methyl ester 
an 
of 
heptacarboxylic acid porphyrin. The molecular weight 
suggested that this peak was the hydroxylated 
heptacarboxylic acid porphyrin. This peak had exactly the 
same retention time as the B-hydroxypropionic acid 
heptacarboxylic acid porphyrin I found in the urine of 
patients with CEP under two different HPLC elution 
conditions. It is therefore identified as the B-
hydroxypropionic acid heptacarboxylic acid porphyrin. Peaks 
1-3 did not give an identifiable MS signal. 
4.3.10. Formation of peroxyacetic acid pentacarboxylic 
acid porphyrinogen I in red cell haemolysates 
Like heptacarboxylic acid porphyrinogen I , 
pentacarboxylic acid porphyrinogen I was also incubated with 
15~1 of RBC in the dark at 37°C for 10min. The reaction 
mixture was again compared with the blanks (pentacarboxylic 
acid porphyrinogen incubated with boiled RBC, incubation 
buffer instead of RBC or pentacarboxylic acid porphyrinogen 
I). There were 7 peaks which were obviously present in 
larger amount than those in the blanks, but in relatively 
small quantities and less than that produced by 
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heptacarboxylic acid porphyrinogen I. It seems that 
porphyrinogens with fewer carboxylic acid groups are more 
difficult to convert to peroxyacid form. To increase the 
yield different pH (7.0, 7.5 and 8.25) were investigated. 
The pH used, 8.25, in the present reaction, however was 
found to be optimum. 
The relatively low rate of conversion made the 
investigation difficult. The reaction mixtures were pooled, 
extracted by C18 cartridge and then separated by HPLC (Fig. 
4.15). The peaks were collected and repurified by HPLC. They 
were esterified and analysed by LSIMS. Peaks 1-3 were 
insufficient for LSIMS analysis and peaks 5-7 did not give 
an identifiable MS signal. Peak 4 gave a MH+ signal at m/z 
771 (Fig. 4.16), which was 2 Da more than the methyl ester 
of pentacarboxylic acid porphyrin. This indicated that the 
compound was peroxyacetic acid pentacarboxylic acid 
porphyrin I. 
acid 4.3.11. Attempted formation of peroxyacetic 
coproporphyrinoqen I in red cell haemolysates 
Coproporphyrinogen I was also incubated with red cell 
haemolysates at different pH and substrate concentrations. 
The reaction mixture was compared with the parallel blanks 
(Copro'gen I incubated with boiled RBC, incubation buffer 
instead of RBC or Copro'gen I), no significant difference 
was found between the reaction and blank mixtures. Therefore 
no peroxyacid or hydroxylated product was formed under all 
reaction conditions (Fig. 17). This would suggest that the 
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production of a peroxyacid derivative requires an acetic 
acid function and since coproporphyrinogen has four 
propionic acid groups and no acetic acid group, no product 
was formed. This is also consistent with the fact that as 
the numbers of acetic acid groups decreased from 
uroporphyrinogen to hepta- and penta-carboxylic acid 
porphyrinogen, peroxylation was progressively more 
difficult. This also confirmed that the assignment of 
peroxyacetic acid uroporphyrin I in Chapter 3 was correct. 
4.4. Conclusions 
The hydroxylated and peroxylated uroporphyrin 
derivatives found in the urine and plasma of patients with 
CEP are true metabolites of uroporphyrinogen I and are a 
common feature of CEP. These derivatives were not found in 
the urine of AlP, thus ruling out the possibility that they 
were formed artifactly due to the high concentration of 
uroporphyrin in the urine. The formation of the peroxyacetic 
acid uroporphyrin I in the incubation mixture of red cell 
haemolysates with uroporphyrinogen I, but not with 
uroporphyrin, as substrates confirmed that these derivatives 
were formed in vivo from uroporphyrinogen. The failure to 
detect these derivatives in duodenal aspirates and faeces 
from the patients with CEP and the faeces from RCP indicated 
that in CEP these derivatives are of erythropoietic origin. 
The failure of formation of a peroxyacid coproporphyrinogen 
suggested that peroxylation can only take place in the 
presence of an acetic acid group, and confirms the 
assignment of the peroxyacetic acid uroporphyrin I structure 
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in Chapter 3. Incubation of PBG with red cell haemolysates 
from patient with CEP produced a much higher proportion of 
peroxyacetic acid uroporphyrin I compound to normal red 
cells. This reaction may be used in conjunction with the 
Uro'gen III-S assay for the diagnosis of CEP. The inhibition 
by reducing reagents on the formation of peroxyacetic acid 
uroporphyrin I indicated that the formation of these 
derivatives was due to an oxidation mechanism. The detailed 
mechanism of the formation of these derivatives is discussed 
in the next Chapter. 
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CHAPTER 5 
MECHANISMS OF THE FORMATION OF HYDROXYLATED AND 
PEROXYACID UROPORPHYRIN DERIVATIVES 
5.1. Introduction 
In the last chapter the in vitro formation of meso-
hydroxy-, B-hydroxypropionic acid-, hydroxyacetic acid-
uroporphyrin I and peroxyacetic acid uroporphyrin I 
derivatives from uroporphyrinogen I by incubation with red 
cells haemolysates was described. The results indicated that 
an oxidation process was involved. To identify which 
oxidizing species is responsible, several chemica~and in 
vitro systems which generate various active oxygen species, 
mainly free radicals, were tested. The term "free radical" 
refers to any species that has one or more unpaired 
electrons (Halliwell and Gutteridge, 1985A). This chapter 
describes experiments carried out to investigate the 
possible mechanisms of formation of hydroxylated and 
peroxylated uroporphyrin I derivatives. 
5.2. Experimental 
5.2.1. Material and reagents 
Ammonium acetate, glacial acetic acid, 
trichloroacetic acid, 1 2 , concentrated HC1, KC1, NaOH, 
ammonium iron (III) sulphate, KOH, 
ethylenediaminetetraacetic acid (EDTA), Triton X-100, 
MgC1
2
, di-sodium hydrogen orthophosphate dihydrate, 
potassium dihydrogen orthophosphate, hydrogen peroxide, 
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FeCI 3 , dimethyl sulphoxide (DMSO), xanthine oxidase (Grade 
IV), xanthine (sodium salt), were from BDH Chemicals 
(Poole, Dorset). Acetonitrile and methanol were HPLC grade 
from Rathburn Chemicals (Walkerburn, Borders, Scotland). 
Human albumin, allopurinol, haemin, dihydroxymalic acid 
(DHM-A), B-nicotinamide adenine dinucleotide phosphate 
(reduced form) (NADPH), uroporphyrin and coproporphyrin were 
from Sigma Chemical Co. (Poole, Dorset) . 
Tris(hydroxymethyl)aminoethane (Tris) was from Boehringer 
Mannheim GmbH. (F.R.G.). Desferrioxamine mesylate (DES) was 
from Ciba Laboratories (Horsham, West Sussex). 3,4,3',4'-
tetrachlorobiphenyl (3,4-TCB) was from Ultra Scientific, 
Hope, RI. 
5.2.2. Incubation of uro'gen I with liver microsomes 
5.2.2.1. Preparation of liver microsomes 
Chick-embryo microsome induced by 3,4-TCB stimulates 
the NADPH-dependent oxidation of uroporphyrinogen (De 
Matteis et al., 1988). chick liver microsomes were given by 
Dr De Matteis and prepared as described by De Matteis et ale 
(1988). Chick embryos, 16 days of age, of the Rhode Island 
Red x white Rock strain, were obtained from Orchard Farm, 
Pinner, Middx., UK. Liver microsomes were prepared 24 h 
after a single dose of 3,4-TCB (145 ~g/embryo)dissolving in 
10 ~l of 1,4-dioxan given by injection through the air sac 
into the fluids surrounding the embryo. The livers were 
perfused in situ by injecting 5 ml of ice-cold phosphate-
buffered saline (pH 7.3) through the heart. The microsomes 
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were then obtained by differential centrifugation as 
described by Unseld & De Matteis (1978)., washed with 1.15% 
(w/v) KCl and stored frozen (at -70°C) as pellet overlaid 
with 0.5 ml of the KCl solution, until use. 
5.2.2.2. Reaction procedure 
Microsomes, equivalent to 454 pmol of cytochrome P-450 
in 1.15% (w/v) KCI, were pre-incubated in 0.1 M Hepes 
buffer, pH7.4, containing 2 roM EDTA and with or without 175 
~g of NADPH in 50 ~l 1.15% (w/v) KCI and 1 ~g of 3,4-TCB in 
5 ~l DMSOin a final volume of 3.48 ml for 5 min at 28°C in 
the dark. The reaction was started by adding 20 ~l of 
Uro'gen I (15 nmol). After mixing the incubation was 
continued for further 30 min under the same condition. The 
reaction was stopped by addition of 3.5 ml of 10% TCA 
containing 0.5% 1 2 . After centrifugation, the supernatant 
was analysed by HPLC. 
Parallel blanks were prepared as follows: reagent blank 
by adding 1.15% (w/v) KCI instead of microsomes; zero time 
blank by adding 10% TCA containing 0.5% 12 before addition 
of Uro'gen I. The reaction mixture of red cell haemolysates 
with Uro'gen I was also performed as a reference to compare 
the formation of peroxyacetic acid uroporphyrin I from 
different systems. 
5.2.3. Incubation of Uro'gen I with Tris-HCl buffer 
Uro'gen I, 20 ~l {15 nmol) , was incubated with 1.4 ml 
of 50 mM Tris-HCI buffer, pH 8.25, containing 74 ~M 
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MgCI 2 ·6H20 and 0.1% Triton X-100, either at 28°C in the dark 
or at room temperature under illumination of a 60W bulb 
within 12 inches of diameter for various time. At the end of 
the incubation the reaction mixture was either directly 
injected into HPLC or mixed with equal volume of 10% TCA 
containing 0.5% 1 2 . 
5.2.4. Incubation of Uro'gen I with haematin, 
methaemalbumin and dihydroxymalic acid in Tris-Hel buffer 
Methaemablumin (MHA) was prepared as described by 
Tenhunen et ale (1968). The stock solution (2.5 mM) was 
obtained by dissolving 13mg of haemin in 2.5 ml of 0.1 M 
NaOH containing 12 mg of Tris base. This solution was mixed 
with 5ml of 2% human albumin and the pH was adjusted to 7.4 
with 1M HCI. This solution was kept frozen at -30°C until 
use. This stock solution was diluted to 250 ~M with H20 just 
before use. 
Haematin was prepared by dissolving haemin in 0.01 M 
KOH to a stock solution of 2.5 rnM. This solution was kept at 
-300C. The stock solution was diluted by 0.01 M KOH to 250 
~M just before use. 
Dihydroxymaleic acid (DHM-A) , also called 
dihydroxyfumaric acid, was freshly prepared on the day of 
the experiment. DHM-A was dissolved in the incubation buffer 
to make 10 mM solution. This solution was kept on ice and 
was diluted to 1 rnM with incubation buffer before use. 
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Uro'gen I (15 nmol) was added to an incubation mixture 
in a total volume of 1.4 ml containing 0.05 M Tris-HCI 
buffer, pH 8.25, 74 ~M MgCI 2 , 0.1% Triton X-100, 1 roM EOTA 
and either 10 nmol of MHA, 10 nmol of haematin, or 300 nmol 
of OHM-A, respectively. This mixture was incubated either 
in the dark at 28°C or under illumination by a electric bulb 
(60 W) within 12 inches of diameter at room temperature for 
various time intervals. At the end of the incubation the 
reaction mixture was either injected into HPLC directly for 
analysis or mixed with an equal volume of 10% TCA containing 
0.5% 12 to oxidise any remaining porphyrinogen before HPLC 
analysis. 
5.2.5. Incubation of Uro'qen I 
oxidase system 
in xanthine-xanthine 
Xanthine-xanthine oxidase system is an oxidizing system 
which generates superoxide, hydrogen peroxide and hydroxyl 
radical sequentially. Xanthine, 26.1 mg was dissolved in 
approximately 3 drops of 1 M NaOH followed by 5 ml of 
distilled water with gentle heating. The concentration of 
the solution was 29.98 roM. Xanthine oxidase, 150 ~l (24.3 mg 
protein/ml, 0.17 unit/mg) was added into 10 ml of 0.1 M 
Tris-HCI buffer, pH 7.4, to make up a solution of 0.062 
unit/mI. 
KH2P04-Na2P04 buffer (0.1 M), pH 7.4 or 0.1 M Tris-HCI 
buffer, pH 7.4, were pre incubated with 0.0087 unit/ml of 
xanthine oxidase and 57 ~M of Fe (ferric) as ammonium 
sulphate salt in the dark at 28°C for 5 min. Then Uro'gen I 
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30 nmol was added followed by addition of 4 roM xanthine and 
the reaction mixture was incubated at 28°C in the dark for 
further 30 min. The final volume of the reaction mixture was 
3 mI. The reaction was stopped by adding 3 ml of 10% TCA 
containing 0.5% 1 2 . After vortexed mixing, the mixture was 
centrifuged and the supernatant was analysed by HPLC. 
5.2.6. Incubation of Uro'gen I with hydrogen peroxide/Fe-
EDTA system 
H20 2 , 30% (w/v) , was diluted to desired concentration 
with 0.1 M Na-K-phosphate buffer containing 1mM EDTA, pH 
7.4. 
Fe-EDTA was prepared as follows. FeCI3 , 4 roM, was made 
by dissolving 27.80 mg in 25.06 ml of H20. EDTA, 5.13 roM, 
was made by dissolving 26.20 mg in 13.72 ml of H20. Then 
equal volumes of the two solutions were mixed together and 
incubated at 37°C for 3 h. Desferrioxamine mesylate (DES), 
0.5 g, was dissolved in 7.6 ml of H20 to make up a stock 
solution of 100 roM. 
H2 0 2 , 85 ~l (of the desired concentration), was 
pre incubated with 0.1 M Na-K-phosphate buffer containing 1 
roM EDTA, pH 7.4, at 28°C in the dark for 5 min. The reaction 
was started by addition of 20 ~l (15 nmol) of Uro'gen I 
followed by 100 ~l of Fe-EDTA. The total incubation volume 
was 3 mI. The incubation was continued under the same 
condition for 30 min. Then the reaction was stopped by 
adding 3 ml of 10% TCA containing 0.5% 12 . 
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5.2.7. Analysis and isolation of the reaction products by 
HPLC 
The HPLC system consisted of a Varian Associates 
(Walton-on-Thames, Surrey, UK) model 5000 pump and a Varian 
UV-100 variable wavelength detector set at 400 nm. Samples 
were directly injected by a Rbeodyne (Cotati, CA, USA) 7125 
injection valve fitted with a 500 ~l loop. The separation 
was carried out on a 25 cm x 25 mm Hypersil-ODS column 
(Shandon Scientific, Runcorn, Cheshire, UK) by either 
isocratic or linear gradient elution. The gradient mixtures 
were 9% (v/v) acetonitrile in 1 M ammonium acetate buffer pH 
5.16 (Solvent A) and 10% (v/v) acetonitrile in methanol 
(solvent B). The flow rate was 1 ml/min throughout. 
1. For measurement of the production of peroxyacetic 
acid uroporphyrin I: 
Isocratic elution at 15% solvent B for 30 min, followed 
by isocratic elution at 95% for 10 min. The column was re-
equilibrated at 15% solvent B for 10 min before next 
injection. 
2. For analysis of the whole porphyrin profile: 
Time 0 to 16 min, 0% solvent B (100% solvent A) to 11% 
solvent B; time 16 to 24 min, isocratic elution at 11% 
solvent B; time 24 to 38 min, 11% solvent B to 24% solvent 
B; time 38 to 60 min, 24% solvent B to 60% solvent Band 
time 60 to 80 min, 60% solvent B to 80% solvent B. The 
column was then re-equilibrated at 0% solvent B for 10 min 
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before injection of next sample. For investigation of the 
porphyrins eluted before Uro I, the gradient was stopped at 
38.1 min and the column was then washed with 95% solvent B 
for 10 min. 
3. For investigation of hydroxylated uroporphyrin I in 
the reaction mixture: 
Time 0 to 30 min, 0% solvent B to 3% solvent B; time 30 
to 40 min, 3% solvent B to 9% solvent B; time 40 to 50 min, 
9% solvent B to 20% solvent B; time 50.1 min, 95% solvent B 
to wash late eluting peaks. 
4. For analysis of the hydroxylated and peroxylated 
derivatives of Copro'gen I: 
Isocratic elution at 55% solvent B. 
5.3. Results and Discussion 
5.3.1 Formation of peroxyacetic acid uroporphyrin I in a 
liver microsomal system induced by 3,4-TCB 
Microsomes isolated from the liver of chick embryos 
which were pre-treated with 3,4-TCB in vivo could greatly 
stimulate the oxidation of Uro'gen in the presence of NADPH 
and 3,4-TCB (Sinclair et al., 1987; De Matteis et al., 
1988). Since the conversion of a carboxylic acid group of 
uroporphyrinogen to peroxyacid group is an oxidative 
reaction, this microsomal system was used to investigate 
possible formation of peroxyacetic acid uroporphyrin I. 
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However, the formation of peroxyacetic acid 
uroporphyrin I was very poor under these conditions, though 
Uro'gen I was oxidised to uroporphyrin I as monitored by 
spectrophotometer at 405 nm in the end of the incubation. 
Prolonging the incubation time to 5 h made no difference to 
the amount of peroxyacetic acid uroporphyrin I formed. Under 
the same conditions, erythrocytes produced much more 
peroxyacetic acid uroporphyrin I than microsomes but gave a 
much lower recovery of Uro I (Table 5.1.). It was also 
noticed that unlike the oxidation of uroporphyrinogen which 
could be greatly stimulated by 3,4-TCB (De Matteis et al., 
1988), 3,4-TCB had little though significant effect on the 
formation of peroxyacetic acid uroporphyrin I. This result 
indicated that this microsomal system was not active in 
formation of peroxyacetic acid uroporphyrin I, and the 
reason will be discussed later. 
5.3.2. Effect of light on the formation of peroxyacetic 
acid uroporphyrin I 
When Uro'gen I was incubated in Tris-HCl buffer at pH 
between 7.4 and 8.2 in the dark there was virtually no 
peroxyacetic acid uroporphyrin I detected, despite the 
addition of 10% TCA containing 0 5 ~ • 0 12 to oxidize the 
porphyrinogens. This incubation mixture was always used as 
reagent blank. When the incubation was carried out under the 
illumination of light, however, significant amount of 
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Table 5.1. Formation of Peroxyacetic Acid uroporphyrin I by Chick-
Embryo Liver Microsomes 
PAAU formed Yield(%) Uro I recovered Recovery(%) 
MC 
MC+NADPH 
MC+3,4-TCB 
MC+NADPH+3,4-TCB 
RBC 
MC: microsomes. 
0.003 
0.006 
0.007 
0.017 
0.311 
0.02 
0.04 
0.05 
0.11 
2.07 
PAAU: peroxyacetic acid uroporphyrin I. 
11.8 
9.78 
9.75 
10.2 
7.11 
78.77 
65.23 
64.98 
67.84 
47.41 
Yield: peroxyacetic acid uroporphyrin I formed as a percentage of 
the starting material Uro'gen I (15 nmol). 
Recovery: Uro I detected in the reaction mixture as a percentage of 
the starting material Uro'gen I (15 nmol). 
unit for PAAU formed and Uro I recovered: nmol/incubation. 
Results were obatined with addition of 0.5% I2 in 10% TCA. 
This is the mean of eight experiments. 
peroxyacetic acid uroporphyrin I was formed. Though the 
maximum production of peroxyacetic acid uroporphyrin I in 
this incubation mixture did not differ from that with an 
incubation mixture of red cell haemolysates with Uro'gen I, 
the rate of the formation was much slower and virtually no 
peroxyacetic acid uroporphyrin I was detected within the 
first 30 min of incubation. The formation of peroxyacetic 
acid uroporphyrin I increased rapidly from 30 to 40 min 
together with a rapid increase of oxidation of Uro'gen I to 
Uro I. The products of peroxyacetic acid uroporphyrin I and 
Uro I reached their maxima between 50 to 60 min and then 
declined gradually as shown in Table 5.2. 
Overnight incubating under light illumination led to 
the disappearance of peroxyacetic acid uroporphyrin I and a 
nearly 50% loss of Uro I comparing with incubation for 1h. 
Addition of EDTA (lmM) to the incubation buffer did not stop 
the loss. 
It was also found that the addition of a tiny amount of 
Uro I to the reaction mixture could speed up the formation 
of peroxyacetic acid uroporphyrin I though it did not 
enhance the total amount of the product formed. 
It is well known that under the illumination with light 
and in the presence of oxygen, porphyrin can absorb light 
and enter a higher electronic excitation state. This excited 
porphyrin then transfers the energy onto the 02 molecule and 
thereby creates "excited oxygen" such as singlet 02 
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(Halliwell & Gutteridge, 1985A) and superoxide (Bickers & 
Pathak, 1987). In some cases the sensitized porphyrin may 
react with oxygen to yield hydrogen peroxide or with water 
to form hydroxyl radicals (Bickers & Pathak, 1987). 
Thus the formation of peroxyacetic acid uroporphyrin I 
from Uro'gen I under light illumination can be explained as 
follows. Uro' gen I undergoes oxidation to Uro I 
spontaneously in the presence of oxygen. Under illumination 
with light the uroporphyrin I formed becomes excited and 
reacts with oxygen to form some sort of active oxygen 
species. These active oxygen species may in turn react with 
the Uro'gen I in the reaction mixture to produce 
peroxyacetic acid uroporphyrin I and also accelerate the 
oxidation of the Uro'gen I at the same time. There were 
several aspects of the formation of peroxyacetic acid 
uroporphyrin I in buffer alone under light which support 
this hypothesis: (1) no peroxyacetic acid uroporphyrin I 
was produced in the first 30min, (2) the appearance of Uro I 
preceded that of peroxyacetic acid uroporphyrin If (3) the 
addition of Uro I could accelerate the formation of 
peroxyacetic acid uroporphyrin I. This too indicates that 
there may be free radicals involved in the formation of 
peroxyacetic acid uroporphyrin I. 
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Table 5.2. Time Course for the Formation of Peroxyacetic 
Acid Uroporphyrin I from Uro'gen I Incubated with Buffer Alone 
under Light Illumination 
Incubation 
Time (min) 
22 
30 
35 
40 
50 
60 
75 
90 
105 
120 
180 
PAAU 
Formed 
< 0.001 
0.024 
0.044 
0.182 
0.209 
0.195 
0.18 
0.149 
0.136 
0.134 
0.114 
Yield 
(%) 
< 0.001 
0.16 
0.29 
1.21 
1.4 
1.3 
1.2 
0.99 
0.91 
0.89 
0.76 
yield and Recovery: see Table 5.1. 
unit: nmoljincubation 
Uro I 
Recovered 
0.28 
2.04 
3.77 
8.97 
9.40 
10.9 
11.4 
10.7 
10.1 
10.6 
9.77 
Recovery 
(%) 
1.89 
13.6 
25.1 
59.8 
62.7 
72.5 
75.8 
71.3 
67.6 
70.9 
65.1 
Results were obtained without addition of 10% TeA containing 
0.5% 12 at the end of the reaction. 
This is the mean of four experiments. 
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5.3.3. The effect of haematin, methaemablumin and 
dihydroxymaleic acid on the formation of peroxyacetic acid 
uroporphyrin I 
The result obtained above pointed to the possibility of 
a free radical reaction. What was the specific reactive 
oxygen species? The role of ferrous iron in promoting free 
radical reaction which catalyzes oxidation of Uro'gen has 
been widely studied (De Matteis, 1988; Wood & Calas, 1989; 
Mukerji & Pimstone, 1990). Iron could initiate a free-
radical chain reaction pathway involving superoxide radical 
and hydroxyl radical (Mukerji & Pimstone, 1990). In 
addition, the major component in the erythrocytes which 
could react with Uro'gen I to produce peroxyacetic acid 
uroporphyrin I may be haem, the protoporphyrin chelated with 
iron. Thus haematin (PFe 3+OH) and methaemalbumin (MHA, 
haematin complex with albumin to increase the solubility) 
were chosen for the investigation of the involvement of Fe. 
Oihydroxymaleic acid (OHM-A), which generates superoxide 
anion and H20 2 chemically, was also employed to test the 
involvement of these species. 
Various amounts of haematin (5, 10 and 25 nmol) , MHA 
(5, 10, 25 and 50 nmol) and OHM-A (50, 100, 150, 200, 250, 
300 and 400 nmol) were incubated with 15 nmol of Uro'gen I 
for different time interval (10 min, 30 min, 1 h, 1 h 30 min 
and 2 h) in the dark at 28°C or under the illumination of 
light (60W bulb, within 12 inches of diameter) at room 
temperature. It was found that 10 nmol (final Conc. 7 ~M in 
the reaction mixture) of haematin or MHA, and 300 nmol 
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(final Conc. 0.2 M in the reaction mixture) of DHM-A gave 
the better yield of peroxyacetic acid uroporphyrin I. 
Therefore, 7 ~M for both haematin and MHA and 0.2 M for 
DHM-A were used for this study. 
When the incubation was carried out in the dark , 
despite the addition of haematin, MHA or OHM-A, both the 
oxidation of Uro'gen I to Uro I and the formation of 
peroxyacetic acid uroporphyrin I were very poor. Prolonging 
the incubation time did not significantly affect the result. 
Addition of 10%TCA containing 0.5% 12 at the end of the 
incubation to ensure the oxidation of any peroxyacetic 
acid uroporphyrinogen I produced did not increase the 
peroxyacetic acid uroporphyrin I detected, though it greatly 
increased the Uro I recovered as shown in Table 5.3 .. The 
different values of peroxyacetic acid uroporphyrin I in 
Table 5.3. (a) and (b) were most probably due to the 
oxidation of the porphyrinogen by I 2 . 
When the incubation was carried out under light 
illumination, significant amount of peroxyacetic acid 
uroporphyrin I could be detected at 30 min in all incubation 
mixtures containing MHA, haematin or OHM-A. However, when 
incubated for 1 h MHA and haematin gave a similar amount of 
peroxyacetic acid uroporphyrin I to that produced by 
incubating Uro'gen I with buffer alone while OHM-A gave a 
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Table 5.3. Effect of Haematin, MHA and DHM-A on the Formation of 
Peroxyacetic Acid Uroporphyrin I in the Dark 
(a) without the addition of 10%TCA containing 12 at the end of the 
incubation: 
Incubation Time (min) PAAU formed Uro I recovered 
MHA 10 < 0.001 0.120 
30 < 0.001 0.470 
60 < 0.001 1.008 
92 0.004 1.402 
120 0.006 2.150 
DHM-A 30 < 0.001 0.672 
60 0.006 3.258 
This is the typical result of two experiments. 
Table 5.3. Effect of Haematin, MHA and DHM-A on the Formation of 
peroxyacetic Acid Uroporphyrin I in the Dark 
(b) with the addition of 10%TCA containing 12 at the end of the 
incubation: 
Buffer 
MHA 
Haematin 
DHM-A 
Incubation Time (min) 
60 
180 
120 
120 
90 
120 
Uro'gen I: 15 nmol/incubation 
unit: nmol/incubation 
PAAU formed 
0.027 
0.023 
0.023 
0.025 
0.026 
0.026 
This is the typical result of two experiments. 
Uro I recovered 
12.4 
10.8 
9.45 
10.2 
10.8 
10.3 
Table 5.4. Effect of Haematin, MHA and DHM-A on the Formation Of 
Peroxyacetic Acid uroporphyrin I under the Illumination of Light 
Incubation time (min) 
Buffer 30 
60 
MHA 10 
30 
60 
Haematin 30 
60 
DHM-A 30 
60 
Uro'gen I: 15 nmol/incubation. 
unit: nmol/incubation. 
P5 produced Uro I recovered 
0.021 2.09 
0.268 9.25 
< 0.001 0.20 
0.069 6.07 
0.255 11.6 
0.056 4.97 
0.234 10.6 
0.066 4.96 
0.141 7.48 
Results were obtained without addition of 10% TeA containing 12 in 
the end of the incubation. 
lower yield as shown in Table 5.4 .. Addition of 10% TeA 
containing 12 at the end of 1 h incubation did not make much 
difference in the formation of peroxyacetic acid 
uroporphyrin I and the oxidation of Uro'gen I to Uro I. It 
seemed that MHA, haematin or DHM-A alone could not produce 
peroxyacetic acid uroporphyrin I but could speed up the 
rate of the reaction. Superoxide dismutase was added into 
one of the incubation mixtures with DHM-A and Uro'gen I. The 
result showed that instead of stopping the reaction, it 
actually increased the product formation from 0.141 to 0.208 
nmoljincubation, the same value as incubating Uro'gen I in 
buffer alone in the presence of light. Superoxidase 
dismutase catalyses the dismutation of 02 to H20 2 . This 
suggests that H2 02 may be involved in the formation of 
peroxyacetic acid uroporphyrin I and that the spontaneous 
dismutation of O2 to H202 may not be vigorous enough for the 
formation of a significant amount of peroxyacetic acid 
uroporphyrin I. 
5.3.4. The formation of peroxyacetic acid uroporphyrin I 
from xanthine-xanthine oxidase system 
A classical oxidation system, the xanthine - Xanthine 
oxidase system, was also employed to investigate the 
formation of peroxyacetic acid uroporphyrin I. Xanthine -
xanthine oxidase system can generate superoxide anion (02) 
in the first place, followed by H2 02 and then hydroxy 
radical (-OH) in the presence of iron. The reaction scheme 
is as follows: 
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Xanthine oxidase 
Uric acid 
°2 + 
12 
~ R202 + °2 
Fe3 + • Fe
2+ 
·OR 
Allopurinol inhibits the catalytic activity of xanthine 
oxidase; superoxide dismutase can protect against the effect 
of 02; catalase can protect against the effect of R202 ; and 
mannitol, DMSO, benzoate can protect against the effect of 
·OR. Thus using the above reagents it is hoped that the 
identity of the active oxygen species responsible fpr the 
formation of peroxyacetic acid uroporphyrin I may be 
clarified. 
In the first experiment with 15nmol of Uro'gen I per 
incubation it was found that xanthine was essential for the 
formation of peroxyacetic acid uroporphyrin I. Iron could 
enhance the formation of peroxyacetic acid uroporphyrin I 
but to a much less extent than that in the oxidation of 
Uro'gen in a similar system (Francis & Smith, 1988). The 
formation of peroxyacetic acid uroporphyrin I increased with 
increasing incubation time as shown in Table 5.5 .. This was 
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different from the time course of incubating Uro'gen I with 
red cell haemolysates or in buffer alone under light 
illumination. Increasing the concentration of xanthine did 
not give a higher yield of peroxyacetic acid uroporphyrin I. 
Increasing the concentration of xanthine oxidase to above 
0.0078 unit/ml increased the formation of peroxyacetic acid 
uroporphyrin I, but led to an extra peak in the reaction 
mixture when analysed by HPLC. This extra peak was increased 
wi th the increase of the concentration of xanthine-xanthine 
oxidase, and may interfere wi th the detection of 
peroxyacetic acid uroporphyrin I. Thus 30 min incubation 
with xanthine oxidase 0.0087 unit/ml, xanthine 4 roM and Fe 
(ferric iron ammounioum sulphate salt) 57 ~M (final 
concentration in the incubation mixture) was chosen as the 
standard procedure for the rest of the experiments. Under 
these conditions, the relationship between Uro'gen I 
concentration in the reaction mixture and the formation of 
peroxyacetic acid uroporphyrin I was investigated. The 
result showed that the formation of peroxyacetic acid 
uroporphyrin I increased linearly with the concentration of 
Uro'gen I up to 30 nmol (final conc. 10 ~M) as shown in Fig. 
5.1. Therefore 30 nmol of Uro'gen I was chosen for the rest 
of the studies. 
To make sure that in this system the catalytic activity 
of xanthine oxidase was required for the formation of 
peroxyacetic acid uroporphyrin I, various concentration of 
allopurinol were added to the reaction mixture. The result 
clearly showed that allopurinol greatly inhibited the 
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Table S.S. Formation of Peroxyacetic Acid Uroporphyrin I from Xanthine -
xanthine oxidase System 
Additional 1 
Components 
x.o. + 
Fe + 
Uro'genI + 
xanthine + 
Inc.Time 10 30 60 
PAAU 0.032 0.050 0.104 
Uro I 9.27 9.27 9.54 
_ .. _._-_.-
X.o.: xanthine oxidase 
Inc.Time: incubation time (min) 
2 
+ 
+ 
+ 
-
10 
0.010 
11.8 
30 
0.008 
12.8 
3 4 
+ + 
- -
+ + 
+ -
10 30 10 30 
0.023 0.032 0.006 0.008 
13.37 11.41 14.3 15.0 
Uro'gen I: 15 nmol/incubation 
unit: nmol/incubation 
rf1h;c ;c +-hp +-vn;rrtl rpc::.1l1+- f'rnm f';"p pvnpr;mpn+-c 
~ 
....,J 
I.D 
.... 
----c 
0 
+-' 
0.20 -, r 25 ro 
..0 
::J 
U 
C 
• ~I 
----
20 -
-
0. 15 1 // 0 c E 0 C +-' 
---C'O 
...0 15 ""0 
:J (J) 
U L-
c 0.10 (J) 
> 
............ 0 
- 10 0 u 
E (J) 
c l 5 a: --- 0.05 :J c ~ L-
<t >-
0... ...c 
0.. 
0.00 0 L-a 
2 4 6 8 10 0.. 
0 
L-
Concentration of Uro'gen I (J-lM) ::J 
Fig. 5.1. Relationship Between the Concentration of Uro'gen I and the Production of 
Peroxvacetic Acid lJronornhvrin I in Xanthine-X~nthine nxid~,p <::\/ctpnl 
formation of peroxyacetic acid uroporphyrin I and the 
formation was decreased as the concentration of allopurinol 
increased (Table 5.6). 
To find out which reactive oxygen species was 
responsible for the formation of peroxyacetic acid 
uroporphyrin I, various amount of superoxide dismutase were 
added to the reaction mixture. Low concentration of 
superoxidase dismutase inhibited the formation of 
peroxyacetic acid uroporphyrin I, but as the concentration 
increased, inhibition was weaker instead of stronger as 
shown in Table 5.7. 
Superoxide dismutase is responsible for dismutating 02 
to H20 2 . since higher concentration of superoxidase 
dismutase did not cause a progressive inhibition, it is 
possible that the products resulting from the activity of 
superoxidase dismutase, either H202 or a further metabolite 
'OH, is responsible for the formation of peroxyacetic acid 
uroporphyrin I. 
SOD 
---------> ·OH 
Thus the scavenger of H20 2 , catalase, was added to the 
xanthine - xanthine oxidase system. The results showed that 
catalase did inhibit the formation of peroxyacetic acid 
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Table 5.6. Effect of Allopurinol 
Acid Uroporphyrin I 
1 (Control) 
Allopurinol (roM) 0 
PAAU (nmol/incubation) 0.065 
% of Control 100 
Uro I recovered 16.8 
(nmol/incubation) 
Uro I recovery (%) 56 
Uro'gen I: 30 nmol/incubation. 
on the Formation of Peroxyacetic 
2 3 4 
1 10 20 
0.027 0.020 0.014 
41.8 31.0 21.7 
18.1 19.2 19.0 
60.3 64 63.3 
Table 5.7. Effect of superoxide Dismutase on the Formation of peroxyacetic 
Acid uroporphyrin I 
SOO(unit/ml) 
PAAU 
% of Control 
URO I recovered 
Uro I recovery (%) 
1 (Control) 
o 
0.131 
100 
19.6 
65.3 
Uro'gen I: 30 nmol/incubation. 
2 
5 
0.053 
40.1 
23.9 
79.7 
unit of PAAU and Uro I recovered: nmol/incubation. 
3 
50 
0.051 
39.3 
24.8 
82.7 
This is the mean of the duplicate results of one experiment. 
In another similar experiment 50 unit/ml of SOD was used and the 
4 
500 
0.075 
57.3 
24.2 
uroporphyrin I, and as its concentration increased the 
inhibition was also increased as shown in Table 5.8 .. 
Addition of both superoxide dismutase (50 unit/ml) and 
catalase (1500 unit/ml) together to xanthine - xanthine 
oxidase system gave 52% peroxyacetic acid uroporphyrin I of 
control reaction mixture, did not further increase the 
inhibition. 
To investigate whether 'OH was involved in the 
formation of peroxyacetic acid uroporphyrin I, the 
scavenger, mannitol was added to the system at various 
concentrations. The result showed that it had no significant 
effect on the formation of peroxyacetic acid uroporphyrin I 
(Table 5.9.). This suggests that hydroxyl radical is not 
responsible for the formation of peroxyacetic acid 
uroporphyrin I. 
5.3.5. Formation of Peroxyacetic Acid Uroporphyrin I by 
H202 
To make sure the H202 was responsible for the formation 
of peroxyacetic acid uroporphyrin I, different 
concentrations of commercial H202 were reacted with Uro'gen 
I in presence of Fe-EDTA as described in Sec. 5.2.6. The 
result showed that at low concentration of H2 02 no 
peroxyacetic acid uroporphyrin I was produced, and as the 
concentration increased the formation of peroxyacetic acid 
uroporphyrin I also increased up to 2.5 mM. When 25 mM of 
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Table 5.8. Effect of Catalase on the 
uroporphyrin I 
Catalase (unit/ml) 
PAAU 
% of Control 
Uro I recovered 
Uro I recovery (%) 
1 (Control) 
o 
0.073 
100 
16.7 
55.6 
Uro'gen 1:30 nmol/incubation 
Formation 
2 
300 
0.051 
69.7 
20.7 
69 
unit of PAAU and Uro I recovered: nmol/incubation 
This is the typical result of two experiments. 
of peroxyacetic Acid 
3 
1500 
0.038 
52.4 
21.6 
72 
4 
3000 
0.034 
46.9 
21.7 
72.3 
Table 5.9. Effect of Mannitol on the Formation of peroxyacetic Acid 
Uroporphyrin I 
1 (Control) 2 3 4 5 
Mannitol (Mm) 0 5 10 50 100 
PAAU (nmol/incubation) 0.076 0.071 0.073 0.073 0.077 
% of Control 100 94 96.7 96.1 1.01 
URO I(nmol/incubation) 21.4 22.1 22.3 22.8 24.3 
% Of URO I recovery 71.4 73.8 74.5 75.8 80.9 
Uro'gen I: 30nmol/incubation. 
This is the mean of three experiments. 
H2 02 was used the formation of peroxyacetic acid 
uroporphyrin I was similar to that produced at 2.5 roM, but 
at this concentration the porphyrins formed in the reaction 
mixture began to decrease soon after the reaction was 
stopped. At concentration higher than 25 mM, almost no 
peroxyacetic acid uroporphyrin I was detected, and Uro I 
recovery was only about 30%. No peaks other than Uro I were 
detected by uv-vis detector at 405 nm or a fluorescent 
detector set at Ex. 400 nm and Em. 618 nm. Omission of Fe-
EDTA which acted as a catalyst (De Matteis, 1988; Aust et 
al., 1985) in H202/ Fe-EDTA system caused very little 
formation of peroxyacetic acid uroporphyrin I as shown in 
Table 5.10 .. Addition of catalase tremendously inhibited the 
formation of peroxyacetic acid uroporphyrin I (0.009 
nmol/incubation formed) and gave more than 80% recovery of 
Uro I. This suggested that the formation of peroxyacetic 
acid uroporphyrin I is indeed due to H20 2 . 
An iron chelator, as well as a scavenger of ·OH, 
desferrioxamine (DES) was added to the H20 2/Fe-EDTA system. 
Its effect on the formation of peroxyacetic acid 
uroporphyrin I was in opposite directions depending on the 
concentration in the reaction mixture. At low concentration 
the formation of peroxyacetic acid uroporphyrin I was almost 
completely abolished, but as the concentration increased the 
inhibition decreased as shown in Table 5.11 .. No 
satisfactory explanation for these findings can as yet be 
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Table 5.10. Effect of H2 02 and Fe-EDTA on the Formation 0 
peroxyacetic Acid Uroporphyrin I 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
0.25 
25 
250 
2500 
25000 
250000 
2500 
0 
Fe-EDTA 
(68.4J.LM) 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Uro'gen I: 30nmol/incubation. 
PAAU 
0.003 
0.019 
0.073 
0.100 
0.106 
0.006 
0.016 
0.010 
Uro I 
Recovered 
26.6 
25.4 
19.9 
16.2 
15.0 
10.3 
29.6 
32.4 
Unit of PAAU and Uro I recovered: nmol/incubation. 
This is the typical result of two experiments. 
187 
Uro I 
Recovery(%) 
88.7 
84.7 
66.3 
54.0 
50.0 
34.3 
98.7 
108 
Table S.ll. Effect of Desferrioxamine on the Formation 
Peroxyacetic Acid uroporphyrin I and the Recovery of Uro I 
1. 2.5 0 
2 . 2.5 0.1 
3. 2.5 1 
4. 2.5 10 
5. 2.5 10 
6. 0 10 
7. 25 10 
Fe-EDTA 
(68.4tJ.M) 
+ 
+ 
+ 
+ 
+ 
PAAU 
0.082 
0.005 
0.021 
0.117 
0.018 
0.011 
0.011 
Uro'gen I: 30nmol/incubation. 
Uro I 
16.9 
26.3 
15.3 
27.9 
32.9 
37.7 
34.8 
Uro I recovery 
(%) 
56.2 
87.8 
50.9 
93 
109.7 
125.5 
115.9 
Unit of PAAU and Uro I recovered: nmol/incubation. 
This is the typical result of two experiments. 
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Q 
provided and further work is needed. At a concentration of 
10 mM, DES could, however protect the loss of porphyrins 
against the high concentration of H20 2 . One reaction mixture 
containing 25 mM of H202 was analysed a day after stopping 
the reaction. It showed that the peroxyacetic acid 
uroporphyrin I had disappeared completely and only 10.8 nmol 
out of original 30 nmol of Uro'gen I was detected. While in 
the parallel reaction mixture with 10 roM of desferrioxamine , 
0.163 nmol/incubation of peroxyacetic acid uroporphyrin I 
and 27.2 nmol/incubation of Uro I were detected. 
Uroporphyrin I was also treated with the H20 2 /Fe-EDTA 
system under various reaction conditions. No peroxyacetic 
acid derivative could be detected by HPLC. This again showed 
that the peroxyacetic acid derivative was derived from 
uroporphyrinogen I rather than uroporphyrin I. 
5.3.6. Disappearance of porphyrins during the formation of 
peroxyacetic acid uroporphyrin I 
It was observed that incubating red cell haemolysates 
with Uro'gen I in the dark overnight and incubating Uro'gen 
I in buffer under light illumination overnight led to a 
significant disappearance of all porphyrins. Addition of 
EDTA (lmM) to the incubation buffer did not stop the loss, 
which indicated that the loss was not due to the formation 
of metalloporphyrin. The loss of the porphyrins could be 
abolished by oxidation with 12 in 10% TCA after the reaction 
has processed for 30 min (with red cell haemolysates) or 1 h 
(with incubation buffer alone). In the xanthine - xanthine 
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oxidase system, the oxidation of Uro'gen I to Uro I at the 
end of the 30 min incubation was recorded by UV-vis 
spectrophotometry at 405 nm before addition of 12 in 10% 
TeA. The result showed that the loss of porphyrins was 
closely related to the formation of peroxyacetic acid 
uroporphyrin I and the oxidation of Uro'gen I to Uro I by 
the enzyme. In the reaction mixture in which most of the 
Uro'gen I had oxidized to Uro I before the addition of 12 in 
10% TeA, the most formation of peroxyacetic acid 
uroporphyrin I and the least recovery of Uro I were detected 
after the addition of 1 2 . In the H20 2 /Fe-EDTA system, this 
loss was even more significant, rapid and related to the 
concentration of H20 2 , the presence of Fe-EDTA and to some 
extent to the formation of peroxyacetic acid uroporphyrin I. 
The result in Sec. 5.3.5. clearly showed that without either 
H202 or Fe-EDTA in the reaction mixture the recovery of Uro 
I would be near 100% (Table 5.10.). When 30nmol of Uro I was 
incubated with H202 (2.5 roM) and Fe-EDTA (68.4 ~M) in which 
no peroxyacetic acid uroporphyrin I was formed, also 100% 
recovery of Uro I was obtained. However, when the incubation 
mixture contained 30nmol of Uro'gen I under the exact same 
condition there was only a 56.2% recovery of Uro I. In 
contrast, when the incubation mixture with 30 nmol of 
Uro'gen I contained 10mM of desferrioxamine, despite the 
higher yield of peroxyacetic acid uroporphyrin I gained, 93% 
recovery of Uro I was obtained (Table 5.11.). This strongly 
suggested that the reaction between Uro'gen I and H20 2/Fe-
EDTA gave two reactions: one was the oxidation of the 
carboxylic acid group of uro'gen I to form peroxyacetic acid 
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uroporphyrin I, the other the formation of hydroxy radical 
which was responsible for the loss of porphyrins. 
The disappearance of porphyrin during porphyrinogen 
oxidation by H20 2 /Fe-EDTA system and hypoxanthine/xanthine 
oxidase/Fe-EDTA system had been reported (De Matteis, 1988; 
Francis & Smith, 1988), in both systems hydroxy radical was 
suggested to be involved in the decomposition of porphyrins. 
This was consistent with the results we obtained above. 
5.3.7. Attempted formation of peroxyacid coproporphyrinogen 
I by the action of H202 
To investigate whether the corresponding peroxyacid 
analogue could be formed by treating corproporphyrinogen I 
or coproporphyrin I with H20 2 /Fe-EDTA system, the porphyrin 
or porphyrinogen (final Conc. 10 ~M) was added to the 
incubation with 25 mM of H202 and 68.4 ~M of Fe-EDTA. The 
reaction was carried out under exactly the same conditions 
as described in Sec. 5.2.6 .. When the reaction mixture was 
analysed by HPLC no peroxyacid coproporphyrin derivative was 
found. This again proved that the presence of an acetic acid 
function is essential for the formation of the peroxyacid 
derivative. 
5.3.8. Mechanisms of formation of peroxyacetic acid and 
hydroxylated uroporphyrins 
The results in Sec. 5.3.5. have clearly shown that the 
formation of peroxyacetic acid uroporphyrin I is due to H202 
in the presence Fe-EDTA. Considering the formation of 
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peroxyacetic acid uroporphyrin I with red cell haemolysates, 
the major component in RBC is haemoglobin. Haemoglobin 
consists of four molecules of haem combined with one 
molecule of globin through the fifth coordinating ligand of 
Fe. The function of haemoglobin is cooperative binding and 
effective delivery of oxygen. When haemoglobin is in the 
deoxy state, the iron has five ligands and is a Fe(II) 
complex. Upon oxygen binding to the sixth coordination site, 
the iron becomes Fe(III) superoxide complex and the 
structure of haemoglobin is changed which leads to high-
affinity to oxygen (Ryan & Aust, 1992). The conversion of Fe 
(III) superoxide complex to Fe(III} complex and superoxide 
radical is a reversible reaction. In the presence of 
porphyrinogen as electron donator the superoxide radical 
could abstract a hydrogen atom from the porphyrinogen and 
start a chain reaction in which 02is a propagating species 
as follows: 
PH6 + 302+ Fe (III) 
Here PH 6 and P are the reduced and oxidised forms of 
porphyrins (Mukerji & Pimstone, 1990). The H202 may then 
react with porphyrinogen in the presence of iron to form 
peroxyacetic acid uroporphyrin I. Fe (III) may be reduced by 
02 and the resulting Fe(II} may then react with H202 to 
produce ·OH which may lead to the formation of the 
hydroxylated uroporphyrin I derivatives and the loss of 
porphyrins. 
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When red cell haemolysates were boiled, the haemoglobin 
was denatured and the ability of combining with oxygen was 
impaired. Thus when the boiled red cell haemolysates were 
incubated with Uro'gen I the formation of peroxyacetic acid 
uroporphyrin I was reduced. pH can also affect the affinity 
of haemoglobin to oxygen significantly. At pH lower than 7.2 
the structure of haemoglobin is modified which reduces its 
affinity to oxygen. While at high pH peroxyacetic acid 
uroporphyrin I is easily converted into Uro I. Thus the 
optimal pH range for the formation of peroxyacetic acid 
uroporphyrin I with red cell haemolysates described in Sec. 
4.3.13. can be explained. 
The oxygen content in plasma is dependent on the 
dissolved oxygen and not by any chemical binding. The 
content of oxygen in plasma is therefore much less than that 
in RBe (less than 4%). Iron in plasma is mainly transferrin 
in which two ferric iron are combined with one molecule of 
protein. It is not involved in the oxidation of 
biomolecules. But "free" iron may be generated and oxidative 
stress would ensure (Ryan & Aust, 1992). Thus in the 
presence of Uro'gen I the formation of peroxyacetic acid 
uroporphyrin I could happen and much lower yield than that 
with red cell haemolysates may be expected. 
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In leucocytes the main oxidation system is as follows: 
NAD(P}H oxidase 
202 + NAD(P}H 
SOD 
peroxidase 
This oxidation procedure is triggered by the phagocytosis of 
leucocytes. The main intracellule ion in leucocytes is 
potassium. This may explain why little product was formed 
when incubating uroporphyrinogen I with leucocytes. 
In liver microsomes, the oxidation system is cytochrome 
P-450. It is suggested that main oxidizing species produced 
by the microsomes is H20 2 (De Matteis, 1988). When Uro'gen I 
was incubated with 3,4-TCB induced chicken embryos 
microsomes, however, only the oxidation of Uro'gen I to Uro 
I was observed and hardly any peroxyacetic acid uroporphyrin 
I was produced. This may be due to the fact that the 
microsomes system was not sufficiently vigorous in producing 
H202 for the formation of peroxyacetic acid uroporphyrin I. 
The liver cytochrome P-450 is an oxidation chain which 
usually transported the electron along the chain and passed 
the electron onto the substrate. Therefore the oxidation 
procedure may be different and may not able to promote the 
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formation of peroxyacetic acid uroporphyrin I. 
It is known that peroxyacid can be formed by direct 
oxidation of carboxylic acids with 30 to 98% hydrogen 
peroxide in the presence of mineral acid as a catalyst 
(Plesnicar, 1978). In our study reacting H2 02 with 
porphyrinogens which containing acetic acid group(s) did 
form peroxyacid. When reacting H2 02 with porphyrinogens 
which contained only propionic acid groups or with 
porphyrins, no peroxyacid formation was observed. This may 
be due to the electron interaction within the porphyrin 
molecule. In porphyrin state the highly conjugated aromatic 
ring withdraws the electron cloud from the side chains to 
the porphyrin nucleus while in the porphyrinogen state the 
side chains, especially acetic acid chain, may themselves 
become the electron withdrawing group. In propionic acid 
chains the carboxylic acid group may be too far from the 
porphyrin nucleus, so it is more difficult to withdraw the 
electron cloud as efficiently as acetic acid group. Thus to 
form peroxyacid function from the propionic acid group of 
porphyrinogen or from porphyrin may require a much higher 
concentration of H2 0 2 . However, this will lead to the 
destruction of porphyrin ring. This may explain why a 
peroxyacid derivative cannot be formed from 
coproporphyrinogen or uroporphyrin. 
In all reaction systems which produced peroxyacetic 
acid uroporphyrin I, there were two peaks which had the same 
retention time as meso-hydroxyuroporphyrin I and B-
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hydroxypropionic acid uroporphyrin I in the incubation 
mixtures. There was also a trace of hydroxyacetic acid Uro I 
detected. These two peaks also eluted out at the same 
positions of natural meso-hydroxyuroporphyrin I and B-
hydroxypropionic acid uroporphyrin I by expanding the 
elution program. That they were meso-hydroxyuroporphyrin I 
and B-hydroxypropionic acid uroporphyrin I was confirmed by 
co-injection with authentic compounds into HPLC. 
The peak height of meso-hydroxyuroporphyrin I was 
similar in the incubation mixtures of Uro'gen I with red 
cell haemolysates, xanthine - xanthine oxidase and H20 2/Fe-
EDTA, but smaller in the incubation mixture of Uro'gen I 
with buffer alone or with buffer containing haematin, 
methaemalbumin and dihydroxymaleic acid. The peak height of 
B-hydroxypropionic acid uroporphyrin I was generally very 
small in all incubation mixtures, except that of Uro'gen I 
with H20 2 /Fe-EDTA in which this peak was 10 times higher 
than in the other systems. The relationship between the peak 
height of these two peaks and the formation of peroxyacetic 
acid uroporphyrin I has not been fully investigated. In the 
system of H20 2 /Fe-EDTA, however, it was certain that as the 
concentration of desferrioxamine increased, the peak height 
of these two peaks were decreased. 
The existence of meso-hydroxyuroporphyrin I and B-
hydroxypropionic acid uroporphyrin I in the reaction mixture 
in which the peroxyacetic acid uroporphyrin I was formed was 
proved by HPLC and LSIMS as described in Chapter 3. Thus the 
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generation of peroxyacetic acid uroporphyrin I also produced 
the hydroxylated uroporphyrins. This was consistent with the 
observation that when hepta- and penta-carboxylic acid 
porphyrinogen I were incubated with red cell haemolysates 
not only peroxyacid but also hydroxylated derivatives were 
formed. It is not clear whether the formation of these 
hydroxylated uroporphyrins was by the same mechanism as the 
formation of peroxyacetic acid uroporphyrin I. It is likely, 
however, that these hydroxylated uroporphyrins were formed 
by a free radical mechanism involving hydroxy radical 
generated during the oxidation of Uro'gen I to peroxyacetic 
acid uroporphyrin'gen I. The increased concentration of 
desferrioxamine resulting in decreased formation of B-
hydroxypropionic acid uroporphyrin I suggested that their 
formation was most probably due to the reaction of Uro'gen I 
with hydroxy radical. 
5.4. Conclusions 
The hydroxylated and peroxyacetic acid uroporphyrin I 
were generated in vitro with various oxidizing systems, and 
had been confirmed that they were similar compounds to those 
detected in the urine from patients with CEP. The formation 
of peroxyacetic acid uroporphyrin I was suppressed by 
catalase but unaffected by mannitol, indicating that H202 
was responsible for the production. The formation of meso-
hydroxy- and B-hydroxypropionic acid- uroporphyrin I was 
decreased by desferrioxamine, suggesting that 'OH was 
responsible for the production of hydroxylated porphyrins. 
The disappearance of porphyrins during the formation of 
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peroxyacetic acid uroporphyrin I was also abolished by 
desferrioxamine, indicating that ·OH is responsible for the 
porphyrin destruction. The failure of the formation of 
peroxyacetic acid uroporphyrin I from uroporphyrin I and 
peroxyacid coproporphyrin I from coproporphyrinogen and 
coproporphyrin I by red cells haemolysates and H202 
confirmed that peroxylation can occur only at porphyrinogen 
stage and only at acetic acid group. The possible mechanism 
of the formation of hydroxylated and peroxyacetic acid 
uroporphyrin I in erythrocytes and the possible reason why 
no peroxyacetic acid uroporphyrin I was formed from Uro I 
and its analogue from coproporphyrin (ogen) were proposed. 
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CHAPTER 6 
GENERAL DISCUSSION AND FUTURE DEVELOPMENT 
6.1. Charcoal Therapy in CEP and Possible Alternative 
Treatment 
The administration of oral charcoal to a patient with 
CEP failed to reduce plasma porphyrin level or to improve 
his clinical status. This is because approximately three 
quarters of excess porphyrins produced in erythropoietic 
system are uroporphyrin I. This highly hydrophilic porphyrin 
is favourably excreted into urine, and is hardly detectable 
in the duodenal aspirates and faeces of the patient. 
Charcoal given orally may be effective in interfering with 
the enterohepatic circulation of porphyrins by preventing 
the enteral absorption of porphyrins excreted into the 
intestinal lumen (Israili & Dayton, 1984; Mukerji et al., 
1985; Pimstone et al., 1987; Morton et al., 1988; Tishler & 
Winston, 1990.). The charcoal adsorption of porphyrins in 
the gut lumen may increase the flux of free porphyrins from 
plasma to the lumen, where the porphyrins are entrapped by 
the charcoal and then excreted in the faeces (Pimstone et 
al., 1987). Therefore, although the oral charcoal treatment 
was ineffective in this case of CEP, it may be beneficial to 
the hepatic porphyrias in which the liver is the major site 
of production and accumulation of the excess porphyrins. 
These porphyrins will diffuse or be excreted into bile and 
thus efficiently eliminated by binding onto charcoal. 
Erythrohepatic protoporphyria may also benefit from charcoal 
adsorption therapy as the highly hydrophobic protoporphyrin 
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can only be excreted into bile and eliminated through the 
intestine. 
other therapies for CEP also have limited efficacy 
which include limiting exposure to sunlight, where barrier 
creams and B-carotene may be of some benefit, and treatment 
of skin infections (Nordmann & Oeybach, 1982; Poh-
Fitzpatrick, 1982; Bloomer & Bonkovsky, 1989). Erythrocyte 
transfusions can correct the anaemia and reduce haemolysis. 
In particular the transfusions inhibit endogenous 
erythropoiesis, decreasing the production of uroporphyrin 
and the derived porphyrin metabolites (Nordmann & Oeybach, 
1982). In our patient erythrocyte transfusions also 
increased the erythrocyte Uro'gen 1II-S (Chapter 2), 
presumably due to the exogenous Uro'gen III-S which may also 
play a role in reducing the porphyrins accumulated. It was 
reported that long-term treatment with high-level 
transfusions led to complete suppression of symptoms in 
one case of CEP in which the iron overload was well 
mitigated by multiple infusions of deferrioxamine (Piomelli 
et al., 1986). However, it is well known that multiple 
transfusions can be harmful. The possible ill-effects of 
blood transfusion include haemolytic transfusion reactions, 
non-haemolytic febrile reactions, allo-immunization, plasma 
and urticarial reactions, effect of bacterial contamination 
and pyrogens and transmission of disease (Gunson, 1983). To 
avoid the dangers of multiple transfusions, haematin was 
proposed as an alternative to erythrocyte transfusions 
(Watson et al., 1974). Haem exerts a negative feedback 
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repression on the haem biosynthetic pathway and leads to a 
reduction of porphyrin synthesis (Rank et al., 1990). 
However the effect is short-lived and does not achieve 
clinical relief (Nordmann & Deybach, 1982, Rank et al., 
1990). Chloroquine may reduce erythrocyte fragility 
(Ippen & Fuchs, 1980) and thus may reduce haemolysis (Moore 
et al. 1990). Splenectomy may also mitigate the haemolysis, 
reduce porphyrin excretion and diminish skin manifestation , 
but in general there seems to be little evidence for 
specific and long-term improvement (Nordmann & Deybach, 
1982; Bloomer & Bonkovsky, 1989). Replacement therapy, such 
as sUbstitution of the defective enzyme, genetic 
modifications and reparation of the impaired gene may be the 
solution. These therapies, however, are not possible at the 
present time. 
6.2. Distribution and Metabolism of Hydroxylated and 
Peroxyacid uroporphyrin Derivatives in vivo 
Meso-hydroxyuroporphyrin I, B-hydroxypropionic acid 
uroporphyrin I, hydroxyacetic acid uroporphyrin I and 
peroxyacetic acid uroporphyrin I have been identified in the 
urine and plasma from patients with CEP. In contrast these 
uroporphyrin I derivatives were not found in the duodenal 
aspirates and faeces of the patient with CEP whose urine 
contained relatively large amount of these compounds. This 
indicated that in the patients with CEP these uroporphyrin 
derivatives are derived from the erythropoietic system, the 
major site of the defective enzyme and where the excessive 
uroporphyrin I are produced and accumulated. In one patient 
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with CEP the plasma and urinary porphyrin levels were 
measured over 51 days with an interval of 4-7 days. The 
percentages of hydroxy- and peroxyacetic acid-uroporphyrin I 
derivatives of the total porphyrins in both plasma and urine 
were calculated. The results showed that in plasma the 
uroporphyrin I derivatives were 0.6 + 0.07% (mean + SO) of 
the total porphyrins while in the urine uroporphyrin I 
derivatives were1.6 + 0.39% (mean + SO). The more than two 
fold higher level of these uroporphyrin I derivatives in 
urine than that in plasma indicated that the formation of 
these derivatives may lead to increased excretion of the 
excess uroporphyrin I. This may be a mechanism of the 
excretion of excess uroporphyrin I. 
The existence of B-hydroxypropionic acid- and 
hydroxyacetic acid-heptacarboxylic acid porphyrin I and the 
absence of meso-hydroxy- and peroxyacetic acid-
heptacarboxylic acid porphyrin I, and the related analogues 
derived from hexa- and penta-carboxylic acid porphyrin I are 
very interesting. In CEP the heptacarboxylic acid porphyrin 
I accumulated is much less than uroporphyrin I which may not 
be enough to promote the formation of hydroxylated 
derivatives from heptacarboxylic acid porphyrinogen I. 
Therefore, it is very likely that the hydroxylated 
heptacarboxylic acid porphyrin I derivatives are the 
metabolites of the corresponding uroporphyrinogen I 
derivatives. Once the porphyrins are hydroxylated, they also 
tend to be excreted into urine due to their hydrophilicity 
and further decarboxylation will thus be less likely. 
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Therefore no hydroxylated hexa- and penta-carboxylic acid 
porphyrin I were found in CEP urine. Meso-hydroxy- and 
peroxyacetic acid- heptacarboxylic acid porphyrin I were not 
detected in the urine of CEP. The most likely reason is that 
the corresponding uroporphyrin I derivatives are less 
stable. Meso-hydroxyuroporphyrin I may be easily ring 
opened, while peroxyacetic acid uroporphyrin I is easily 
converted to uroporphyrin I. The conversion of a peroxyacid 
group to a carboxylic acid is a reduction reaction, 
therefore an oxidation reaction may occur simultaneously 
which may playa role in the pathogenesis of CEP. However, 
these need further investigation. 
6 • 3 • Formation of Hydroxy- and Peroxyacetic Acid-
Porphyrins In vivo 
The present study has shown that peroxyacetic acid 
porphyrins and hydroxylated porphyrins are derived from the 
corresponding porphyrinogens which have acetic acid group(s) 
under one of the following three conditions: 1. the presence 
of erythrocytes; 2. light illumination; and 3. the presence 
of H202 and iron. The formation of peroxyacetic acid 
uroporphyrin I in vitro is proportional to the concentration 
of uroporphyrinogen I. In vivo higher concentrations of 
uroporphyrin I derivatives are found in the patients with 
CEP whose urinary uroporphyrin I was greatly excessive but 
much less in the patient with CEP whose urinary uroporphyrin 
I level is much lower (2.28-4.22 ~mol/24h). This indicated 
that any enzyme defect which led to the accumulation of 
porphyrinogens with side-chain acetic acid sUbstituents may 
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induce the formation of these derivatives. Thus these 
/ 
derivatives can be formed not only in CEP but also in PCT in 
which Uro'gen-D defect lead to the accumulation of 
uroporphyrin I and III isomers, heptacarboxylic acid 
porphyrin (dominated by isomer III) and to a lesser extent 
coproporphyrin, hexa-, penta-carboxylic acid porphyrins and 
typically isocoproporphyrin. In fact the hydroxylated and 
peroxyacetic acid uroporphyrin, heptacarboxylic acid 
porphyrin and pentacarboxylic acid porphyrin derivatives 
have been isolated and identified from the patients with PCT 
(Luo, 1992). In CEP the metabolic defect is expressed in the 
erythropoietic system, and the excessive porphyrins are 
mainly distributed in the bone marrow and the peripheral 
blood. The porphyrin content in the spleen is frequently but 
variably increased and may bear a relationship to the rate 
of RBC destruction by this organ. In the liver porphyrin 
level is usually not greatly increased with occasional 
exceptions (Kappas et al., 1983). Thus the highly elevated 
hydrophillic uroporphyrin I and its hydroxylated and 
peroxyacid uroporphyrin derivatives tend to be excreted out 
in the urine. In PCT, on the other hand, the predominant 
site of the metabolic abnormality is the liver where 
uroporphyrinogens and heptacarboxylic acid porphyrinogens 
are accumulated due to the Uro'gen-D defect. The 
corresponding peroxyacetic acid- and hydroxy- derivatives 
may be generated because certain amount of H2 02 is 
continuously being formed in the liver (Halliwell and 
Gutteridge, 1985B), which together with the existence of 
excessive porphyrinogens and iron lead to the production of 
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these derivatives. The derivatives and the side product, 
hydroxyl radicals, may play a role in the liver damage. Due 
to the particular location and the function of the liver, 
the derivatives together with the highly accumulated 
porphyrins may partially circulated in the blood stream and 
excreted into urine according to their polarity or partially 
diffused into ductus biliferi due to their high 
concentration and undergo the enterhepatic circulation to be 
excreted in the faeces. The sUbstitution of hydroxy- or 
peroxyacid- group onto the side chains of uroporphyrinogen 
or hepta-, hexa- and penta-carboxylic acid porphyrinogens 
may affect the action of Uro'gen-D and result in the 
formation of unusual decarboxylation products. These 
derivatives, especially the B-hydroxypropionic acid 
derivatives, are structurally possible to be converted to 
the isocoproporphyrin series which are commonly found in PCT 
(Elder & Chapman, 1970; Elder, 1971Bi 1972). This may 
explain why isocoproporphyrins are only found in peT. 
6.4. possible Inhibition of Enzyme Activities by the 
Hydroxy- and peroxyacetic Acid- uroporphyrin Derivatives 
In CEP the enzyme defect is Uro'gen 111-5 and its 
activity is usually decreased to about half or one third of 
normal values in erythrocytes (Kappas et ale 1983). There 
invariably is also an absolute increase in the excretion of 
Uro III, although much less than the type I isomer (Miyagi 
et al.,1976i Ippen & Fuch, 1980; Nordmann & Deybach, 1982). 
It was suggested that though the primary abnormality in CEP 
was the deficiency of Uro'gen 111-5, there may be a 
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secondary increase of the activities of ALA-S and/or HMB-S, 
perhaps as a result of feedback depression (Moore et al., 
1978; Nordmann & Deybach, 1982; Kappas et al., 1983). The 
overproduction of the uroporphyrin I was due to the 
imbalance between HMB-S and Uro'gen III-S activities 
(Nordmann & Deybach, 1982; Bloomer & Bonkovsky, 1989). Some 
studies found that in cultured fibroblasts from patients 
with CEP, the activity of Uro'gen III-S was significantly 
decreased but no uroporphyrin I and coproporphyrin I were 
accumulated. Thus it was suggested that the activity of 
Uro'gen III-S was lower in all tissues, but only in 
erythropoietic tissue the rate of porphyrin synthesis was 
high enough to exceed the reduced capacity of the residual 
Uro'gen III-S (Romeo et al., 1970; Nordmann & Deybach, 
1982) . 
The isolation and characterization of the hydroxy- and 
peroxyacetic acid- uroporphyrin derivatives provides an 
explanation for the elevated Uro III level in CEP. The 
uroporphyrin derivatives and/or the hydroxyl radical 
generated during the formation of these derivatives may 
inhibit the activity of Uro'gen-D causing the accumulation 
of Uro I, III, and their decarboxylated metabolites. It is 
known that peroxyacid is a very powerful oxidizing reagent 
which can oxidize various organic compounds (Plesnicar, 
1978). In vitro experiments with Uro'gen I as the substrate 
under various reaction conditions always produced 
peroxyacetic acid uroporphyrin I as the major product among 
other derivatives. Though B-hydroxypropionic acid 
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uroporphyrin I was isolated and identified in the reaction 
mixture, the amount was less than 10% of that of 
peroxyacetic acid uroporphyrin I under most of the 
conditions studied. The exception was the reaction with H 0 2 2 
/ Fe-EDTA system where the B-hydroxypropionic acid 
uroporphyrin I was about 70% of peroxyacetic acid 
uroporphyrin I. There was always a trace of hydroxyacetic 
acid uroporphyrin I in the reaction mixtures and sufficient 
compound had not been obtained for the identification. In 
the urine of CEP the peroxyacetic acid uroporphyrin I was 
always present in the smallest amount among the uroporphyrin 
I derivatives. This indicated that the peroxyacetic acid 
uroporphyrin I was not only produced but might also be 
consumed in vivo. Thus it is possible that peroxyacetic acid 
uroporphyrin I may oxidize the Uro'gen-D or impair its 
function in some way. Hydroxyl radicals which may be 
generated during the formation of the hydroxy- and 
peroxyacetic acid- uroporphyrin I derivatives are also a 
very powerful oxydizing reagent may also play a role in the 
inhibition of Uro'gen-D. It is also possible that 
peroxyacetic acid uroporphyrin I and hydroxyl radical may 
oxidize porphyrinogens and result in the accumulation of 
porphyrins. 
It has been suggested that in uroporphyria the block in 
uroporphyrinogen metabolism may arise, at least in part, 
from the oxidation of uroporphyrinogens to the corresponding 
porphyrins (Heikel et al., 1958; Ferioli et al., 1984; 
Mukerji et al., 1984; Sinclair et al., 1986). Later, a 
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clearly defined suggestion was put forward that an inhibitor 
or an oxidised derivative of porphyrin (ogen) was produced 
from the oxidation of the porphyrinogen which may inhibit 
the activity of Uro'gen-D (De Matteis et al., 1988; 
Lambrecht et al., 1990). One experiment gave the evidence 
that incubating uroporphyrinogen III with the hydroxyl 
radical-producing systems hypoxanthine/xanthine oxidase/Fe-
EDTA and H20 2 /Fe-EDTA caused a modest but consistent 
inhibition of Uro'gen-D activity (Francis & Smith, 1988). 
These results are consistent with the present study and 
emphasised the need for investigating the potential of the 
hydroxy- and peroxyacetic acid 
derivatives as inhibitors of Uro-D. 
6.5. cutaneous Photosensitivity in CEP 
uroporphyrin I 
cutaneous photosensitivity is the major clinical 
problem in CEP. The skin lesions of CEP was not 
distinguishable from PCT but are very different from those 
of EHP. This difference is usually thought to be the result 
of the differing polarities of the porphyrins and the 
differing affinities of porphyrins to cell components. 
However the detection of hydroxy- and peroxyacetic acid-
uroporphyrin I derivatives and the understanding of the 
mechanism of their formation may allow alternative 
explanations. In both CEP and PCT, especially in CEP, the 
plasma porphyrin (ogen) levels are increased and may deposit 
in the skin. When these compounds are illuminated by light, 
the oxidised porphyrins may catalyse the reaction of 
porphyrinogens to form the peroxyacetic acid- and hydroxy-
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porphyrin derivatives with the generation of hydroxyl 
radicals which may in turn damage the skin. Thus the 
photosensitivity may not only be due to the excited 
porphyrins but also to the production of hydroxy- and 
peroxyacetic acid- porphyrin derivatives and hydroxyl 
radicals. The absence of acute photosensitivity is 
consistent with the light catalysed formation of the 
uroporphyrin derivatives from uroporphyrinogen incubated 
with the incubation buffer alone. Exposure to light 
destroyed porphyrins in the area illuminated by light (Runge 
& Watson, 1962; Malina et al., 1978), in agreement with the 
finding that porphyrins disappeared on prolonging the 
exposure to light of the incubation mixtures of 
uroporphyrinogen I and buffer. The above suggested that in 
CEP and PCT the hydroxy- and peroxyacetic acid porphyrin 
derivatives themselves, and/or the process of formation of 
these derivatives may be responsible at least in part for 
the skin damage caused by light. 
6.5. Further Studies 
6.5.1. Further Studies of the Mechanism of the Formation of 
Hydroxy- and Peroxyacetic Acid- uroporphyrin I Derivatives 
The H20 2 /Fe-EDTA chemical system may involve different 
reaction mechanisms. (1), H202 and Fe 3+ act similarly to a 
peroxidase and result in porphyrinogen oxidation (Mason, 
1987); (2), If Fe 3+ is to some extent reduced by the 
porphyrinogen (De Matteis, 1988) or by H202 (Aust et al., 
1985), Fenton reaction will occur resulting in the formation 
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of ·OH (De Matteis, 1988) and consequent formation of 
hydroxylated uroporphyrin I derivatives and destruction of 
porphyrins; (3), iron-oxygen complex may be formed in this 
system (Ryan & Aust, 1992) which may playa role in the 
formation of hydroxy- and peroxyacetic acid- uroporphyrin I 
derivatives. It requires further investigation to clarify 
which mechanism is responsible for the formation of hydroxy-
and peroxyacetic acid- uroporphyrin I derivatives. 
It is proposed that the formation of peroxyacetic acid 
uroporphyrin I is due to H20 2 and not hydroxyl radical, 
because the addition of hydroxyl radical scavengers, 
mannitol into the xanthine-xanthine oxidase system and high 
concentration of desferrioxamine into the H20 2 /Fe-EDTA 
system, did not prevent the formation of peroxyacetic acid 
uroporphyrin I. This, may however, not be a strong enough 
evidence to confirm the conclusion, especially at lower 
concentration of desferrioxamine the formation of 
peroxyacetic acid uroporphyrin I was inhibited. Thus other 
hydroxyl radical scavengers such as benzoate and DMSO may be 
used to further prove that the hydroxyl radical does not 
involve the formation of peroxyacetic acid uroporphyrin I 
but does involve the formation of hydroxylated uroporphyrin 
I derivatives. 
6.5.2. Isolation and Identification of Novel components in 
the Urine and Plasma from Patients with CEP 
A small peak in front of hydroxyacetic acid 
uroporphyrin I in the urine (Fig. 3.3.) and peak 1 and 4 in 
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the plasma (Fig. 3.4.) of a patient with CEP have not been 
identified. These components displayed pink fluorescence, 
therefore they are most probably also porphyrins. The 
isolation and characterisation of these compounds require 
further work. 
6.5.3. Biological significance of Hydroxy- and peroxyacetic 
Acid- uroporphyrin I Derivatives 
Evidences for the inhibition of Uro-D by these 
compounds have not yet been obtained. They should be 
isolated or synthesised in sufficient quantity for in vitro 
studies on whether they inhibit erythrocyte and hepatic 
Uro-D activities. The role of these compound in liver damage 
and in cutaneous photosensitivity also require further 
investigation. 
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